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1 Chapter 1 
Introduction and Scope 
In the late 1970 Dyerberg and Bang associated high endogenous levels of 
omega-3 fatty acids (n3-PUFA) in Greenland Inuit with a low risk of myocardial 
infarction [1]. Since then, dietary intake of omega-3 fatty acids has not only 
been correlated with beneficial effects on atherosclerosis and related diseases, 
such as coronary heart disease, but also on inflammatory diseases [2, 3]. 
On a molecular level, biological effects of n3-PUFA are diverse: For instance, 
the membrane composition and fluidity is altered and the transcription of pro-
inflammatory genes is reduced, e.g. by inhibition of NF-κB translocation to the 
nucleus [2, 3]. A relevant part of n3-PUFA related effects has been attributed to 
their oxidative metabolites – oxylipins – which are formed by enzymes of the 
arachidonic acid cascade or via autoxidation [4]. However, the power of dietary 
n3-PUFA to modulate the endogenous oxylipin profile and details on changes in 
individual enzyme pathways is not completely understood. Current knowledge 
about the modification of the oxylipin pattern by n3-PUFA is summarized in 
chapter 2 of this thesis. 
Today, the effectivity of n3-PUFA is discussed controversially and many 
questions regarding clinical importance of n3-PUFA related effects or 
mechanisms of action of individual n3-PUFA (and their oxylipins) remain 
unanswered [2, 3, 5]. Interpretation of the observed effects is further impeded 
by high inter-individual variations in the response to dietary n3-PUFA (chapter 
2). 
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In order to investigate biological effects of n3-PUFA and their role in 
pathophysiology, analytical methods are required allowing a quantification of 
fatty acids and their oxidative metabolites in biological samples, such as plasma 
and tissues. For this purpose, in chapter 3 extraction and derivatization 
strategies for lipids from small biological samples (plasma and liver) are 
compared in order to find the most suitable one for the analysis of total fatty 
acids. In chapter 4 and 5 analytical tools for the investigation of oxylipins in 
plasma and cell culture medium are established. While the aim in chapter 4 is to 
find the extraction procedure most suitable to extract free oxylipins from all 
groups in plasma, chapter 5 deals with the optimization of a fast, liquid 
chromatography-mass spectrometry (LC-MS) method for the quantification of 
hydroxy fatty acids in cell culture medium and plasma samples.  
For the investigation of n3-PUFA related effects in animal models, two 
strategies are dominantly used: i.) feeding of diets enriched with n3-PUFA and 
ii.) the use of transgenic fat-1 mice which can biosynthesize n3- from n6-PUFA. 
In chapter 6, for the first time these approaches are comprehensively compared 
regarding their power to modulate the endogenous fatty acid and oxylipin 
profile. 
An interesting observation in described in chapter 6 was the modulation of the 
cerebral oxylipin pattern upon rather short dietary feeding with n3-PUFA (30 
days). In chapter 7, this finding is therefore investigated in more detail, utilizing 
two independent feeding experiments and transcription analysis. Based on the 
changes in epoxy-PUFA to dihydroxy-PUFA ratios, it was found that n3-PUFA 
elevate the expression of the soluble epoxide hydrolase. 
Overall, this thesis contributes to a better understanding of n3-PUFA biology by 
providing detailed data on the modulation of oxylipins, including several potent 
lipid mediators, following elevation of endogenous n3-PUFA level. This 
information is important for the interpretation of changes in the oxylipin pattern 
in the context of n3-PUFA related effects on (patho)physiology. 
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2 Chapter 2 
Effects of Omega-3 Fatty Acid Supplementation on the 
Pattern of Oxylipins – A Short Review About the 
Modulation of Hydroxy-, Dihydroxy-, and Epoxy-Fatty 
Acids* 
A growing body of evidence suggests that intake of the long chain omega-3 
polyunsaturated fatty acids (n3-PUFA) eicosapentaenoic acid (C20:5 n3, EPA) 
and docosahexaenoic acid (C22:6 n3, DHA) is linked to beneficial health effects, 
particularly in the prevention of cardiovascular and inflammatory diseases. 
Though the molecular mode of action of n3-PUFA is still not fully understood, it 
is not controversial that a significant portion of the (patho)-physiological effects 
of PUFA are mediated by their oxidative metabolites, i.e. eicosanoids and other 
oxylipins. Quantitative targeted oxylipin methods allow to comprehensively 
monitor changes in the pattern of oxylipins. In this short review, results from 
intervention studies are summarized analyzing >30 oxylipins from different PUFA 
in response to n3-PUFA supplementation. The results are not only qualitatively 
compared with respect to the study design, n3-PUFA dose and trends in the lipid 
mediators, but the induced changes are also quantitatively compared based on 
the relative change in oxylipin level induced by n3-PUFA. The evaluation of the 
data from these studies shows that the change in hydroxy-, epoxy- and 
dihydroxy-PUFA generally corresponds to the observed changes in their 
precursor PUFA. Thus, the lower the individual n3-status is at baseline, the 
higher the increase in EPA and DHA derived oxylipins. Strongest relative 
increases were found in EPA derived oxylipins, while changes ARA derived 
eicosanoids were heterogeneous. After 3-12 weeks of supplementation similar 
relative changes were observed in free and total (free + esterified) oxylipins in 
plasma and serum. Regarding EPA derived oxylipins, trends for a linear increase 
with dose can be deduced. However, interpretation of the quantitative oxylipin 
patterns between studies is hampered by strong inter-individual variances in 
oxylipin levels between and also within the studies. In the future, the reason for 
these varying oxylipin plasma concentrations needs to clarified in order 
understand oxylipin and n3-PUFA biology. 
* Ostermann AI and Schebb NH. 2017. Submitted for publication. 
Author contributions: AO, NHS: Designed study and wrote the manuscript. 
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 Introduction 2.1
In many epidemiological and intervention studies, high endogenous levels of 
omega-3 polyunsaturated fatty acids (n3-PUFA), including eicosapentaenoic 
acid (C20:5 n3, EPA) and docosahexaenoic acid (C22:6 n3 DHA) have been 
correlated with beneficial effects on human health, e.g. in cardiovascular [1] or 
inflammatory diseases [2]. However, results are conflicting and in some studies 
these positive effects have not been observed, e.g. in intervention studies on 
the effectivity of n3-PUFAs on the relapse in Crohn’s Disease [3], or on major 
cardiovascular events (fatal and nonfatal cardiovascular events and cardiac 
interventions) in a population with previous myocardial infarction, receiving 
medication [4]. Moreover, a recent meta-analysis did not find a risk lowering 
effect of n3-PUFAs for all-cause mortality, cardiac death, sudden death, 
myocardial infarction and stroke [5].  
On a molecular level, a part of n3-PUFA related effects has been attributed to a 
shift in the pattern of lipid mediators formed in the arachidonic acid (ARA, C20:4 
n6) cascade by competing with ARA for conversion in the three enzymatic 
pathways of this signaling cascade (Fig. 2.1 [2, 6]). Conversion of ARA by 
cyclooxygenases (COX) leads to prostaglandin (PG) H2 which is further 
metabolized by downstream enzymes to series 2 prostanoids, such as PGE2, a 
potent mediator in the regulation of pain, fever and inflammation [2, 7, 8]. By 
contrast, conversion of EPA is slower, thereby reducing the levels of formed 
mediators [9] and leads to less potent series 3 PG [2, 8]. Similarly, leukotriene 
(LT) B4, formed by lipoxygenase (LOX) action on ARA, acts pro-inflammatory by 
neutrophil attraction [7], while its EPA derived counterpart (LTB5) shows much 
lower potency [2, 8]. Beyond that, EPA and DHA can also give rise to highly 
potent lipid mediators. For instance, in the third branch of the ARA cascade, 
enzymes of the cytochrome P450 (CYP) 2C and 2J family act as epoxygenases 
on PUFA. The main products of EPA and DHA, 17(18)-epoxy eicosatetraenoic 
acid (EpETE) and 19(20)-epoxy docosapentaenoic acid (EpDPE) are potent 
anti-arrhythmic acting mediators [10] and 19(20)-EpDPE has been shown to 
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inhibit angiogenesis, while Ep-FA deriving from ARA promote angiogenesis 
[11]. Also, multiple hydroxylation of EPA and DHA leads to potent inflammation 
resolving oxylipins, termed specialized pro-resolving mediators (SPM), like 
resolvins or maresins [12]. 
 
Fig. 2.1: Simplified overview over selected CYP, LOX and COX pathways of LA, ALA, ARA, 
EPA and DHA in the ARA cascade. HpETE – hydroperoxy eicosatetraenoic acid; Lx – lipoxin; 
Mar – maresin, PD – protectin; RvD – D series resolvins; HpEPE – hydroperoxy 
eicosapentaenoic acid. 
Overall, the influence of EPA and DHA on the profile of lipid mediators formed 
in the ARA cascade is diverse and biological effects of n3-PUFA seem to result 
more from a shift in the whole pattern of oxylipins rather than from changes of 
selected metabolites. For an interpretation of EPA and DHA derived effects and 
the characterization of the impact of individual metabolites, it is therefore 
important to monitor a comprehensive set of oxylipins from all branches of the 
ARA cascade and supplementation induced shifts therein [13, 14]. Oxylipin 
patterns in healthy subjects on different diets can be correlated with those 
during onset and progression of diseases allowing to evaluate the (patho-) 
physiological role of (n3-PUFA derived) mediators. However, most studies in 
this field analyze and/or report only selected (groups) of oxylipins of interest, 
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e.g. SPM and Ep-FA [15], SPM and precursor thereof [16, 17], Ep-FA [18] or 
mainly ARA derived mediators [19].  
Nonetheless, several studies characterized n3-PUFA (EPA+DHA) 
supplementation induced changes in a comprehensive set of oxylipins derived 
from different n6- and n3-PUFA (ARA, EPA and DHA amongst others) and 
across the different branches of the ARA cascade (COX, LOX, CYP and 
autoxidation) [13, 20-29] and in one study [30] the effects of individual EPA and 
n3 docosapentaenoic acid (n3-DPA) supplementation were compared. 
However, the outcome of these studies has not been systematically compared. 
The aim of the present work is therefore to summarize the results of n3-PUFA 
intervention, to evaluate if they lead to similar quantitative results and pinpoint 
differences which have to be addressed in future studies. In order to allow the 
quantitative comparison of the effects of n3-PUFA treatment on all three 
branches of the ARA cascade, only studies analyzing a comprehensive set of 
>30 oxylipins from different precursor FA and reporting mediators from different 
groups of oxylipins (e.g. hydroxy-, dihydroxy-, and epoxy-fatty acids) are 
included and a focus was set on supplementation induced changes in healthy 
subjects. 
 Dose, intervention period and study population 2.2
EPA, DHA and other n3-PUFAs can be biosynthesized in humans from the 
essential n3-PUFA alpha linolenic acid (C18:3 n3, ALA) in multiple steps, 
involving conversion by delta-5 and delta-6 desaturases and elongases [31]. 
However, conversion rates of ALA to EPA are low in populations on a western 
diet rich in n6-PUFA [32], resulting in low shares of EPA and DHA in blood (red 
blood cells (RBC) and plasma) [33]. The way to supply humans with EPA and 
DHA is consumption of long-chain n3-PUFA rich seafood, like oily fish [1, 2], or 
by intake of dietary supplements [34]. Dietary recommendations for the uptake 
of EPA+DHA range from ≥250 mg/d to ≥500 mg/d (e.g. Academy of Nutrition 
and Dietetics, AHA, EFSA, WHO) [35] and according to the German Society for 
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Nutrition, prevention of primary coronary heart disease with a daily intake of up 
to 250 mg EPA and DHA seems probable [36]. However, in order to achieve the 
triglyceride lowering effects, daily doses need to be higher (2-4 g/d) and a 
higher intake is recommend for patients with coronary heart disease (~1g/d) 
[35]. Moreover, special recommendations for pregnant or lactating women 
concerning the intake of DHA exist [35].  
In supplementation studies investigating the effect of n3-PUFA in healthy 
subjects [13, 20, 21, 23-28], daily intakes of EPA ranged from 0.36-1.9 g/d and 
DHA doses ranged from 0.24-1.5 g/d (Table 2.1). With a sum of EPA+DHA from 
0.6-3.4 g/d, this is higher than the minimum dietary recommendations for the 
intake of n3-PUFA in healthy subjects. It should be noted that a linear 
relationship between dose and endogenous n3-PUFA levels in different blood 
compartments exists in this dose range (linearity at least up to 4 meals of oily 
fish per week, equaling 1.87 g EPA+DHA (1:1.2, w:w) per day [37]). At a dose 
of 3 g EPA+DHA (3:2, w:w) per day, incorporation of EPA into plasma 
phospholipids is still linear, while DHA incorporation seemed to reach saturation 
[38].  
The effect of n3-PUFA supplementation on the oxylipin pattern in non-healthy 
subjects was investigated in patients with mild to moderate asthma [22], 
hyperlipidemia [25] and IgA nephropathy [29] and combined EPA and DHA 
doses ranged from 2.7-6.0 g/d (Table 2.1).  
In most studies, EPA and DHA were administered as capsules, dominantly 
containing refined fish oil (Table 2.1). However, binding forms were slightly 
different which might have an impact on bioavailability of the PUFAs [39]. For 
instance, Schuchardt et al. used re-esterified triglycerides in their studies [25, 
26], while n3-PUFA ethyl esters were used by Fischer and Konkel et al., 
Keenan et al. and Schebb at al. amongst others [13, 20-22, 24, 29]. Indeed, in 
some studies a higher bioavailability of re-esterified triglycerides in comparison 
to ethyl esters [39] was found which might influence the effect of n3-PUFA 
supplementation on the oxylipin pattern. However, not only the lipid binding 
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form is crucial for bioavailability of the fatty acids, but also galenic or matrix [39]. 
For example, pre-emulsified n3-PUFA ethyl esters show a significantly higher 
absorption and thus bioavailability [40]. Given the importance of the formation of 
an emulsion, the bioavailability of n3-PUFA from a supplementation product is 
thus influenced if it is ingested together with a meal containing a substantial 
amount of fat (releasing bile acids, and colipase).  
The dietary intervention lasted 3-12 weeks in most studies investigating the 
effects of n3-PUFA on the oxylipin pattern, and one study monitored the effects 
up to 6 months and 12 months, respectively (Table 2.1). Heterogeneous study 
populations were used, comprising male and female subjects, aged roughly 21-
70 years with a body mass index (BMI) of 19-35 kg/m2 (Table 2.1). In 
Schuchardt et al., 2014 (A) only a single dose of omega-3 fatty acids was 
administered [26] and study participants from the study of Watkins et al. were 
older compared to other studies (75±6 years [27]). 
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Table 2.1: Overview over the study designs. 
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 Methods for the quantitative comparison of results 2.3
For the quantitative comparison of changes in the pattern of oxylipins and their 
precursors (linoleic acid (C18:2 n6, LA), ALA, ARA, EPA and DHA), fold 
changes between concentrations post- and pre-n3-PUFA-supplementation 
(post/pre) were calculated in the different studies, based on the means of the 
analytes pre- and post-supplementation provided in the respective study (Table 
2.2). This relative comparison of study results was chosen to compensate for 
differences in absolute concentrations between the studies, originating, e.g., 
from different standards used for calibration [41]. Variances in the analytes’ 
concentrations were not considered in this calculation. If sampling was 
conducted at more than one time point, basal levels of oxylipins and FA were 
compared to the longest supplementation period. If an analyte was described in 
the analytical method, or if an analyte was graphically presented in the 
manuscript, but no concentration was shown, authors were asked to kindly 
provide the exact concentration of the respective analytes. In case raw data (or 
raw means) were provided, calculations of the post/pre ratio for all analytes 
from the respective study were based on the raw data. For analytes below the 
limit of quantification (LOQ) the LOQ was used for calculation. Means from the 
raw data for the post/pre ratios were calculated if the analyte was detectable in 
≥50% of the samples in one group. For the quantitative comparison of n3-PUFA 
induced effects on the oxylipin profile, exemplary oxylipins of the precursor 
PUFAs LA, ARA, ALA, EPA and DHA from all three enzymatic branches of the 
ARA cascade were chosen. The analytes were selected based on two criteria: 
i.) they were reported in most of studies and ii.) analogous biochemical 
formation route in the AA cascade: 15-LOX products, terminally epoxygenated 
PUFA and their hydrolyzation products. For oxylipins originating from the COX 
pathway, ARA derived products PGE2 and thromboxane (Tx) B2 were selected 
as well as their EPA derived counterparts (PGE3 and TxB3). 
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 Modulation of the n6- and n3-oxylipin pattern following 2.4
n3-PUFA supplementation 
In order to understand oxylipin biology in the course of a disease or in response 
to a treatment, it would be most appropriate to analyze oxylipin concentrations 
in the tissue of interest. However, in humans this is rarely feasible. Therefore, 
plasma and serum are often used as a proximate for tissues to quantitatively 
evaluate changes in oxylipins, e.g. in response to a dietary intervention. 
Relative changes in exemplary plasma and serum oxylipins (post/pre fold 
change) from all three branches of the ARA cascade induced by 
supplementation with n3-PUFAs in different studies are presented in Table 2.2.  
Based on the findings that low doses of EPA and DHA led to a maximum in the 
incorporation of EPA into plasma phosphatidylcholine after about 14 days of 
supplementation [37] and that EPA metabolites were rapidly increased after a 
single dose n3-PUFA [26], we assumed a maximum modulation of the oxylipin 
pattern after about 14 days. Thus, the oxylipin pattern obtained following 3-12 
weeks of supplementation (Table 2.2) would be maximally modulated, allowing 
the direct comparison of changes between the studies.  
The major portion of circulating oxylipins, esp. epoxy-FA and hydroxy-FA, is 
found esterified in lipids [24, 42]. While the role of esterified oxylipins in (patho-) 
physiology is not as well understood as the role of free oxylipins, esterified 
oxylipins have also been shown to be biologically active [43]. Thus, the question 
of analyzing free or esterified oxylipins is of importance for the interpretation of 
the results in a biological context. Liberation of oxylipins from their esterified 
form is often achieved using base hydrolysis, leading to a sum parameter of 
free and esterified oxylipins (“total oxylipins”) [41]. In a direct comparison, 
relative changes induced by dietary n3-PUFA supplementation revealed similar 
trends in free and total oxylipins [24]. This finding is further supported by a 
comparison of changes induced in free and total oxylipins across different 
studies (Table 2.2). Although some trends were slightly different between free 
and total oxylipins (see below) the overall data indicates that after 3-12 weeks 
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of supplementation, shifts occurring in the oxylipin pattern are similarly 
represented by both, free and total oxylipins. 
Table 2.2: Fold changes of precursor fatty acid and selected oxylipins. 
a
 no information 
provided; 
b
 analyte was below the limit of quantification in at least one of the groups (pre- or 
post-supplementation); 
c
 analyzed, but not shown; 
d
 analysis not possible due to analyte 
degradation during alkaline hydrolysis; * post/pre ratios for FA calculated based on [mol%]; for 
all other studies, FA rations were calculated based on [% of total FA]; 
#
 shown is comparison of 
supplementation vs. placebo group. 
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In response to n3-PUFA supplementation, concentrations of free and total EPA 
and DHA metabolites in plasma and serum of healthy subjects increased. 
Generally, relative increases in EPA metabolites were more pronounced than 
changes in DHA metabolites, a trend that was found in all studies, and elevation 
in EPA and DHA oxylipins roughly corresponded to changes in the respective 
precursor FAs. Free DHA metabolites increased up to twofold, while changes in 
total DHA derived docosanoids were slightly higher in most studies (1.9-2.4-fold 
increase). However, in the study by Schebb et al., total 19(20)-EpDPE was only 
slightly increased (post/pre ratio of 1.1) and its hydrolysis product was 
decreased (post/pre ratio of 0.77). EPA oxylipins increased up to sevenfold and 
no trend was observable discriminating free (post/pre ratio of 1.5-7.0) and total 
oxylipins (post/pre ratio of 1.7-7.1). Differences in administered doses between 
the studies might be a variable leading to this variance (0.36 vs 1.9 g EPA/d see 
below). 
It should be noted that high relative increase does not necessarily correspond to 
higher absolute concentration changes. For instance, in the study by 
Schuchardt et al. [25], relative changes in free 15-hydroxy eicosapentaenoic 
acid (HEPE) were more pronounced than changes in 17,18- dihydroxy 
eicosatetraenoic acid (DiHETE) (post/pre ration of 4.3 vs. 3.4), while the 
absolute increase in 17,18-DiHETE was much higher due to the higher 
concentrations of this analyte (post-pre15-HETE = 360 pM; post-pre17(18)-DiHETE = 
1060 pM). Similarly, the relative increase in 19(20)-EpDPE was lower (post/pre 
= 1.6) compared to 15-HETE, while the absolute increase was higher (post-
pre19(20)-EpDPE = 600 pM). Likewise, in the study by Keenan et al. [21], the 
post/pre ratio of total 17(18)-EpETE was 7.1 versus 2.0 for the hydrolyzation 
product 19,20-DiHETE, while the respective absolute differences (post-pre) 
were 4.4 and 7.0 nM. The relative modulation of 17-hydroxy docosahexaenoic 
acid (HDHA) was similar to 17(18)-DiHETE (2.4), while the concentration of the 
17-HDHA was increased by 55 nM post supplementation [21]. In the other 
studies, similar trends can be found [13, 20, 24, 27, 28]. For the interpretation of 
biological effects it is thus crucial to not only consider relative changes, but also 
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absolute changes since one can assume that the concentration of the bioactive 
substance in the tissue mediates its effects. 
Regarding (intra study) responses to n3-PUFA supplementation in the individual 
pathways of the ARA cascade, results between the studies are heterogenous. 
For instance, some studies indicated highest changes in the CYP pathway [20, 
23]. However, a comparison of terminally epoxy-EPA and epoxy-DHA (CYP) 
with 15-LOX products (15-HEPE and 17-HDHA) in healthy subjects across 
different studies led to different results. For instance, changes in free 17(18)-
EpETE compared to 15-HEPE were higher in the studies by Schebb et al. [24] 
and Watkins [27], while changes in 15-HEPE were more pronounced in the 
studies by Schuchardt et al. [25]. Similarly, results from total oxylipins show 
different outcomes: Fischer and Konkel [20] as well as Keenan [21] found 
higher modulation of 17(18)-EpETE and Schebb et al. [24] as well as  Shearer 
et al. [13] found a higher modulation of 15-HEPE. A comparison of changes in 
17-HDHA to 19(20)-EpDPE in healthy subjects was only possible for few 
studies and total oxylipins; however, results suggest a comparable modulation 
of both pathways [13, 20, 21]. In another study, a distinct decrease in Ep-FA 
derived from ARA, LA and ALA as well as DiH-FA from ARA (but not LA and 
ALA) was found, while changes in LOX products were inconsistent (Table 2.2 
and [25]). Again, these trends were not found in all studies (Table 2.2).  
Changes in the COX pathway could not be evaluated due to insufficient data 
availability (Table 2.2). Only Zhang et al. reported a decrease in TxB2 (post/pre 
ratio of 0.70 [28]), while other studies did not provide an information on PGE2 
and TxB2. Since most prostaglandins and thromboxanes are instable during 
alkaline hydrolysis [41], these analytes were not reported in the studies 
analyzing total oxylipin concentrations. However, due to their physiological 
function in platelet activation (TxA2) and regulation of inflammation (PGE2) [7, 
8], low concentrations of these mediators would be expected in healthy 
subjects. 
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While ARA was slightly decreased in all studies, irrespective of the blood 
fraction analyzed (red blood cells, plasma, serum phospholipids (PL)), changes 
in free plasma ARA derived oxylipins in healthy subjects were inconsistent. For 
instance, while 14(15)- epoxy eicosatrienoic acid (EpETrE) was slightly 
increased in the studies by Watkins et al. (1.1 fold [27]), this analyte was slightly 
decreased in the study by Schebb et al. (fold change of 0.92 [24]) and highly 
decreased in the study by Schuchardt et al. (fold change of 0.58 [25]). 15-HETE 
and 14(15)-dihydroxy eicosatrienoic acid (DiHETrE) showed similar trends. By 
contrast, in the studies analyzing total oxylipins, ARA metabolites uniformly 
decreased (post/pre ratio of 0.95-0.55). Indeed, when evaluating changes in 
free ARA metabolites for each individual, it was shown that they were 
decreased in some, while they increased in others [23]. Thus, modulation of 
ARA derived oxylipins detectable in plasma seems to be highly variable 
between subjects. Changes in EPA and DHA oxylipins in response to n3-PUFA 
supplementation were also highly variable, but did show an increasing trend in 
most subjects [23]. This inconsistent trend in ARA oxylipins might be explained 
by the dietary and endogenous n6-PUFA status of the study subjects, strongly 
influencing the individual response of n6-PUFA derived oxylipins to n3-PUFA 
supplementation. By contrast, variance in the study population’s dietary uptake 
of EPA and DHA is low, due to low background intake of EPA and DHA in 
comparison to the supplementation level, as discussed by Keenan et al. [21]. In 
response to n3-PUFA supplementation, oxylipins from the LA and ALA 
metabolomes were mostly decreased, as were their precursor FA. 
Although serum and plasma are used in an  analogous manner as a 
proximate to describe changes in tissue oxylipin concentrations, care must be 
taken when directly comparing absolute oxylipin concentrations from plasma 
and serum due to increased production of docosanoides and eicosanoids 
during coagulation. Regarding relative changes in oxylipins, the results from 
different studies (in healthy and diseased subjects) indicate that both, plasma 
and serum might be comparable in identifying trends in eicosanoids and other 
oxylipins induced by dietary supplementation. However, neither plasma, nor 
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serum oxylipins reflect the actual situation in an inflamed tissue. Serum can be 
regarded as “ex vivo” blood coagulation assay resulting in a massive activation 
of platelet COX-1 and 12-LOX. In order to induce an immunological response 
and thus to mimic inflammation, e.g., a septic shock, ex vivo assays with 
stimulation of whole blood with lipopolysaccharides (LPS) to induce monocyte 
activation [44] or with the calcium ionophore A23187 to induce platelet 
activation [45] are additionally used. Beyond increased TxB2 formation, the 
production of other oxylipins from the COX and LOX pathways, esp. 12-LOX, 
have been shown to be increased in A23187 activated whole blood [46]. Fischer 
et al. [20] treated whole blood of subjects supplemented with n3-PUFA with the 
calcium ionophore A23187. Following supplementation with n3-PUFAs, the 
levels of LTB4, PGE2 and TxB2 were barely altered and concentrations of EPA 
derived counterparts LTB5 and PGE3 were low compared to ARA derived 
eicosanoids. Correlating LTB5/LTB4 and PGE3/PGE2 with the ratio of precursor 
FA revealed slopes <1, indicating a preference of ARA versus EPA for the 
formation of LTB and PGE. No change was found in TxB3 following dietary 
intervention, probably due to insufficient supplementation doses to induce 
changes in TxB3 formation [20]. Interestingly, while in non-activated plasma, 
LOX pathways did show a higher efficiency in converting EPA and DHA 
compared to ARA (esterified oxylipins, slope of the product ratios vs parent FA 
ratios correlations at least 1.9, except 7-HDHA [20]), ARA was more efficiently 
converted in Ca-ionophore activated whole blood (free oxylipins, slopes of the 
product ratios vs parent FA ratios correlations 0.01-1.3 [20]). 
 Dose and time dependent responses in the oxylipin 2.5
pattern to dietary n3-PUFA supplementation 
Previous studies suggest a dose and time dependent response for the 
incorporation of EPA and DHA, e.g. into plasma lipid classes or blood cells in 
low doses which equaled up to four meals oily fish per week [37]. Interestingly, 
a maximum level of incorporation was reached in the different tissues and blood 
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compartments which showed a clear dose dependency [37]. However, the 
extent of incorporation was depended on the tissue and blood compartment. 
For instance, while the relative amount of EPA+DHA in plasma 
phosphatidylcholine was linear up to a dose corresponding to four meals oils 
fish per week (1.87 g/d), a saturation of EPA+DHA in red blood cells was found 
in the highest concentration [37]. Similarly, Flock et al. found a saturation of 
%EPA+DHA of total fatty acids in red blood cells in the highest dose 
supplemented (1800 mg(EPA+DHA)/day, ~5 months [47]). With regard to 
plasma phospholipids, a linear incorporation of EPA was found up to 3 g 
(EPA+DHA)/d (3:2, w:w) for 12 weeks, while DHA incorporation seemed to 
reach saturation at the same dose [38].  
By contrast, almost no information is available on dose and time dependent 
changes in the oxylipin pattern in response to dietary n3-PUFA 
supplementation. In a study by Schuchardt et al. with a single dose n3-PUFA 
(1.008 g EPA and 0.672 g DHA), most free EPA metabolites in plasma were 
significantly elevated six hours post ingestion, indicating that EPA oxylipin level 
can be readily modified in a short period of time [26]. DHA and oxylipin level 
were not altered which is consistent with the overall lower relative modulation of 
DHA in response to n3-PUFA supplementation. In the study by Fischer and 
Konkel et al. the study participants received a daily dose of 460 mg EPA + 
380 mg DHA for four weeks and twice as much in the following four weeks [20]. 
The ratio of the sum of CYP derived EPA and DHA epoxy and dihydroxy-
metabolites and the sum of ARA analogs increased approximately twofold in the 
first week of intervention. In the following weeks only a slight increase occurred. 
With the doubled dose in week 4, the ratio was rapidly increased until week 8 by 
about 1.6-fold [20]. These results indicate a distinct time- and dose dependency 
in the modulation of metabolites in the third branch of the ARA cascade. Given 
the biological activity of the epoxy-n3-PUFA [10, 11], this warrants further 
investigation.  
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Doses supplied to healthy volunteers in studies investigating the effect of n3-
PUFA supplementation on the oxylipin pattern were in the range of up to 3.4 g 
EPA+DHA and the intervention period in most studies was 3 to 12 weeks (Table 
2.1). Based on the assumption that time dependent changes in EPA 
metabolites occur in a similar manner as changes in their precursor FA (see 
above), we compared the magnitude of change in different EPA derived 
oxylipins with the supplemented dose in order to evaluate dose response 
relations  
 
Fig. 2.2: Correlation of the post/pre concentration ratio (Table 2.1) for selected free (A) and total 
(B) EPA derived eicosanoids with the supplemented dose (Table 2.2) across the different 
studies. 
Across the different studies, relative changes in total 15-HEPE seem to 
correlate linearly with the supplied dose (Fig. 2.2B I). However, total 17(18)-
EpETE, 17(18)-DiHETE and the sum of both do not show a consistent trend 
across the studies (Fig. 2.2B II-IV). For free 15-HEPE and 17(18)-EpETE, a 
linear increase could be deduced combining the data of the studies by 
Schuchardt et al. and Schebb et al. However, observed changes in the study by 
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Watkins et al. did not correspond to the results (Fig. 2.2A I-II). Interestingly, 
relative changes in 17,18-DiHETE and in the sum of 17(18)-EpETE+17,18-
DiHETE seem to increase linearly with the dose between the three studies. 
However, for 17,18-DiHETE, a lower dose of EPA in the study by Zhang et al let 
to a higher change (Fig. 2.2A III). 
One should note that the correlations shown in Figure 2 can only be a rough 
estimate, because of different human subjects and different study designs. 
Taking the conflicting results on the clinical efficacy of n3-PUFA in different 
diseases into account, further studies on dose dependent modulations of the 
oxylipin profile are urgently needed. These studies should not only correlate 
changes in the overall oxylipin pattern with the n3-PUFA dose but also monitor 
the genetic variability, e.g. single-nucleotide polymorphism as well as 
expression levels of the enzymes from the pathways of the ARA cascade. This 
will not only allow deducing dose-response dependencies but also lead to a 
better understanding about the molecular mode of action of n3-PUFA and may 
explain why n3-PUFA are effective in some subjects while others do not 
respond to n3-PUFAs. 
 Inter-individual variations in responses to n3-PUFA 2.6
supplementation 
Although the change of EPA and DHA derived oxylipins showed the same 
increasing trend, high variances were observed, esp. in changes of EPA and its 
metabolites between the studies. This is in accordance with findings within the 
different studies, showing high variances in the individual responses of the 
study participants to dietary intervention with n3-PUFA although compliance 
was high in the studies [21, 23, 25, 27]. 
Schuchardt et al. found that increases in serum EPA metabolites correlated well 
with increases of EPA in erythrocytes [25] and EPA metabolites in plasma 
correlated well with EPA plasma phospholipid level after a single dose of n3-
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PUFA [26]. Consistently, Nording et al. described a correlation of changes in 
EPA/DHA in specific lipid classes (e.g. triglycerides, cholesterol ester) with their 
oxidative metabolites in plasma [23]. Moreover, it has been found that the study 
participants’ individual responses in EPA+DHA in red blood cells (omega-3 
index) [21] correlated well to the respective basal status, in a way that a lower 
basal omega-3 index was associated with higher supplementation induced 
increases. This was also found in a study by Flock et al., investigating the dose 
response of the omega-3 index to increasing doses of n3-PUFA 
supplementation. The authors found a positive correlation of changes with the 
initial omega-3 index. Furthermore, a lower bodyweight and a higher n3-PUFA 
dose were associated with a higher increase in the omega-3 index [47]. Keenan 
et al. correlated individual baseline PUFA and oxylipin concentrations with the 
respective dose-dependent change. The x-intercept of the resulting inverse 
correlation was introduced as the “change threshold”. This concentration 
defines the threshold for supplementation induced changes by n3-PUFA. Study 
participants entering the study with this PUFA/oxylipin concentration will most 
likely show only little changes after supplementation. The larger the difference 
of a subject’s basal PUFA/oxylipin status from the “change threshold” the higher 
the change that will be observed with supplementation [21].  
These results indicate that changes in PUFA as well as oxylipin concentrations 
are dependent parameters and correlate with the basal level of PUFA/oxylipins. 
Thus, variances in basal n3-PUFA level might account for part of the observed 
differences in individual responses to n3-PUFA supplementation. 
Fischer and Konkel et al. found a positive correlation between the (dose [mg/kg 
bodyweight/d]*basal omega-3 index) and the omega-3 index in week 8 [20]. By 
contrast, in an explorative study by Nording et al., no significant correlations 
between changes in EPA, DHA, ARA or their oxylipins and age, body weight or 
BMI was found  [23]. Similarly, Schebb et al. did not found statistically different 
concentrations in oxylipins before and after supplementation between men and 
women for most analytes [24]. 
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Schuchardt et al. observed that variances between the study participants were 
much higher for oxylipins compared to fatty acids: While trends in fatty acids 
induced by n3-PUFA supplementation were similar between the individuals, 
trends in oxylipins differed [25]. These results indicate inter-individual 
differences in the metabolism of fatty acids. Indeed, Stephenson et al. reported 
differences in the response to n3-PUFA supplementation which were correlated 
to variants in the ALOX5 genotype [48]. In another study, it was shown that 
dietary intervention influenced the expression of different PUFA metabolizing 
enzymes, e.g. ALOX5, or CYP2J2, in study participants that did not show a 
response (in form of lowered triglyceride level) to n3-PUFA supplementation 
[49]. 
Most oxylipins in plasma are found in the lipoprotein fraction [42]. However, only 
little information exists on the profile of oxylipins in lipoproteins and their 
modulation, e.g. by n3-PUFA supplementation. In statin-treated, hypertriglyceri-
demic patients, the different lipoprotein fractions showed a distinct pattern of 
oxylipins, which shifted from dominantly ARA metabolites to EPA and DHA 
derived ones following supplementation with EPA and DHA. Thus, it seems 
likely that modulations in individual lipoprotein levels and distribution – e.g. 
dietary PUFA induced modulation of the LDL/HDL ratio – contribute to the 
varying plasma oxylipin levels observed in different subjects.  
Overall, it seems crucial to address the high inter-individual variances in future 
studies, especially in the light of using oxylipins as biomarker for diseases. 
 Modulation of oxylipins by n3-suplementation in (the 2.7
onset of) diseases 
Few studies investigated the effects of n3-PUFA supplementation on the 
oxylipin pattern in non-healthy subjects, including mild to moderate asthma [22], 
hyperlipidemia [25] and IgA nephropathy [29]. The changes in the oxylipin 
pattern in these subjects depicted in Table 2.2 were comparable to healthy 
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individuals. Indeed, Schuchardt et al. directly compared normo- vs. 
hyperlipidemic subjects and concluded that no differences between the oxylipin 
profiles in both study groups were observable [25]. Based on patients with n3-
PUFA supplementation, Zivkovic et al. identified oxylipins which were changed 
the most between responders and non-responders in terms of n3-PUFA 
induced improved kidney function [29]. Here, the highest differences between 
both groups were not found for EPA and DHA epoxy- and dihydroxy-
metabolites, but in hydroxy-LA and hydroxy-ARA. Based on this finding one 
could conclude that – at least plasma levels of – EPA and DHA oxylipins are not 
linked to the improvement of kidney function by n3-PUFA. 
 Conclusion 2.8
In this short review we compared the effects of supplementation with the n3-
PUFAs EPA and DHA on the oxylipin pattern across different studies. However, 
due to restrictions in data availability only few oxylipins could be quantitatively 
compared. In particular, it was not possible to evaluate changes in the COX 
branch of the ARA cascade and in bioactive SPMs.   
Overall, EPA and DHA derived oxylipins were increased compared to baseline, 
while changes in ARA were less consistent with a trend to decreasing levels. 
However, interpretation of these results is hampered by high inter-individual 
variances in oxylipin concentration in response to n3-PUFA supplementation 
while changes in fatty acids were consistent. Nonetheless, the currently 
available data indicate that the response in the oxylipin profile to n3-PUFA 
supplementation correlates with the basal fatty acid status. However, only 
scarce information is available on dose- as well as time-responses.  
Thus, in future studies it will be important to understand the underlying reasons 
for the high variability of inter-individual responses in oxylipins to n3-PUFA 
supplementation. Moreover, the investigation of time- and dose dependencies 
in n3-PUFA induced changes in the oxylipin pattern are still lacking. This 
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information will help to understand n3-PUFA biology, especially with regard to 
recent studies finding no beneficial effect of n3-PUFAs on human health, and to 
identify and establish oxylipin(ratios) as biomarker for disease status and the 
effectiveness of (pharmacological) treatment. Moreover, studies investigating 
the effect of the background diet (high n6, mediterranean) and supplementation 
with individual PUFAs [30] will be helpful to understand the regulation of the 
endogenous oxylipin profile. 
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3 Chapter 3 
Determining the Fatty Acid Composition in Plasma and 
Tissues as Fatty Acid Methyl Esters Using Gas 
Chromatography – A Comparison of Different 
Derivatization and Extraction Procedures 
Analysis of the FA composition in biological samples is commonly carried out using gas 
liquid chromatography (GC) after transesterification to volatile FA methyl esters (FAME). 
We compared the efficacy of six frequently used protocols for derivatization of different 
lipid classes as well as for plasma and tissue samples. Transesterification with 
trimethylsulfonium hydroxide (TMSH) led to insufficient derivatization efficacies for 
polyunsaturated FAs (PUFA, <50%). Derivatization in presence of potassium hydroxide 
(KOH) failed at derivatizing free FAs (FFAs). Boron trifluoride (BF3) 7% in hexane/MeOH 
(1:1) was insufficient for the transesterification of cholesterol ester (CE) as well as 
triacylglycerols (TGs). In contrast, methanolic hydrogen chloride (HCl) as well as a 
combination of BF3 with methanolic sodium hydroxide (NaOH+BF3) were suitable for the 
derivatization of FFAs, polar lipids, TGs and CEs (derivatization rate >80% for all tested 
lipids). Regarding plasma samples, all methods led to an overall similar relative FA 
pattern. However, significant differences were observed, e.g., for the relative amount of 
EPA+DHA in plasma. Absolute FA plasma concentrations differed considerably among 
the methods, with low yields for KOH and BF3. We also demonstrate that lipid extraction 
with tert-butyl methyl ether/methanol (MTBE/MeOH) is as efficient as the classical 
method according to Bligh and Dyer, making it possible to replace (environmentally) 
toxic chloroform. We conclude that HCl-catalyzed derivatization in combination with 
MeOH/MTBE extraction is the most appropriate among the methods tested for the 
analysis of FA concentrations and FA pattern in small biological samples.  
Reprinted from Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 91(6), 
Ostermann AI, Müller M, Willenberg I and Schebb NH, Determining the fatty acid 
composition in plasma and tissues as fatty acid methyl esters using gas 
chromatography – a comparison of different derivatization and extraction procedures, 
pp. 235-241, Copyright (2014), with permission from Elsevier. 
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 Introduction 3.1
For half a century, fatty acids have been routinely quantified using GC with 
flame ionization detection (GC-FID) following transesterification to FAMEs [1]. 
This well-established technique is an integral tool in the characterization of 
authenticity and nutritional value of food. As food analysis is a highly regulated 
area, several standard methods for the analysis of FAs have been suggested by 
food authorities in the United States and European Union [2, 3]. 
With the finding that the dietary intake of long-chain PUFAs (LC-PUFAs) has 
direct impact on human health, numerous studies aimed to investigate the 
effects of a modulation of the PUFA pattern in blood and tissues in response to 
the diet [4-7]. At last, the broad recognition of the physiological importance of 
LC-n3-PUFA and their oxylipins caused a renaissance in GC-FID FAME 
analysis in bioanalysis laboratories. In fact, most modern liquid 
chromatography-mass spectrometry (LC-MS) based targeted oxylipin 
metabolomics studies are backed up by classic GC-FID FAME analysis of the 
precursor FA [8-12]. 
Compared to the area of food analysis dealing with rather large volumes, 
sample preparation and derivatization methods for the analysis of small 
amounts of tissue and low plasma volumes is less standardized. Most 
commonly acid derivatization with BF3 [5, 7, 10-14] or HCl [4, 15-17] are 
employed and have been used to characterize FA pattern in plasma and tissues 
[8, 15]. Moreover, TMSH [18-20] has been used in these kinds of studies and 
alkaline derivatization with sodium or potassium methanolate [6] or hydroxide 
[19] have been proven to be suitable for the analysis of different lipid classes. 
Moreover, combinations of different reagents, such as BF3 and methanolic 
sodium hydroxide, have been developed [21-23]. 
Lipid extraction is generally carried out according to Bligh and Dyer [24] or for 
samples with high fat content according to Folch [25, 26] albeit several years 
ago Matyash et al. described an extraction strategy allowing a replacement of 
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halogenated solvents [27]. Most studies start with an extraction of lipids from 
plasma or (homogenized) tissue, while few apply the derivatization agent 
without any prior sample preparation [15, 28]. 
Because GC-FID FAME analysis is such a well-established technique, only little 
information on method details and validation data are given in recent articles. 
As a consequence, it is difficult to deduce the most suited sample preparation 
method for quantitative FAME analysis in small biological samples based on 
current literature data. In effort to establish GC-FID FAME analysis in our 
laboratory, we compared the performance of six common derivatization 
methods. Most techniques led to comparable relative FA patterns. However, 
absolute concentrations of the different FA and sums of all FA determined in a 
plasma or tissue sample varied between the different methods. In this article, 
we therefore systematically elucidated reasons for these differences by analysis 
of derivatization efficacy for all relevant classes of lipids and different FA. 
Furthermore, we compared two different extraction protocols (Bligh and Dyer as 
well as MTBE/MeOH) and tested alkaline hydrolysis as additional sample 
preparation step to improve tissue homogenization and extraction. 
 Experimental 3.2
3.2.1 Chemicals and biological material  
Chloroform (uvasolv grade), ethanol (uvasolv grade), ammonium acetate (p.a.), 
sodium chloride (p.a.) and KOH (p.a.) were obtained from Merck (Darmstadt, 
Germany). n-Hexane (hexane in the following) (HPLC grade), NaOH (p.a.) and 
MTBE (HPLC grade) were purchased from Carl Roth (Karlsruhe, Germany). 
TMSH was obtained from CS Chromatographie Service (Langerwehe, 
Germany). MeOH (HPLC grade) was purchased from J.T. Baker (Deventer, 
Holland). Methyl tricosanoate used as internal standard (FAME C23:0, >98%) 
and cholesteryl heptadecanoate (CE C17:0, >98%) were obtained from Santa 
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Cruz Biotechnology (Santa Cruz, CA, USA). Dihenarachidoyl-sn-glycero-3-
phosphocholine (PC C21:0, >99%) was purchased from Avanti Polar Lipids 
(Alabaster, AL, USA). Arachidonic acid (C20:4n6), eicosapentaenoic acid 
(C20:5n3) and docosahexaenoic acid (C22:6n3) were obtained from Cayman 
Chemicals (Ann Arbor, MI, USA). Acetic acid (Acros Organics) was obtained 
from Fisher Scientific (Nidderau, Germany). Sodium bisulfate (p.a.) was 
obtained from Riedel de Haën (Seelze, Germany). All other chemicals were 
purchased from Sigma Aldrich (Schnelldorf, Germany). Rat liver tissues were 
collected from male Fischer 344 rats (250-300 g bodyweight, Charles River, 
Sulzfeld, Germany). Pooled human plasma was obtained from healthy male 
volunteers. 
3.2.2 GC-FID analysis  
Gas liquid chromatography was carried out on a 30 m x 0.25 mm FAMEWAX 
capillary column with a 0.25 µm thick polar polyethylene coating (Restek, Bad 
Homburg, Germany) equipped with a 5 m x 0.25 mm Guard Column (Restek). 
Separation was performed with the following temperature gradient on a 6890 
series GC instrument (Agilent, Weilbronn, Germany): 140 °C to 210 °C with 10 
°C/min, 210 °C to 230 °C with 2 °C/min and 230 °C for 7 min (total run time 24 
min). Helium was used as carrier gas at a constant flow of 1.5 mL/min. One 
microliter of the sample was injected into an injector kept a 275 °C and the split 
was set to 1:50. The flame ionization detector was operated at 300 °C with 45 
mL/min hydrogen flow, 450 mL/min air flow and a make-up flow of 45 mL/min 
helium. Under these conditions, all biologically relevant FA were baseline 
separated as shown by a 37 FAME standard from Supelco (CRM47885, Sigma 
Aldrich) supplemented with 22:5n3 and 22:4n6 (Sigma Aldrich) as well as a 20 
FAME fish oil mix (35066, Restek). ChemStation B01.03 (Agilent) was used for 
instrument control and data handling. Quantification of FAMEs was carried out 
based on their peak areas compared to the internal standard (FAME C23:0) 
peak area by using response factors introduced by Ackman and Sipos [29, 30]. 
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Linear range and the accuracy of the method were validated by the analysis of 
FAME standards (see above). 
3.2.3 Sample preparation  
Alkaline hydrolysis/sample saponification 
10 µL internal standard solution (IS; FAME C23:0, in chloroform/ethanol 1:9) 
and 10 µL of antioxidant solution (0.2 mg/mL ethylenediaminetetraacetic acid, 
butylated hydroxytoluene and triphinylphosphine in methanol:water 50:50), were 
added to 35-45 mg liver tissue. Thereafter, 100 µL MeOH and 60 µL 10 M 
aqueous sodium hydroxide were added and the samples were homogenized in 
a ball mill (20 Hz, 5 min, 22 °C, MM 400, Retsch, Haan, Germany). The crude 
suspension was then hydrolyzed for 30 min at 60 °C. Directly after hydrolysis, 
samples were neutralized (pH 6-7) on ice with 70 µL of 50% acetic acid and 
extracted as described below. 
Lipid extraction 
Following addition of 10 µL IS solution, pooled human plasma (50 µL) and rat 
liver tissue (35-45 mg) were extracted by the method of Bligh and Dyer [24] and 
Matyash [27] with slight modifications. For Bligh and Dyer [24] extraction, 
plasma was extracted with 750 µL of chloroform:MeOH (1:2), and the liver 
tissue was homogenized with 750 µL of chloroform:MeOH (1:2) and 50 µL of 
water in a ball mill (see above). Thereafter, 250 µL of chloroform as well as 250 
µL of water were added; the samples were mixed for 1.5 min and centrifuged for 
10 min at 4500 xg at room temperature. Following collection of the lower 
organic phase, the aqueous phase was re-extracted with 250 µL of chloroform. 
The organic phases were combined and the sample was evaporated in a 
vacuum centrifuge (1 mbar, 35 °C; Christ, Osterode, Germany). 
For the extraction according to Matyash [27] plasma was mixed with 300 µL of 
MeOH and the liver tissue was homogenized with 300 µL of MeOH and 50 µL of 
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water in a ball mill (see above). Thereafter, 600 µL of MTBE was added; the 
samples were vigorously shaken for 1.5 min and mixed with 300 µL of 0.15 
mmol/L ammonium acetate. After centrifugation for 5 min at 3500 xg at 4 °C the 
upper organic layer was collected and the surface of the residual aqueous 
phase was washed with another 300 µL MTBE. The organic phases were 
combined and evaporated in a vacuum centrifuge (see above).  
Derivatization 
The dried lipid extracts were transesterified to FAME by six different methods as 
previously described with slight modifications [15, 19, 20, 22, 28]. For TMSH 
derivatization, the dried lipid extract was dissolved in 100 µL of hexane and 50 
µL of methanolic TMSH (0.2 mol/L). The samples were shaken at 400 U/min for 
30 min at room temperature [20]. For BF3 derivatization the dried lipid extract 
was dissolved in 500 µL BF3 solution (12-14% in MeOH) and 500 µL of hexane. 
The solution was heated for 1 h in a tightly closed vial in a metal block kept at 
90-95°C. After cooling, 750 µL of water were added. The sample was shaken 
vigorously for 4 min, centrifuged at 3500 xg for 5 min and the hexane layer was 
collected [28]. For the HCl derivatization the dried lipid extract was dissolved in 
600 µL of acetylchloride in MeOH (1:9) and 400 µL hexane and the sample was 
heated to 90-95 °C for 1 h in a tightly closed vial. After cooling, 750 µL of 
aqueous potassium carbonate (0.44 mol/L) were added. The sample was 
shaken vigorously for 4 min, centrifuged at 3500 xg for 5 min and the hexane 
layer was collected [15]. For KOH derivatization the lipid extract was dissolved 
in 200 µL of hexane and 100 µL of methanolic KOH (2 mol/L). After incubation 
at room temperature for 5 min, 40 mg of sodium bisulfate were added and the 
supernatant was collected [19]. For the combined NaOH+BF3 protocol, the dried 
lipid extract was dissolved in 100 µL methanolic sodium hydroxide (0.5 mol/L) 
and heated for 15 min at 90-95 °C in a tightly closed vial. Thereafter, 500 µL 
BF3 solution (12-14% in MeOH) was added and the sample was heated for 
another 30 min at 90-95 °C. 750 µL of saturated aqueous sodium chloride and 
500 µL of hexane were added after cooling of the sample. The sample was 
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shaken vigorously for 4 min, centrifuged at 3500 xg for 5 min and the organic 
phase was collected [22].  
Following all derivatization protocols, the organic phases were evaporated in a 
vacuum centrifuge (1 mbar, 35 °C; see above), reconstituted in 50 µL of 
MTBE:MeOH (9:1) and analyzed by GC-FID. Only for direct TMSH 
derivatization the dried lipid extract was reconstituted in 50 µL of methanolic 
TMSH (0.2 mol/L) and 50 µL of MTBE and directly subjected to GC analysis 
[19]. 
The derivatization efficacies were analyzed by treating 5 µL of a standard 
solution containing 2 mmol/L of FFAs, a phosphatidylcholine (PC), a CE and 
TGs, with 10 µL IS as lipid extract. 
 Results 3.3
3.3.1 Derivatization efficacy for different lipid classes  
The efficacy of the six different protocols for the transesterification of FFA, a 
PC, TGs and a CE are shown in Fig. 3.1.  
KOH led to good derivatization efficacies for PC and TG (>90%), while FFA as 
well as CE were not derivatized (<3%). Except for polyunsaturated FFA 
(derivatization ≤11%), all tested lipid classes were acceptably methylated using 
TMSH (≥80%). Direct injection of the TMSH derivatization mixture into the hot 
injector (TMSH inj) led to higher but still low derivatization of polyunsaturated 
FFA (≤50%). Moreover, this procedure caused inefficient transesterification 
efficacies for TG C19:0 (rec=41%). Derivatization in presence of BF3 led to 
good efficacies (>95%) for FFA and the PC; however, the CE and TG were not 
efficiently transesterified (≤30%). Derivatization rates with methanolic HCl were 
good for all tested lipid classes (>80%). The protocol combining derivatization in 
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presence of methanolic NaOH+BF3 also led to a good derivatization efficacy 
(≥85%) for all tested lipid classes. 
 
Fig. 3.1: Derivatization efficacy of FAME generation by the different methods: A: saturated 
FFAs C17:0 and C21:0, B: polyunsaturated FFAs C20:4n6, C20:5n3 and C22:6n3, C: PC 
C21:0 and CE C17:0 and D: TGs C18:1n9 and C19:0. For each lipid the recovery rate of a 
derivatized standard (200 µM) is shown as mean ± SD (n=5). 
3.3.2 Derivatization of lipid extracts from plasma  
The sums of quantified saturated FAs (SFA), monounsaturated FAs (MUFA), 
n3- and n6- PUFAs as well as the sum of all quantified FAs in human plasma 
extracted with MTBE/MeOH utilizing the six different derivatization protocols are 
summarized in Table 3.1. The plasma concentrations of the biologically relevant 
PUFA ALA, ARA, EPA and DHA are highlighted in Fig. 3.2A. 
The concentrations of ALA, ARA, EPA and DHA were overall in the same range 
with all six protocols. However, the concentrations of these PUFA obtained with 
DETERMINING THE FATTY ACID COMPOSITION IN PLASMA AND TISSUES USING GC-FID 
 
39 
 
KOH and BF3 derivatizations were significantly lower compared to HCl 
(p<0.001, Fig. 3.2A). The sums of the concentrations of all detected SFA, 
MUFA and total n6- and n3-PUFA showed a similar trend (Table 3.1). As a 
consequence, the sum of the concentrations of all fatty acids was dramatically 
lower for the KOH and BF3 protocol (Table 3.1). For all other derivatization 
methods, the sums of SFA, MUFA, PUFA and total FA concentrations were 
comparable.  
Table 3.1:  Determined plasma PUFA levels utilizing different derivatization methods. Shown is 
the sum of the concentration and the relative amount of SFA, MUFA, n6-PUFA and n3-PUFA 
quantified in the same pooled human plasma (50 µL). All results are shown as mean ± SD 
(n=5). 
Plasma 
[µg/mL] 
KOH TMSH TMSH 
direct 
injection 
BF3 HCl NaOH+BF3 
SFA 810 ± 21 1200 ± 72 1200 ± 36 750 ± 15 1200 ± 16 1100 ± 39 
MUFA 480 ± 13 910 ± 64 760 ± 57 390 ± 8.4 860 ± 14 870 ± 55 
n6-PUFA 500 ± 12 1100 ± 100 820 ± 120 490 ± 8.1 1000 ± 24 1100 ± 120 
n3-PUFA  190 ± 3.3 230 ± 38 240 ± 18 180 ± 5.5 300 ± 14 300 ± 15 
total FA 2000 ± 49 3400 ± 270 3000 ± 230 1800 ± 37 3300 ± 69 3400 ± 230 
                   
Relative distribution [%] 
      
SFA 41 ± 1.0 35 ± 2.1 40 ± 1.2 42 ± 0.83 35 ± 0.49 33 ± 1.2 
MUFA 24 ± 0.66 26 ± 1.9 25 ± 1.9 21 ± 0.47 26 ± 0.42 26 ± 1.6 
n6-PUFA 25 ± 0.60 32 ± 2.9 27 ± 3.9 27 ± 0.45 30 ± 0.74 32 ± 3.5 
n3-PUFA  9.5 ± 0.17 6.8 ± 1.1 8.1 ± 0.59 9.9 ± 0.31 9.0 ± 0.42 8.9 ± 0.46 
The obtained variation of repeated measurements, calculated as standard 
deviation (SD) of five independent replicates differed considerably between the 
protocols. The lowest SD and thus the best precision for the sum of all FAs was 
found for HCl and BF3 with relative SDs of ≤2% compared to up to 8% for 
TMSH. 
The six different protocols led to distinct differences in the relative pattern of 
SFA, MUFA and PUFA (Table 3.1). For n6-PUFA, for example, the relative 
amount of the different FA classes ranged from 25% (KOH) to 32% (TMSH and 
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NaOH+BF3) and for SFA between 33% (NaOH+BF3) and 42% (BF3). Regarding 
the relative content of EPA+DHA of all FA in plasma (a modification of the n3-
index [31], Fig. 3.2B), the lowest value was calculated based on the data 
obtained by TMSH derivatization (5.3%), and the highest value resulted from 
the BF3 method (8.3%). Derivatization with HCl, KOH and NaOH+BF3 led to a 
consistent index of 7.4±0.2%. No statistical differences were observed between 
the three protocols (Fig. 3.2B). However, with 5.3% and 6.5%, both TMSH 
protocols led for the same samples to significantly lower, and BF3 with 8.3% to 
significantly higher %EPA+DHA level compared to HCl. 
 
Fig. 3.2: Plasma PUFA levels determined with different derivatization methods. A: 
concentration of ALA (C18:3n3), ARA (C20:4n6), EPA (C20:5n3) and DHA (C22:6n3), B: 
Relative DHA+EPA content of all detected FA. For all samples the same pooled human plasma 
was extracted with MTBE/MeOH and analyzed. Significant differences were determined in 
comparison to the HCl method by independent sample t-test. * p<0.05, ** p<0.005, *** p<0.001. 
All results are shown as mean ± SD (n=5). 
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3.3.3 Efficacies of the Bligh and Dyer versus the MTBE/MeOH extraction 
The lipid extraction efficacy for plasma and liver tissue was compared for Bligh 
and Dyer and the MTBE/MeOH protocol (Tables 3.2 and 3.3). Derivatization of 
the resulting lipid extracts was carried out with the HCl and the combined 
NaOH+BF3 method.  
As summarized in Tables 3.2 and 3.3 both, the determined FA concentrations 
as well as the relative FA patterns and SDs were comparable for both protocols 
and derivatization techniques. 
Table 3.2: Comparison of the lipid extraction efficacy of the protocol according to Bligh and 
Dyer and MTBE/MeOH using NaOH+BF3 or HCl derivatization. Shown are the sums of the 
concentrations of SFA, MUFA, n6-PUFA and n3-PUFA quantified in the same pooled human 
plasma (50 µL). The relative DHA+EPA content of all detected FA is presented in the bottom 
panel of the table. All results are shown as mean ± SD (n=5). 
 Bligh & 
Dyer 
MTBE Bligh & 
Dyer 
MTBE 
Derivatization NaOH + BF3 HCl 
Plasma [µg/mL]     
SFA 1200 ± 80 1100 ± 39 1100 ± 33 1200 ± 16 
MUFA 900 ± 65 870 ± 55 820 ± 27 860 ± 14 
n6-PUFA 1100 ± 94 1100 ± 120 960 ± 37 1000 ± 24 
n3-PUFA  290 ± 33 300 ± 15 280 ± 10 300 ± 14 
total FA 3500 ± 270 3400 ± 230 3100 ± 110 3300 ± 69 
%(EPA+DHA)  
of all FA 
6.9 ± 0.81 7.3 ± 0.40 7.3 ± 0.28 7.4 ± 0.38 
3.3.4 Saponification of tissue samples prior extraction 
In addition to homogenization and extraction of liver, the tissue was heated 
under harsh alkaline conditions. This led to an almost complete dissolving of the 
tissue improving the handling of the following extraction. Lipid extraction was 
conducted by the methods of Bligh and Dyer and MTBE/MeOH, and HCl as well 
as NaOH+BF3 were used for derivatization (Table 3.3). 
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Compared to the direct extraction, the sample saponification caused neither a 
difference in the absolute concentrations of the FAs, nor in the relative pattern 
of SFA, MUFA and PUFA. However, for both extraction protocols, there was a 
slight trend towards a higher extraction efficacy for the hydrolyzed samples 
 
Table 3.3: Comparison of the extraction efficacy of the protocol according to Bligh and Dyer and 
MTBE/MeOH with either NaOH+BF3 or HCl derivatization with or without alkaline hydrolysis 
prior extraction of liver samples. Shown are the sums of the concentrations of SFA, MUFA, n6-
PUFA and n3-PUFA quantified in rat liver (35-45 mg) of the same animal. The relative 
DHA+EPA content of all detected FA is presented in the bottom panel of the table. All results 
are shown as mean ± SD (n=5). 
 Direct extraction of the sample 
  Bligh & Dyer MTBE Bligh & Dyer MTBE 
Derivatization NaOH + BF3 HCl 
Liver [µg/mg]     
SFA 16 ± 1.9 18 ± 2.1 15 ± 0.99 16 ± 1.6 
MUFA 5 ± 0.96 6 ± 0.77 4.8 ± 0.46 5.2 ± 0.74 
n6-PUFA 12 ± 0.42 12 ± 1.5 12 ± 0.48 12 ± 1.3 
n3-PUFA  1.9 ± 0.36 2.1 ± 0.27 2 ± 0.25 5.9 ± 0.24 
total FA 34 ± 3.6 38 ± 4.6 34 ± 2.2 35 ± 3.9 
%EPA+DHA of all FA 4.3 ± 0.91 4.3 ± 0.56 4.5 ± 0.61 4.7 ± 0.42 
             
 
Akaline hydrolysis prior extraction 
 
Bligh & Dyer MTBE Bligh & Dyer MTBE 
Derivatization NaOH + BF3 HCl 
Liver [µg/mg]         
SFA 16 ± 0.87 16 ± 1.3 17 ± 1.2 17 ± 0.88 
MUFA 5.6 ± 0.86 5.8 ± 1.4 5.5 ± 0.49 5.9 ± 0.37 
n6-PUFA 13 ± 1.9 14 ± 2.9 13 ± 0.65 14 ± 0.58 
n3-PUFA  2.3 ± 0.36 2.3 ± 0.5 2.3 ± 0.17 2.4 ± 0.17 
total FA 37 ± 4 38 ± 6 38 ± 2.5 39 ± 2 
%EPA+DHA of all FA 4.8 ± 0.81 4.7 ± 0.98 4.5 ± 0.27 4.7 ± 0.29 
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 Discussion 3.4
FA quantification as FAMEs by means of GC-FID is a well-established 
technique. Numerous studies describe the sample preparation procedure 
particularly derivatization to FAME [2, 3, 14, 15, 18, 20, 22, 24, 25, 27, 28]. 
However, for small biological samples a variety of different methods are used, 
making it difficult to deduce the most suitable. Therefore, we compared the 
most established derivatization methods to elucidate which is the most 
appropriate technique to analyze the PUFA pattern in plasma and tissue 
samples. 
When analyzing standards of FFA, PC, CE and TG, our results show that only 
the derivatization protocols utilizing HCl and NaOH+BF3 yielded FAME with 
satisfying efficacy (>80%). The other four protocols using BF3, KOH and TMSH 
failed to derivatize at least one of the lipids (Fig. 3.1), which are all present in 
plasma [32]. As described previously, KOH treatment does not esterify FFA to 
FAME [33]. Low efficacies were also observed for the derivatization of 
unsaturated FFA using TMSH (≤50%) with direct injection (pyrolysis of the salt 
formed from the FA and TMSH in the injector [34]) or derivatization at room 
temperature followed by evaporation. Similar observations have been made for 
TMSH derivatization before, e.g. Firl et al. reported lower recovery rates for 
PUFA in comparison to MUFA and SFA [19]. Interestingly, CE derivatization 
has been described to be problematic using TMSH because of long reaction 
times required [34]. However, our results indicate efficient transesterification. 
The BF3 protocol is often used in literature for the derivatization of lipid extracts 
from biological samples [5, 7, 10-13, 31] or direct conversion of crude samples 
[28]. In our analysis, derivatization with 7% BF3 in hexane/MeOH inefficiently 
transesterified CE and TG, two of the major lipid fractions in plasma [32]. 
However, it should be noted that the transesterification efficacy depends on the 
solvent composition [35]. Thus, a lower hexane/MeOH ratio could lead to a 
better conversion of CE and TG. When comparing different BF3 protocols, it 
also should be noted that several described “BF3 protocols” are two steps 
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procedures of an alkaline treatment followed by BF3 methylation [36], similar to 
the highly efficient protocol using NaOH+BF3 described here. Nevertheless, 
several authors report potential artifact formation by derivatization of PUFA with 
BF3, hence giving reasons to prefer other derivatization procedures [37]. 
Despite the varying derivatization of the standards (Fig. 3.1), it is interesting that 
all derivatization protocols led to an overall similar relative pattern of SFA, 
MUFA and PUFA in plasma (Fig. 3.2B, Table 3.1). Particularly the determined 
relative amount of EPA and DHA in plasma, (a modification of the n3-index [31]) 
was fairly consistent between the methods (Fig. 3.2B). Hence, our results 
indicate that all protocols are suitable to detect changes in the relative FA 
pattern, as carried out in numerous studies [4-13, 19, 21, 23, 31]. However, due 
to the low derivatization efficacy for PUFA, TMSH led to an underestimation of 
the absolute and relative levels of n3-PUFA and thus to a significantly lower  
%EPA+DHA (Fig. 3.2B). Similarly, too low levels for SFA and MUFA in plasma 
are obtained for BF3 in hexane/MeOH (1:1), most likely caused by the low 
derivatization efficacy of CE and TG. In combination with the high 
transesterification rate of phospholipids by this BF3 protocol, the lipid fraction 
that contains most of all n3-PUFA in plasma [32], a significantly higher sum of 
%EPA and %DHA results (Fig. 3.2B).  
These results demonstrate that great care should be taken when comparing 
relative FA pattern reported in different studies. Therefore, a comparison only 
seems possible between analyses using the HCl, KOH, and NaOH+BF3 
derivatization protocols.  
Regarding the absolute concentration of FA determined in plasma, much more 
pronounced differences were obtained between the protocols (Fig. 3.2A, Table 
3.1). Following KOH and BF3 derivatization, the sum of all FA concentrations 
were with 2000 and 1800 µg/mL almost 50% lower than for the TMSH, HCl and 
NaOH+BF3 protocols which led to concentrations of 3000-3400 µg/mL (Table 
3.1). This poor yield seems to be even problematic for the analysis of the 
relative FA pattern, e.g. by sacrificing detection sensitivity of low abundant FA. 
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Our results compelled us to conclude that among the procedures tested only 
HCl and NaOH+BF3 are suitable protocols for the analysis of an overall FA 
pattern in plasma without discriminating individual classes of lipids. However, 
KOH derivatization leads to a consistent FA pattern in plasma, probably 
because of the low FFA content [32]. Thus, each derivatization method tested 
here might be suitable for specific samples. For example, BF3 and KOH 
protocols might be applicable for the analysis of the relative FA pattern in 
samples rich in polar lipids, e.g. the composition of erythrocyte membranes.  
Aside from the derivatization procedure, extraction of the lipids is the crucial 
sample preparation step for the analysis of biological samples. Utilizing a 
slightly modified extraction protocol as described by Matyash [27] about six 
years ago, a comparable extraction efficacy for plasma and tissues was found 
for the MTBE/MeOH extraction compared to the method of Bligh and Dyer [24] 
(Table 3.2 and Table 3.3). Based on the application of two derivatization 
protocols and the analysis of plasma and liver tissue, our results clearly 
demonstrate that both, the absolute concentration of FA as well as the relative 
FA pattern, are comparable between the two extraction protocols. Interestingly, 
the MTBE/MeOH extraction led to slightly higher concentrations of degradation-
prone PUFA (Table 3.2 and Table 3.3). Thus, the extraction conditions seem to 
be milder in comparison to the traditional method. It should be noted that the 
results cannot be applied for the analysis of high fat tissues (>2% fat in the 
homogenate) where extraction to Folch yields better results than extraction 
according to Bligh and Dyer [26]. However, the good comparability of 
MTBE/MeOH with Bligh and Dyer encourages to further investigate if, for the 
analysis of high fat tissues, also Folch extraction could be replaced by this 
halogenated solvent-free procedure. 
Regardless the method, extraction of tissues is a challenging task requiring 
labor-intensive and error-prone homogenization techniques. To improve 
extraction efficacy, we added a saponification step prior to sample preparation. 
The tissue almost dissolves in the applied sodium hydroxide solution within 30 
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min at 60 °C and the neutralized samples can be extracted as plasma or other 
liquid samples. As summarized in Table 3.3, the extraction efficacy for liver 
tissue was comparable for samples prepared with or without hydrolysis prior to 
extraction. Actually, the extraction is slightly, however not significantly, improved 
with saponification of the sample. Thus, it is concluded that saponification of 
tissue samples does not negatively influence fatty acid analysis. Therefore, this 
sample preparation strategy is a promising tool particularly for the FAME 
analysis of tough tissues, such as gut or other organs rich in connection tissue. 
Overall, we suggest MTBE/MeOH extraction followed by HCl derivatization as 
sample preparation technique for FAME analysis in small amounts of biological 
samples, such as plasma and tissues. For the analysis of tissues, base 
hydrolysis prior extraction can be included in the sample preparation making 
homogenization easier and more reliable without negatively affecting the 
results. It should be noted that the combined protocol with NaOH+BF3 is equally 
suitable, however, requires more working steps and has the risk of artifact 
formation [37]. The traditional extraction according to Bligh and Dyer also yields 
excellent results. Nonetheless, our data indicate no scientific need in continuing 
to use (environmentally) toxic chloroform for extraction. 
Most importantly, our studies demonstrate that both the absolute 
concentrations, but also in part the relative FA pattern, significantly differ 
between derivatization methods. Therefore, we urge all authors of future articles 
using FAME analysis to provide details about their methods. Otherwise, a 
comparison of different studies might not be possible and potentially valuable 
information about PUFA biology might be lost. 
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4 Chapter 4 
Comparison of Sample Preparation Methods for the 
Quantitative Analysis of Eicosanoids and other 
Oxylipins in Plasma by Means of LC-MS/MS 
 
Oxylipins are potent lipid mediators. For the evaluation of their biological roles, 
several LC-MS based methods have been developed. While these methods are 
similar, the described sample preparation procedures for the extraction of 
oxylipins differ considerably. In order to deduce the most appropriate method for 
the analysis of non-esterified oxylipins in human plasma, we evaluated the 
performance of seven established sample preparation procedures. Six 
commonly used solid phase extraction (SPE) and one liquid-liquid extraction 
(LLE) protocol were compared based on the recovery of 13 added internal 
standards, extraction efficacy of oxylipins from plasma and reduction of ion-
suppressing matrix. Dramatic differences in the performance in all three 
parameters were found. LLE with ethyl acetate was overall not a sufficient 
sample preparation strategy. The protocols using Oasis- and StrataX-material 
insufficiently removed interfering matrix compounds. Removal of matrix was 
nearly perfect on anion-exchanging BondElut cartridges and recovery of internal 
standards was good. However, extraction of unpolar epoxy fatty acids seemed to 
be better on a C18-material with removal of matrix by water and n-hexane prior 
elution with methyl formate. 
Adapted from Analytical and Bioanalytical Chemistry, Comparison of sample 
preparation methods for the quantitative analysis of eicosanoids and other oxylipins in 
plasma by means of LC-MS/MS, vol. 407(5), 2015, pp. 1403-1414, Ostermann AI, 
Willenberg I and Schebb NH. With permission of Springer. 
Author contributions: AIO: Designed research, performed experiments and wrote the 
manuscript; IW: Contributed to research design and manuscript writing; NHS: Designed 
research and wrote the manuscript. 
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 Introduction 4.1
Oxidative metabolites of polyunsaturated fatty acids (PUFA) are an important 
class of lipid mediators. The conversion of arachidonic acid (C20:4n6, ARA) by 
cyclooxygenases (COXs) and lipoxygenases (LOXs) leads to highly potent 
eicosanoids controlling a multitude of biological functions [1]. A large number of 
eicosanoids and oxidation products of other PUFA, particularly 
docosahexaenoic acid (C22:6n3, DHA) and eicosapentaenoic acid (C20:5n3, 
EPA), generally referred to as oxylipins, have been described in recent years [2, 
3]. Their routes of formation are diverse, catalyzed by LOX, COX, Cytochrome 
P450 and soluble epoxide hydrolase among further enzymes and non-
enzymatic (aut)oxidation [1, 3]. For many of the formed oxylipins, the biological 
role has not been fully understood, however, several are implicated to regulate 
physiological processes such as blood pressure, inflammation and pain, but 
also cellular functions, e.g. proliferation [1]. Quantitative analysis in biological 
samples is the key to a mechanistic understanding of the biological roles of 
oxylipins. Monitoring changes in a comprehensive pattern of oxylipins in 
different (patho)physiological conditions and in response to pharmacological 
treatment is one of the most promising strategies in the investigation of 
oxylipins. This led in the past, e.g. to the understanding of the remarkably 
different actions of n3- and n6-epoxides in angiogenesis and cancer growth [4, 
5] as well as their antiarrhythmic effects [6] or the discovery of inflammation 
resolving hydroxy- [7] and multiple hydroxylated n3-PUFA, such as resolvins [2]. 
Several liquid chromatography (LC) mass spectrometry (MS) methods have 
been described allowing parallel quantification of a large number (~100) of 
oxylipins in biological matrices [8-11]. These approaches make targeted 
metabolomics analysis of the arachidonic acid cascade feasible because a 
comprehensive set of products is covered. 
On the level of instrumental analysis, almost all current methods address the 
challenges of quantitative oxylipin analysis such as (i) very low concentrations 
(ii) huge concentration range of the different oxylipins in one sample (up to 104 
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fold) [12] and (iii) large number of structurally similar analytes with several 
(regio)isomers with a similar approach: Separation is carried out by modern 
reversed phase chromatography with sub-2-µm particles. Electrospray 
ionization (ESI) is used in negative ion mode and the analytes are detected in 
selected reaction monitoring (SRM) mode on a highly sensitive triple 
quadrupole (QqQ) MS [8-11, 13]. In fact, even the same transitions are used for 
quantification, e.g., beta fragmentation of hydroxy-FA by collision-induced 
dissociation (CID) [11, 13]. Overall, the differences in the well-optimized 
methods are minor and mainly depend on analyte-coverage and sensitivity, 
most likely limited by standard availability and instrumental performance, 
respectively. 
Regarding sample preparation the methods vary considerably. Mixing of the 
sample with organic solvents and direct injection is only possible for specific 
questions because of the low oxylipin concentrations in biological samples [14]. 
Thus, sample preparation techniques are required allowing efficient extraction 
from the matrix and pre-concentration prior instrumental analysis. For this 
purpose, both liquid-liquid extraction (LLE) with ethyl acetate (EA) [15] and 
different solid-phase extraction (SPE) protocols [6, 8, 10, 11, 13, 16, 17] have 
been described. For SPE, classical RP material [11, 16] as well as modern 
polymeric stationary phases with embedded polar groups such as Oasis HLB 
(Waters, Eschborn, Germany) [8, 10, 17] or StrataX (Phenomenex, Torrance, 
CA, USA) [9] are employed. Moreover, materials with anion exchange 
properties are used [6, 13] to extract the slightly acidic oxylipins from biological 
samples. Taking the different solvents used in the washing and eluting steps of 
the SPE into account, the described protocols are even more diverse. 
Isotope-labeled internal standards (IS) are only available for few oxylipins 
because of the large diversity of analytes. As a consequence a single heavy 
atom labeled IS is used for a whole group of oxylipins, e.g. 2H4-PGE2 for all 
prostaglandins (PGs) and 5-hydroxy eicosatetraenoic acid (HETE) for all 
hydroxy-FA [10]. Even though structurally similar IS are used, their retention 
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times differ. As a consequence, the IS cannot correct for all interferences 
caused by influence of matrix compounds on the ionization process. Ion 
suppression is in fact the Achilles heel for quantification using ESI-MS, since 
the signal is strongly affected by coeluting matrix compounds [18]. Thus, 
efficient removal of the matrix by sample preparation is the key for a successful 
quantification of oxylipins in complex biological samples. 
However, neither the extraction efficacy of oxylipins from biological samples by 
the different sample preparation strategies nor their ability to remove ion-
suppressing matrix compounds has been investigated so far. In the present 
study, we therefore compared the performance of seven commonly used 
sample preparation techniques for the analysis of free (i.e. non-esterified) 
oxylipins in human plasma. The methods were thoroughly evaluated according 
to three criteria: (i) IS recovery (ii) ion suppression and (iii) extraction efficacy. 
The most efficient sample preparation protocols are identified and could be 
used as a basis for further optimization procedures. 
 Experimental 4.2
4.2.1 Chemicals and biological materials 
LC-MS grade acetonitrile (ACN), acetic acid (HAc) and methanol (MeOH) were 
from Fisher Scientific (Nidderau, Germany). Oxylipin standards and internal 
standards (Table 4.1) were purchased from Cayman Chemicals (local 
distributor: Biomol, Hamburg, Germany). Further standards such as epoxy 
octadecadienoic acids (EpODEs) and dihydroxy octadecadienoic acids 
(DiHODEs) were a kind gift from the laboratory of Bruce Hammock, UC Davis, 
CA, USA. 1-(1-(Ethyl-sulfonyl)piperidin-4-yl)-3-(4-(triflouromethoxy)phenyl)urea 
synthesized as described [19] was used as internal standard 2 (IS 2). Sodium 
acetate was obtained from Merck (Darmstadt, Germany). n-Hexane (HPLC 
Grade) was purchased from Carl Roth (Karlsruhe, Germany) and formic acid 
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(Acros Organics) was obtained from Fisher Scientific (Nidderau, Germany). All 
other chemicals were from Sigma Aldrich (Schnelldorf, Germany). Pooled 
human plasma was generated by mixing ethylenediaminetetraacetic acid 
(EDTA) plasma obtained from healthy male volunteers. The pooled plasma was 
centrifuged (10 min, 4 °C, 10 000 xg) and stored at -80 °C in 1-2-mL aliquots. 
4.2.2 Oxylipin extraction 
For each analysis, a freshly thawed 500 µL aliquot of the same human plasma 
pool was used. In the first step, 10 µL of IS solution in MeOH (100 nM of 2H4-6-
keto-PGF1α, 
2H4-PGE2, 
2H4-PGD2, 
2H4-TxB2, 
2H4-LTB4, 
2H4-9-hydroxy 
octadecadienoic acid (HODE), 2H8-5-HETE, 
2H8-12-HETE, 
2H6-20-HETE, 
2H11-
14,15-dihydroxy eicosatrienoic acid (DiHETrE), 2H11-14(15)-epoxy 
eicosatetraenoic acid (EpETrE), 2H4-9(10)-epoxy octadecenoic acid (EpOME) 
and 2H4-9(10)-dihydroxy octadecenoic acid (DiHOME) and 10 µL of antioxidant 
solution (0.2 mg/mL EDTA, butylated hydroxytoluene and triphinylphosphine in 
MeOH/water (50/50, v/v)) were added to the plasma.  Extraction was carried out 
according to 6 different established SPE protocols (a detailed description of all 
procedures can be found in the appendix (App. Table 9.1.1)) and one LLE 
protocol:  
For LLE [15], 500 µL of 1 M sodium acetate (pH 6.0) was added to 500 µL 
plasma. The sample was extracted twice with 750 µL EA. In each step, the 
sample was vortexed for 3 min and centrifuged for 5 min at 4 °C at 20 000 xg.  
For Oasis-EA SPE [10] the plasma sample was mixed with 500 µL MeOH/water 
(5/95, v/v) acidified with 0.1% HAc. After centrifugation (10 min, 4 °C, 20 000 
xg) the supernatant was loaded to a preconditioned Oasis HLB SPE-column (3 
mL, 60 mg, 30 µm particles; Waters, Eschborn, Germany). The column was 
washed with 6 mL MeOH/water (5/95, v/v) acidified with 0.1% HAc and the 
cartridge was dried by low vacuum (~200 mbar) for 20 min. Oxylipins were 
eluted by gravity with 0.5 mL MeOH and 1.5 mL EA. 
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For the Oasis-MeOH SPE [17] the plasma sample was mixed with 500 µL 
MeOH/water (40/60, v/v) acidified with 0.1% formic acid. The sample was 
centrifuged (10 min, 4 °C, 20 000 xg) and loaded to a preconditioned Oasis HLB 
SPE-column (3 mL, 60 mg, 30 µm particles; Waters). The cartridges were 
washed with 3 mL of MeOH/water (20/80, v/v), acidified with 0.1% formic acid, 
dried with low vacuum (~200 mbar, 20 min) and eluted by gravity with 2 mL of 
MeOH. 
For the extraction on the anion exchange column BondElut Certify II [6, 13] the 
plasma was mixed with 500 µL of 1 M sodium acetate buffer (pH 6.0) /MeOH 
(95/5, v/v). The sample was centrifuged (10 min, 4 °C, 20 000 xg) and the 
supernatant was loaded onto a preconditioned BondElut Certify II column (3 
mL, 200 mg, 40 µm particles; Agilent). The cartridges were washed with 3 mL of 
MeOH/water (50/50, v/v) and dried by low vacuum (~200 mbar) for 20 min. 
Analytes were eluted with 2 mL of 75/25 (v/v) n-hexane/EA with 1% HAc 
(AnionEx-Strong) [6], or with 2 mL 25/75 (v/v) n-hexane/EA with 1% HAc 
(AnionEx-Weak) [13]. 
For StrataX SPE [9], 500 µL plasma was mixed with 500 µL MeOH/water 
(20/80, v/v) centrifuged (10 min, 4 °C, 20 000 xg) and loaded onto the 
preconditioned cartridge (3 mL, 100 mg, 33 µm; Phenomenex, Aschaffenburg, 
Germany). The columns were washed with 3.5 mL of 10% MeOH, dried (~200 
mbar, 20 min) and eluted by gravity with 1.0 mL of MeOH. 
For the SepPak tC18 SPE [11,16] 500 µL plasma were mixed with 1500 µL 
MeOH/water (20/80, v/v), centrifuged (10 min, 4 °C, 20 000 xg) and acidified 
with 80 µL pure HAc to a pH of 3.0 directly before loading onto the 
preconditioned SPE column (6 mL, 500 mg, 37-55 µm particle, Waters). 
Samples were washed with 10 mL of water and 6 mL of n-hexane, dried and 
eluted by gravity with 8 mL of methyl formate. 
All organic phases from the protocols were collected in sample tubes containing 
6 µL of 30% glycerol in MeOH. The extracts were centrifuged (10 min, 4 °C, 
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20 000 xg) and evaporated in a vacuum centrifuge (1 mbar, 30 °C, 90-120 min; 
Christ, Osterode, Germany) until only the 2 µL glycerol plug was left. The dried 
residues were immediately frozen at -80 °C. Within 48 h the residues were 
reconstituted in 50 µL of MeOH containing 40 nM of IS2, centrifuged (10 min, 
4 °C, 20 000 xg) and analyzed by LC-MS. 
In a further set of samples, the IS was added after the LLE/SPE to the extracts 
to distinguish between a loss of IS during the extraction and a suppressed ESI 
signal. Samples for ion suppression analysis were prepared without addition of 
IS. 
In order to investigate the effect of the cartridge size, the SepPak was carried 
out with a 3 mL (200 mg) cartridge and the AnionEx-Weak was additionally 
carried out on 6 mL cartridges (500 mg). The volumes for cleaning, 
equilibration, washing and elution were adjusted to the cartridge size. In brief, 3 
mL SepPak cartridges were washed with 5 mL of water and 3 mL of n-hexane 
and eluted with 4 mL of methyl formate. Samples loaded on the 6 mL AnionEx 
columns were washed with one column volume of MeOH/water (50/50, v/v) and 
eluted with 5 mL of 25/75 (v/v) n-hexane/EA with 1% HAc. 
4.2.3 LC-MS analysis 
Quantification of oxylipins was carried out by LC-MS according to the method of 
Yang et al. [10, 20] adapted to the instrument in our laboratory as described in 
detail in the appendix (App. Meth. 9.1.1, Table 9.1.2). 
In brief, separation was carried out utilizing an Agilent 1290 LC on an Agilent 
Zorbax Eclipse Plus C-18 reversed phase column (2.1 x 150 mm, particle size 
1.8 μm) with a gradient of 0.1% aqueous HAc as solvent A and 
ACN/MeOH/HAc (800/150/1, v/v/v) as solvent B. Samples (5 µL) were injected 
by an xt-PAL autosampler (CTC Analytics, Zwingen, Switzerland). The outlet of 
the analytical column was connected to a Valco six-port two-position valve 
implemented in the MS allowing a reduced contamination of the MS source by 
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directing the void volume to waste. Mass spectrometric detection was carried 
out on an AB Sciex 6500 QTRAP instrument (AB Sciex, Darmstadt, Germany) 
in scheduled SRM mode following negative ion electrospray ionization. 
Instrument controlling was performed with Analyst 1.6.2. and data analysis was 
carried out with Multiquant 2.1.1. (AB Sciex). 
Recovery of IS (2H4-6-keto-PGF1α, 
2H4-PGE2, 
2H4-PGD2, 
2H4-TxB2, 
2H4-LTB4, 
2H4-9-HODE, 
2H8-5-HETE, 
2H8-12-HETE, 
2H6-20-HETE, 
2H11-14,15-DiHETrE, 
2H1114(15)-EpETrE, 
2H4-9(10)-EpOME and 
2H4-9,10-DiHOME) was calculated 
by an external calibration (2-40 nM) based on the peak areas. Quantification of 
oxylipins in plasma was performed by an external calibration using 13 
deuterated internal standards (App. Table 9.1.2). For calibration, the analyte to 
IS area ratios were linearly fitted reciprocally weighted by concentration. 
Additionally, the IS 2 peak area (added in the last step of sample preparation) 
was monitored as measure for precision of injection and detection signal over 
the analysis batch and was found to be within (100±10%). For ion suppression 
analysis a 30 nM solution of the IS (2H4-PGE2,
 2H4-PGD2, 
2H4-TxB2, 
2H4-LTB4, 
2H4-9-HODE, 
2H8-5-HETE, 
2H8-12-HETE, 
2H6-20-HETE, 
2H11-14,15-DiHETrE, 
2H1114(15)-EpETrE, 
2H4-9(10)-EpOME and 
2H4-9,10-DiHOME) in MeOH was 
post-columnly added to the eluate of the LC column (flow 0.8 mL/h) and the 
transitions of the compounds (App. Table 9.1.3) were monitored with a dwell 
time of 20 ms. 
 Results 4.3
4.3.1 Recoveries of internal standards 
The % recoveries of the 13 deuterated IS spiked to 500 µL human plasma using 
the SPE protocols are shown in Fig. 4.1 and recoveries with the LLE protocol 
are presented in the appendix Fig. 9.1.1. The results are also shown in more 
detail in the appendix (App. Fig. 9.1.2 and Table 9.1.4). With the LLE protocol, 
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recoveries of all 13 deuterated IS were below 40% (App. Fig. 9.1.1, Table 
9.1.4), which is clearly below the performance of all SPE protocols (Fig. 4.1). 
Furthermore, the intersample (in batch) precision was low with a relative 
standard deviation (RSD) of the IS concentration of >34% for 2H4-6-keto-PGF1α, 
2H4-TxB2, 
2H4-PGE2, 
2H4-PGD2, 
2H4-LTB4 and 
2H4-9,10-DiHOME and 15-26% 
for the other IS (App. Fig. 9.1.1, Table 9.1.4).  
Using the Oasis-MeOH SPE protocol, recoveries of internal standards were 
below 62% (Fig. 4.1), except 2H11-14(15)-EpETrE (68±2.1%). Compared to the 
other SPE protocols the recovery rates were generally low being the lowest 
among all protocols, e.g., for 2H4-LTB4, 
2H4-9,10-DiHOME, 
2H8-12-HETE and 
2H11-14(15)-EpETrE (Fig. 4.1).  
 
Fig. 4.1: Recoveries of internal standards (IS) for the tested SPE protocols. IS was added to the 
samples either at the beginning of the analysis (panel A) or after the SPE-step (panel B). Shown 
is the mean recovery rate ± SD (n=5). 
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Overall good recovery rates (≥65%) were obtained with the AnionEx-Weak 
protocol (Fig. 4.1). Following addition of the IS after the SPE step the 
determined IS concentrations were slightly higher. This indicates that small 
amounts of the analytes were lost during the SPE, probably due to incomplete 
elution from the sorbent bed. Using a less polar elution solvent (AnionEx-
Strong), the polar IS 2H4-6-keto-PGF1α, 
2H4-TxB2, 
2H4-PGE2 and 
2H4-PGD2 were 
almost completely lost during SPE (recovery rates 0-54%) while recoveries 
were above 65% for all other IS. These losses are probably a result of 
insufficient elution during the SPE because recovery rates ≥55% were found 
when adding the IS directly after the SPE step (Fig. 4.1). The AnionEx-Strong 
protocol was designed for the analysis of medium to non-polar hydroxy-, 
dihydroxy- and epoxy-FA [6], thus low recovery rates of the polar prostanoids 
might be less important. However, it is interesting that even the recovery rates 
for the non-polar analytes were slightly better with a more polar elution solvent 
(AnionEx-Weak), though being acceptable (>65%) for the AnionEx-Strong. 
Moreover, the precision of the AnionEx-Strong protocol was low (RSD >17% for 
medium to non-polar analytes) while RSD of the determined IS concentration in 
all other SPE protocols were <10% (App. Table 9.1.4). 
Good overall recoveries (≥68%) were observed for all IS with the SepPak 
protocol, except for 2H4-PGE2 (recovery 41±2.4%). Losses during extraction can 
be ruled out, since there was no difference in the recovery rate of 2H4-PGE2 
between the addition of IS at the beginning of the sample preparation and 
addition of the IS directly after the SPE step (Fig. 4.1, App. Fig. 9.1.2). This is 
consistent with the results from the ion suppression analysis for the 2H4-PGE2 
and 2H4-PGD2 signal (Fig. 4.2A). Strong ion suppression of about 75% of the 
signal was observed exactly at the retention time of 2H4-PGE2 (tR=4.56 min) 
leading to the low recovery rate of 2H4-PGE2 with this protocol. 
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Fig. 4.2: Ion suppression analysis for (A) 
2
H4-PGE2 with SepPak-SPE, (B) 
2
H4-9-HODE with the 
Oasis-EA-SPE and (C-E) for 
2
H4-9(10)-EpOME with all SPE protocols. The retention time 
window of each IS is highlighted in dark grey, the elution window of all analytes using this IS is 
depicted in light grey. 
The Oasis-EA protocol yielded recovery rates ≥64% for all IS, except for 2H4-9-
HODE, 2H8-5-HETE and 
2H4-9(10)-EpOME. Nevertheless, when comparing 
recoveries with direct addition of IS and addition of IS after the SPE step it 
becomes clear that significant amounts of almost all IS were lost during the SPE 
step (e.g., 2H6-20-HETE, 
2H4-9(10)-EpOME and 
2H11-14(15)-EpETrE). For 
2H4-
9-HODE, no differences in the recoveries were observed (Fig. 4.1, App. Fig. 
9.1.2) when adding the IS before the SPE step or after the SPE step. As shown 
in Fig. 4.2B a significant ion suppression takes place in the 2H4-9-HODE signal 
at its retention time providing a mechanistic explanation for the poor recovery 
rate. Similarly, the recovery rate of 2H8-5-HETE with post-SPE addition of IS 
was with 69±4.1% significantly lower than for the other medium to non-polar IS 
(e.g., 89-97% for both epoxides). Ion suppression also occurred for 2H8-5-HETE 
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(App. Fig. 9.1.3E), though not as pronounced as for 2H4-9-HODE. Slight ion 
suppression was also observable for 2H4-9(10)-EpOME (Fig. 4.2F) although the 
recovery rate with post-SPE addition of IS was 89%. 
With the StrataX protocol, low recovery rates (≤55%) were observed for 2H4-
PGD2, 
2H4-9-HODE, 
2H8-5-HETE and 
2H4-9(10)-EpOME (Fig. 4.1). Ion 
suppression accounted significantly for the loss of 2H4-9-HODE (App. Fig. 
9.1.3D) and 2H4-9(10)-EpOME (Fig. 4.2G), although 
2H4-9(10)-EpOME was also 
lost during the SPE step (Fig. 4.1). The loss of 2H4-PGD2 and 
2H8-5-HETE can 
in part also be explained by slight ion suppression (App. Fig. 9.1.3A, Fig. 
9.1.3E). The low recovery rate of 2H8-5-HETE could partly be explained by 
incomplete extraction (Fig. 4.1). Low extraction losses could also be observed 
for 2H4-9,10-DiHOME and 
2H8-20-HETE (Fig. 4.1). 
Overall, the ESI-signal in the ion suppression analysis was flattest with the 
AnionEx protocols followed by the SepPak protocol. Intense negative signals, 
particularly at late retention times occurred with the Oasis-EA, Oasis-MeOH and 
StrataX protocols (Fig. 4.2F-H, App. Fig. 9.1.3). A large number of oxylipins 
elutes at these retention times (App. Table 9.1.2). Thus, ion suppression 
strongly influenced the signal of these oxylipins.  
4.3.2 Extraction of oxylipins from plasma 
Aside from removing ion suppressing matrix compounds, SPE should lead to an 
efficient extraction of oxylipins from plasma. Since all IS were more or less 
affected by the matrix, the absolute peak areas were used as measure for the 
extraction efficacy of oxylipins. Table 4.1 shows the absolute areas of a 
representative set of oxylipins following extraction of 500 µL plasma with the 
different protocols. The areas of all other determined analytes can be found in 
the appendix (App. Table 9.1.5). Consistent with the poor recovery of IS, the 
Oasis-MeOH protocol yielded low peak areas compared to the other protocols 
(e.g., prostanoids, diols, 20-HETE, 5-HETE). With the StrataX protocol low peak 
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areas were obtained, being in the lower range for several epoxy-FA and 
hydroxy-FA and lowest, e.g. for 9(10)-EpOME, 19(20)-epoxy docosapentaenoic 
acid (EpDPE), 9-HODE and 12-HETE. Furthermore, some epoxy-FA could not 
be detected at all, i.e., 11(12)-epoxy eicosatetraenoic acid (EpETE), 8(9)-
EpETE and 13(14)-EpDPE (Table 4.1, App. Table 9.1.5). However, for several 
dihydroxy-FA, the StrataX protocol yielded absolute areas in the higher range 
being highest, e.g., for 14,15-DiHETrE or 17,18-dihydroxy eicosatetraenoic acid 
(DiHETE) (Table 4.1, Table 9.1.5). 
Both AnionEx protocols led to absolute areas of epoxy-FA in the lower range 
compared to the other SPEs and several epoxy-FA could not be detected in the 
AnionEx extracts, e.g., 8(9)-EpETE and 13(14)-EpDPE (Table 4.1, App. Table 
9.1.5). For various hydroxy-FA both protocols yielded areas in the higher range, 
e.g., 9-HODE and 12-HETE, while for dihydroxy-FA overall low peak areas 
were found, e.g. 14,15-DiHETrE (Table 4.1). The Oasis-EA protocol yielded 
intermediate results for the analytes. In a few cases, it led to the highest or 
lowest peak areas, e.g., 5,6-DiHETrE and 15(16)-epoxy octadecadienoic acid 
(EpODE) (App. Table 9.1.5). 
The SepPak protocol yielded for many analytes the highest peak areas (Table 
4.1, App. Table 9.1.5). Only for a few polar analytes, e.g., TxB2 as well as 
PGE2, and for 15-oxo eicosatetraenoic acid (oxo-ETE) larger peaks were found 
with the other SPE protocols. Particularly non-polar epoxy-FA were found to be 
higher with this protocol (Table 4.1, App. Table 9.1.5): Compared to the 
AnionEx-Weak protocol up to 9-fold higher peak areas were found (16(17)-
EpDPE, App. Table 9.1.5) and epoxides could be detected in human plasma 
which were below LOQ using AnionEx and StrataX protocols, e.g., 13(14)-
EpDPE (Table 4.1).  
 
CHAPTER 4 
 
64 
 
Table 4.1:  Peak areas of selected oxylipins obtained after the extraction of 500 µL plasma. 
Shown is the mean ± SD (n=5). The areas of all oxylipins detected are presented in the 
appendix, Table 9.1.5. 
 
*protocol not suited for the analysis of these oxlipins, IS rec <60% 
4.3.3 Cartridge size 
A possible reason for the differences in extraction efficacy is the varying 
cartridge size of the different SPE protocols (60-500 mg stationary phase) [1, 2, 
8, 9, 11, 18, 21]. In order to assess the influence of the amount of stationary 
phase, the SepPak and AnionEx-Weak protocols were compared using 3 mL 
(200 mg) and 6 mL (500 mg) cartridges. The absolute areas of selected 
analytes are shown in Table 4.2 and all analytes are displayed in the appendix, 
Table 9.1.6. Using the SepPak protocol with the smaller column the peak areas 
were for most analytes in the same range as with the original protocol (±20%), 
e.g., TxB2, 14,15-DiHETrE or 20-HETE. However, several analytes, especially 
epoxides, showed significantly higher absolute areas with the larger cartridge 
(120-290% of the area with the smaller cartridge), e.g. 9(10)-EpOME or 14(15)-
EpETE (App. Table 9.1.5 and Table 9.1.6).  
A similar trend was observed for the AnionEx-Weak SPE. With the larger 
column, peak areas of most analytes were within a range of ±20% of the 
[1000 counts]
SepPak 31 ± 1.7 21 ± 2.2 30 ± 1.7 2200 ± 140 220 ± 16 29 ± 5 6500 ± 280
AnionEx-Strong 15 ± 2.0* 22 ± 5.0* 1500 ± 300 180 ± 35 22 ± 4 6000 ± 1100
AnionEx-Weak 39 ± 0.72 36 ± 1.9 27 ± 2.1 1700 ± 53 190 ± 4.2 27 ± 2 6100 ± 180
Oasis-EA 44 ± 14 41 ± 4.4 18 ± 1.6 1500 ± 35 220 ± 7.4 24 ± 2 2400 ± 100
StrataX 29 ± 1.2 62 ± 6.7 4.9 ± 0.95 1400 ± 83 250 ± 19 24 ± 2 2200 ± 97
Oasis-MeOH 26 ± 2 26 ± 1.9 16 ± 2.2 1300 ± 36 150 ± 6.3 23 ± 3 2500 ± 110
SepPak 580 ± 21 340 ± 21 48 ± 9.3 1200 ± 150 32 ± 6.1 63 ± 11 11.6 ± 2.2
AnionEx-Strong 860 ± 180 300 ± 60 8.8 ± 2 260 ± 53 11 ± 2 2.9 ± 0.56
AnionEx-Weak 740 ± 38 280 ± 8.3 10 ± 0.88 310 ± 18 14 ± 1 3.4 ± 0.51
Oasis-EA 370 ± 28 330 ± 13 23 ± 5.8 520 ± 160 6.8 ± 3.2 22 ± 8 9.1 ± 3.8
StrataX 320 ± 18 260 ± 11 11 ± 0.56 180 ± 16 13 ± 1 3.2 ± 0.44
Oasis-MeOH 330 ± 19 200 ± 26 15 ± 1.5 450 ± 29 7 ± 0.8 20 ± 1 4.4 ± 0.65
<LOQ
<LOQ
<LOQ
8(9)- EpETrE
9-HODE
<LOQ*
12-HETE 5-HETE
14(15)-
EpETrE
9(10)-
EpOME
13(14)-
EpDPE
10(11)-
EpDPE
TxB2 PGE2 PGD2
9,10-
DiHOME
14,15-
DiHETrE
20-HETE
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original protocol, while several analytes, mostly dihydroxy-FA, were in a range 
of 120-160% of the original protocol with extraction on the larger column, e.g., 
13,14-dihydroxy docosapentaenoic acid (DiHDPE) or 13-hydroxy 
octadecatrienoic acid (HOTrE) (App. Table 9.1.5 and Table 9.1.6).  
Nevertheless, when comparing the SepPak and the AnionEx-Weak SPE (both 
500 mg, 6 mL cartridge) the absolute areas of most epoxides were still up to 
six- to seven-fold higher with the SepPak SPE, e.g., 16(17)-EpDPE and 9(10)-
EpODE, while peak areas of dihydroxy-FA and hydroxy-FA was in the same 
range (±20%, App. Table 9.1.5 and Table 9.1.6 ). 
Table 4.2: Effect of SPE-cartridge size on the extraction efficacy. Peak areas obtained after 
extraction of 500 µL plasma on 6 mL cartridges (500 mg) were compared to 3 mL cartridges 
(200 mg). Shown is the mean ± SD (n=5). The areas of all oxylipins detected are presented in 
the appendix Table 9.1.6). 
 
4.3.4 Calculated concentrations 
Finally, plasma concentrations of oxylipins were calculated using the analyte/IS 
ratio (App. Table 9.1.2) and external calibrations. Fig. 4.3 shows the 
concentrations of a representative set of eicosanoids determined with the 
different protocols. The concentration of all analytes can be found in the 
appendix, Table 9.1.7.  
[1000 counts]
SepPak 6 mL 31 ± 1.7 21 ± 2.2 30 ± 1.7 2200 ± 140 220 ± 16 29 ± 5.2 6500 ± 280
SepPak 3 mL 36 ± 3.2 10 ± 0.9 23 ± 5.7 2100 ± 150 270 ± 30 29 ± 5.7 7400 ± 320
AnionEx-Weak 3 mL 39 ± 0.7 36 ± 1.9 27 ± 2.1 1700 ± 53 190 ± 4.2 27 ± 2.1 6100 ± 180
AnionEx-Weak 6 mL 40 ± 6.9 24 ± 4.3 24 ± 4.7 2000 ± 330 240 ± 48 28 ± 8.7 8200 ± 830
SepPak 6 mL 580 ± 21 340 ± 21 48 ± 9.3 1200 ± 150 32 ± 6.1 63 ± 11 11.6 ± 2.2
SepPak 3 mL 660 ± 47 340 ± 41 17 ± 1.7 680 ± 46 20 ± 2.5 50 ± 5.1 7.2 ± 0.71
AnionEx-Weak 3 mL 740 ± 38 280 ± 8.3 10 ± 0.88 310 ± 18 14 ± 1.1 3.4 ± 0.51
AnionEx-Weak 6 mL 680 ± 92 300 ± 32 12 ± 2.3 280 ± 39 16 ± 3.3 3.9 ± 0.85
<LOQ
<LOQ
8(9)-EpETrE
9-HODE
12-HETE 5-HETE
14(15)-
EpETrE
9(10)-
EpOME
13(14)-
EpDPE
10(11)-
EpDPE
TxB2 PGE2 PGD2
9,10-
DiHOME
14,15-
DiHETrE
20-HETE
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Fig. 4.3: Calculated oxylipin plasma concentrations with the different SPE protocols: (A) 
prostanoides (B) hydroxy-ARA, (C) dihydroxy-ARA and (D) epoxy-ARA. Internal standards used 
for the quantification of the analytes are shown in the appendix, Table 9.1.2. All results are 
shown as mean ± SD (n=5). It should be noted that panel A does not include the AnionEx-
Strong protocol because it is not suited for the analysis of polar oxylipins. 
For the ARA-derived polar prostanoids TxB2, PGE2 and PGD2, which were all 
quantified with an isotopically labeled surrogate as IS, concentrations were in 
the same range with the different protocols. However, for TxB2 the Oasis-EA led 
to a higher concentration and for PGD2 the StrataX protocol yielded a 
significantly lower concentration. These results were consistent with the peak 
areas of the analytes which were highest for TxB2 with the Oasis-EA and lowest 
for PGD2 with the StrataX protocol (Table 4.1). Though group-specific IS were 
used (App. Table 9.1.2), all protocols also led to overall similar concentrations 
for HETEs and DiHETrEs. However, the plasma concentration of 12-HETE was 
significantly higher for both AnionEx protocols, consistent with the high peaks 
areas for this analyte (Table 4.1). For 11,12-DiHETrE the Oasis-EA and the 
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StrataX protocol yielded lower concentrations compared to the other SPE 
protocols. 
High differences were observed in the concentrations of epoxy-FA. Consistent 
with the peaks areas, the SepPak protocol clearly led to the highest 
concentrations followed by the Oasis-EA and the Oasis-MeOH protocol. 
Interestingly, the precision of the Oasis-EA protocol was low for some epoxides, 
e.g., 11(12)-EpETrE, 8(9)-EpETrE, 5(6)-EpETrE (RSD=43-53%). For the 
AnionEx SPE, 8(9)-EpETrE could not be quantified and 11(12)-EpETrE as well 
as 14(15)-EpETrE for example were detected in a concentration ≤0.20 nM while 
the SepPak protocol yielded concentrations ≥1.1 nM. 
 Discussion 4.4
The aim of the present study was to identify the most appropriate protocol for 
the analysis of free (non-esterified) oxylipins in EDTA plasma. Aside from 
analysis of total oxylipins after liberation of esterified oxylipins by saponification, 
quantification of free oxylipins in plasma is the most commonly carried out 
analysis in studies on the biology of oxylipins (for discussion, see [21, 22]).  
Taking the high costs for standards, cartridges and instrument time into 
account, we did not perform the common tiered step-by-step-optimization 
procedure to develop a sample preparation strategy. Instead, we compared the 
efficacy of well-established sample preparation protocols. All these protocols 
are “fit for purpose” as they have been successfully used to study oxylipin 
biology: The Oasis-EA method is from the Hammock lab (Davis, CA, USA) [10] 
and has also been successfully employed by other groups [8]. Modifications of 
this protocol, e.g., with different eluents, are also commonly used and elution 
with methanol (Oasis-MeOH) according to Balvers et al. [17] was included in the 
comparison. The AnionEx SPE protocols originate from the contract research 
organization (CRO)/laboratory Lipidomix, Berlin, Germany and have been 
successfully employed by the groups of Schunck and Weylandt (Berlin, 
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Germany) [6, 13] among others. The StrataX and the SepPak SPE protocols 
are from the major laboratories in the field of oxylipin research, i.e., Dennis (San 
Diego, CA, USA) [9] and Serhan (Boston, MA, USA) [11]. Also, the LLE protocol 
is commonly used, e.g., by the lab of Fleming (Frankfurt, Germany) [15]. All 
methods were carried out as described by these groups. However, sample 
preparation was in some cases adapted for plasma and the overall procedure 
(waiting times, used glassware, plastic tubes, etc.) was kept the same in order 
to assure comparability (App. Table 9.1.1). The sample volume was set to 500 
µL, since lower volumes are, because of the low concentration of most 
oxylipins, doomed to failure in plasma despite highly sensitive LC-MS 
instruments [14]. 
Regarding the IS recovery rates (Fig. 4.1, App. Fig. 9.1.1, Fig. 9.1.2, Table 
9.1.4), LLE and the Oasis-MeOH SPE are clearly outperformed by the other 
protocols. With the low IS recovery and the low precision, LLE is in our hands 
not an appropriate sample preparation for the analysis of oxylipins in plasma 
and thus excluded from further discussion. With acceptable recovery rates 
(>60%) for few oxylipins Oasis-MeOH SPE seems to be appropriate for specific 
questions. However, compared to the other protocols, there is no reason to 
choose this protocol in targeted oxylipin metabolomics particularly because 
eluting with MeOH and EA (Oasis-EA) yielded much better results and 
acceptable IS recoveries (>60%) except for 2H4-9-HODE, 
2H8-5-HETE and 
2H4-
9(10)-EpOME. The StrataX SPE showed a similar performance, leading to low 
recoveries (<60%) for four IS (2H4-PGD2, 
2H4-9-HODE, 
2H8-5-HETE and 
2H4-
9(10)-EpOME). Ion suppression analysis of the extracts unveiled that both 
StrataX and Oasis SPE insufficiently remove interfering matrix compounds (Fig. 
4.2, App. Fig. 9.1.3). These compounds led to massive ion suppression and 
caused for example the poor recovery of 2H4-9-HODE (Fig. 4.2B, App. Fig. 
9.1.3D) or 2H4-9(10)-EpOME (Fig. 4.2F-H). In comparison, the SepPak and 
AnionEx SPE led to a better removal of matrix and the ion suppression signals 
were smoother and more flat (Fig. 4.2, App. Fig. 9.1.3). For the SepPak SPE 
only a single, strong signal occurred in the ion suppression analysis at tR=4.56 
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min. As a consequence, the recovery of the coeluting 2H4-PGE2 is poor while 
the recovery rate of all other IS is good (68-97%). Nevertheless, the ion 
suppression analysis showed several signals of potentially interfering matrix 
compounds in the SepPak extract. However, these seem not to be prone to 
disturb the analysis since for example the small peak at 15.95 min does not 
cause a relevant suppression of the coeluting 2H4-9(10)-EpOME. The ion 
suppression analysis of the AnionEx extracts was even superior and showed 
only few small peaks. Consistently, the IS recovery for the AnionEx-Weak is 
nearly perfect (all analytes ≥65%). The AnionEx-strong SPE led also to good – 
however not better – recoveries for IS eluting later than 2H4-LTB4, while the 
polar oxylipins were lost.  
The solvent used to elute the broad diversity of oxylipins from the SPE material 
has to be polar enough to elute the polar analytes (AnionEx-Strong vs. 
AnionEx-Weak), but must also possess a sufficiently strong elution power (see 
Oasis-EA vs. Oasis-MeOH) to elute all analytes quantitatively. While all 
protocols simply use polar eluents for equilibration, sample loading and washing 
followed by non-polar eluents for elution, the SepPak protocol utilizes the poor 
elution power of highly non-polar eluents for oxylipins: Here, the polar washing 
step (with water) is followed by a washing step with pure n-hexane (eluting 
potentially interfering lipids [23]), before the oxylipins are eluted with the 
medium polar methyl formate. This results in an efficient reduction of ion 
suppressing matrix, particularly compounds of low polarity are removed. Thus, 
at run times >10 min, the ion suppression signal of the SepPak protocol is 
dramatically better than that of Oasis and StrataX protocols (Fig. 4.2, App. Fig. 
9.1.3). Regarding IS recovery and ion suppression only the AnionEx-Weak 
protocol, making use of the acidic properties of all oxylipins (oxidative fatty acid 
derivatives) can compete with the SepPak protocol. Because of the poor 
recovery of 2H4-PGE2 in the SepPak SPE (Fig. 4.1, Fig. 4.2), the AnionEx-weak 
SPE is overall the best protocol in terms of IS recovery. 
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It is somewhat striking that our results demonstrate that good IS recovery 
seems to not necessarily translate to a high extraction efficacy of oxylipins from 
the plasma matrix (Table 4.1, App. Table 9.1.5). While several oxylipins were 
extracted in the same range by SepPak, StrataX, AnionEx-Weak and Oasis-EA, 
e.g., TxB2, 9,10-DiHOME, 20-HETE, high differences were found for the 
extraction efficacy of analytes of low polarity, e.g., 9(10)-EpOME and 10(11)-
EpDPE. 
The AnionEx-Weak protocol led, even for the latest eluting epoxides, to a better 
extraction efficacy than the AnionEx-Strong protocol (Table 4.1), and thus is for 
all oxylipins investigated, clearly the more appropriate protocol compared to the 
AnionEx-Strong procedure. However, the peak areas of epoxides with the 
AnionEx-Weak were up to seven-fold lower compared to the SepPak SPE. 
Because of the flat ion suppression (Fig. 4.2E, App. Fig. 9.1.3), this effect might 
be caused by poor extraction efficacy rather than by ion suppression. 
Interestingly, the ratio between column dimension and sample volume (analyte 
and matrix amount) was found to be only of minor importance for the extraction 
efficacy. Even with a large 6 mL (500 mg) cartridge, the peak areas of epoxy-FA 
resulting from the AnionEx-Weak protocol were lower than those of the SepPak 
SPE (Table 4.2, App. Table 9.1.6). 
The central aim of the LC-MS analysis of oxylipins is to provide quantitative 
information about their concentration in biological matrices. Compared to other 
LC-MS-based analyses, e.g., residues of pesticides where a heavy isotope 
surrogate is used as internal standard for each analyte, only few isotopically 
labeled oxylipins are available as IS. Thus, a single IS is used for the 
quantification of a group of oxylipins. Typically, 2H4-PGE2 is used for PGs, one 
or few deuterated hydroxy-FA are used as IS for the whole group of hydroxy-
FA, one or few deuterated dihydroxy-FA for the class of dihydroxy-FA and so 
on. Though being structurally similar, the retention time of the analyte differs 
from that of the IS. Thus, the IS cannot compensate for ion suppressing effects 
from the matrix, which directly influence the calculated concentrations. As a 
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result, the different SPE protocols lead to significantly different plasma 
concentrations of the oxylipins (Fig. 4.3, App. Table 9.1.7). One example is the 
ion suppression observed for 2H4-PGE2 with the SepPak protocol and the use of 
2H4-PGE2 for the quantification of other PGs and trihydroxy-ocadecenoic acids 
(TriHOMEs) as carried out in our method (App. Table 9.1.2). As shown in Fig. 
4.3, the determined PGE2 levels are consistent with the other SPE methods 
because the use of the isotopologue as IS is correcting for the ion suppression. 
However, the use of 2H4-PGE2 (rec=41±2.4%) for other PGs leads to an 
overestimation of the analytes and another IS, e.g., 2H4-PGD2 should be used 
for quantification of PGE3, TriHOMEs, PGF2α, PGE1 and LXA4. With these 
adjustment, about 50% lower concentrations for these analytes result (App. 
Table 9.1.8) which are consistent with the concentrations obtained with the 
other protocols (App. Table 9.1.7). 
Overall, the obtained concentrations of several prostanoids, hydroxy-FA and 
dihydroxy-FA were in same range, the determined concentrations of epoxy-FA 
were highly different (Fig. 4.3). Therefore, care must be taken when comparing 
results from studies using different SPE methods. In order to investigate the role 
of oxylipins in biology, their levels always have to be compared within the same 
study using exactly the same analytical method. 
So what is the most appropriate protocol for the analysis of free oxylipins in 
plasma?  
The Oasis-EA protocol efficiently extracts oxylipins from plasma (Table 4.1, 
App. Table 9.1.5). However, IS recovery and analytes are strongly affected by 
severe ion suppression caused by matrix compounds not removed by the 
sample preparation procedure (Fig. 4.1, Fig. 4.2, App. Fig. 9.1.2, Fig. 9.1.3, 
Table 9.1.4). Particularly, the concentration of analytes with a retention time >10 
min could significantly be underestimated because the few IS used cannot 
compensate for the strong ion suppression in the analyte signals. Similarly, ion 
suppression was strong with StrataX and Oasis-MeOH protocols. Despite a 
near perfect removal of ion suppressing matrix and good recovery rates of 
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internal standards, the use of the AnionEx-Weak protocol seems to be 
problematic since the concentration of epoxy-FA is underpredicted or these 
potent lipid mediators [3, 6, 20] are not detected at all. The SepPak protocol 
showed good extraction efficacy and reduction of matrix compounds. 
 Conclusion 4.5
Overall, our data clearly demonstrates that the AnionEx-Weak protocol is most 
efficient in removing interfering matrix components and leads to the overall best 
recovery rates of internal standards. However, the SepPak protocol led to 
higher peaks areas and concentrations of epoxy-FA indicating higher extraction 
efficiency of this analyte group from the plasma samples, while removal of 
interfering matrix was inferior compared to the AnionEx-Weak procedure. 
It should be noted that the ion suppression effects presented here might affect 
other LC-MS methods in another way. Different gradients and RP columns will 
lead to slightly different elution profiles and different coelutions of oxylipins and 
matrix. Further, due to a high inter-individual and inter-species variability of 
biological samples, some of the observed ion suppression effects might be 
different in other samples. Moreover, our conclusions for extraction efficacy and 
precision are only valid for analysis of free oxylipins in human plasma. Other 
sample matrices, e.g. saponified samples or tissue extracts, might lead to 
different results and conclusions. 
  
SAMPLE PREPARATION METHODS FOR OXYLIPINS IN PLASMA 
 
73 
 
 References 4.6
1. Buczynski MW, Dumlao DS, Dennis EA. Thematic Review Series: Proteomics. An 
integrated omics analysis of eicosanoid biology. J Lipid Res. 2009;50(6):1015-1038. 
2. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to 
resolve or not? Am J Pathol. 2010;177(4):1576-1591. 
3. Fischer R, Konkel A, Mehling H, Blossey K, Gapelyuk A, Wessel N, von Schacky C, 
Dechend R, Muller DN, Rothe M, Luft FC, Weylandt K, Schunck WH. Dietary omega-3 fatty 
acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway. J 
Lipid Res. 2014;55(6):1150-1164. 
4. Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnes CM, 
Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, 
Vergilio JA, Pietramaggiori G, Scherer-Pietramaggiori SS, Short SM, Seth M, Lih FB, Tomer 
KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthati VL, Ingber DE, Kaipainen 
A, D'Amore PA, Kieran MW, Zeldin DC. Epoxyeicosanoids stimulate multiorgan metastasis 
and tumor dormancy escape in mice. J Clin Invest. 2012;122(1):178-191. 
5. Zhang G, Panigrahy D, Mahakian LM, Yang J, Liu J-Y, Stephen Lee KS, Wettersten HI, Ulu 
A, Hu X, Tam S, Hwang SH, Ingham ES, Kieran MW, Weiss RH, Ferrara KW, Hammock 
BD. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, 
and metastasis. Proc Natl Acad Sci U S A. 2013;110(16):6530-6535. 
6. Arnold C, Markovic M, Blossey K, Wallukat G, Fischer R, Dechend R, Konkel A, von 
Schacky C, Luft FC, Muller DN, Rothe M, Schunck WH. Arachidonic acid-metabolizing 
cytochrome P450 enzymes are targets of {omega}-3 fatty acids. J Biol Chem. 
2010;285(43):32720-32733. 
7. Chiu CY, Gomolka B, Dierkes C, Huang NR, Schroeder M, Purschke M, Manstein D, Dangi 
B, Weylandt KH. Omega-6 docosapentaenoic acid-derived resolvins and 17-
hydroxydocosahexaenoic acid modulate macrophage function and alleviate experimental 
colitis. Inflamm Res. 2012;61(9):967-976. 
8. Strassburg K, Huijbrechts AM, Kortekaas KA, Lindeman JH, Pedersen TL, Dane A, Berger 
R, Brenkman A, Hankemeier T, van Duynhoven J, Kalkhoven E, Newman JW, Vreeken RJ. 
Quantitative profiling of oxylipins through comprehensive LC-MS/MS analysis: application in 
cardiac surgery. Anal Bioanal Chem. 2012;404(5):1413-1426. 
9. Dumlao DS, Buczynski MW, Norris PC, Harkewicz R, Dennis EA. High-throughput lipidomic 
analysis of fatty acid derived eicosanoids and N-acylethanolamines. Biochim Biophys Acta. 
2011;1811(11):724-736. 
10. Yang J, Schmelzer K, Georgi K, Hammock BD. Quantitative profiling method for oxylipin 
metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. 
Anal Chem. 2009;81(19):8085-8093. 
11. Masoodi M, Mir AA, Petasis NA, Serhan CN, Nicolaou A. Simultaneous lipidomic analysis of 
three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related 
hydroxy-fatty acids by liquid chromatography/electrospray ionisation tandem mass 
spectrometry. Rapid Commun Mass Spectrom. 2008;22(2):75-83. 
CHAPTER 4 
 
74 
 
12. Schuchardt JP, Schmidt S, Kressel G, Dong H, Willenberg I, Hammock BD, Hahn A, 
Schebb NH. Comparison of free serum oxylipin concentrations in hyper- vs. normolipidemic 
men. Prostag Leukotr Ess. 2013;89(1):19-29. 
13. Gomolka B, Siegert E, Blossey K, Schunck WH, Rothe M, Weylandt KH. Analysis of 
omega-3 and omega-6 fatty acid-derived lipid metabolite formation in human and mouse 
blood samples. Prostag Oth Lipid M. 2011;94(3-4):81-87. 
14. Tsikas D, Zoerner AA. Analysis of eicosanoids by LC-MS/MS and GC-MS/MS: a historical 
retrospect and a discussion. J Chromatogr B. 2014;964:79-88. 
15. Fromel T, Jungblut B, Hu J, Trouvain C, Barbosa-Sicard E, Popp R, Liebner S, Dimmeler S, 
Hammock BD, Fleming I. Soluble epoxide hydrolase regulates hematopoietic progenitor cell 
function via generation of fatty acid diols. Proc Natl Acad Sci U S A. 2012;109(25):9995-
10000. 
16. Giera M, Ioan-Facsinay A, Toes R, Gao F, Dalli J, Deelder AM, Serhan CN, Mayboroda OA. 
Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by 
means of LC-MS/MS. Biochim Biophys Acta. 2012;1821(11):1415-1424. 
17. Balvers MGJ, Verhoeckx KCM, Bijlsma S, Rubingh CM, Meijerink J, Wortelboer HM, 
Witkamp RF. Fish oil and inflammatory status alter the n-3 to n-6 balance of the 
endocannabinoid and oxylipin metabolomes in mouse plasma and tissues. Metabolomics. 
2012;8(6):1130-1147. 
18. Taylor PJ. Matrix effects: The Achilles heel of quantitative high-performance liquid 
chromatography-electrospray-tandem mass spectrometry. Clinical Biochemistry. 
2005;38(4):328-334. 
19. Schebb NH, Inceoglu B, Rose T, Wagner K, Hammock BD. Development of an ultra fast 
online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass 
spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in 
pharmacokinetic studies. Anal Methods. 2011;3(2):420-428. 
20. Inceoglu B, Wagner KM, Yang J, Bettaieb A, Schebb NH, Hwang SH, Morisseau C, Haj FG, 
Hammock BD. Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-
related behavior in a rat model of type I diabetes. Proc Natl Acad Sci U S A. 
2012;109(28):11390-11395. 
21. Schebb NH, Ostermann AI, Yang J, Hammock BD, Hahn A, Schuchardt JP. Comparison of 
the effects of long-chain omega-3 fatty acid supplementation on plasma levels of free and 
esterified oxylipins. Prostag Oth Lipid M. 2014. 
22. Shearer GC, Newman JW. Impact of circulating esterified eicosanoids and other oxylipins 
on endothelial function. Current Atherosclerosis Reports. 2009;11(6):403-410. 
23. Yang R, Chiang N, Oh SF, Serhan CN. Metabolomics-lipidomics of eicosanoids and 
docosanoids generated by phagocytes. Curr Protoc Immunol. 2011;Chapter 14:Unit 14 26. 
 
 75 
 
5 Chapter 5 
Development of an Online-SPE-LC-MS/MS Method for 26 
Hydroxylated Polyunsaturated Fatty Acids as Rapid 
Targeted Metabolomics Approach for the LOX, CYP and 
Autoxidation Pathways of the Arachidonic Acid Cascade 
Hydroxylated fatty acids (OH-FAs) are formed in all branches of the arachidonic acid 
(C20:4n6, ARA) cascade from polyunsaturated fatty acids (PUFA). OH-FAs act as potent 
lipid mediators and serve as activity marker for pathways of the ARA cascade, 
particularly the lipoxygenase branch. Current targeted metabolomics methods of the 
ARA cascade cover several OH-FAs among other oxylipins, yet they require long 
runtimes and laborious sample preparation. In the present study we developed a new 
rapid LC-MS method with automated sample preparation for the simultaneous 
quantification of 26 OH-FAs within 6.5 min. Crude biological samples are directly injected 
following addition of four isotopically labeled internal standards and centrifugation. The 
analytes are extracted from the matrix by means of online solid phase extraction on an 
Oasis HLB column at 3.5 mL min
-1
 flow rate. LC separation was carried out on a RP-18 
column with fused core 1.3 µm particles. The method showed a high sensitivity with a 
limit of detection of 0.5-10 fmol on column and a broad linear range. Intra- and inter-batch 
precision and accuracy for the analytes were characterized for cell culture medium as 
well as human plasma and were found to be generally within 100 ± 15%. The method was 
applied to the investigation of OH-FA formation in five cell lines following incubation with 
ARA, eicosapentaenoic acid (C20:5n3, EPA) and docosahexaenoic acid (C22:6n3, DHA). 
The colon cancer cell lines HCA-7 and SW-480, as well as the fibroblast line Balb/c 3T3 
showed significant formation of OH-FAs in the cell culture medium, with dominant 
formation of 15-HETE, 18-HEPE, 20-HDHA and 8-HDHA from the precursor PUFAs. 
Chromatographia, Development of an Online-SPE–LC–MS/MS Method for 26 
Hydroxylated Polyunsaturated Fatty Acids as Rapid Targeted Metabolomics Approach 
for the LOX, CYP, and Autoxidation Pathways of the Arachidonic Acid Cascade, vol. 
78(5), 2015, pp. 415–428, Ostermann AI, Willenberg I, Weylandt KH and Schebb NH. 
With permission of Springer. 
Author contributions: AIO, IW, NHS: Designed research, performed experiments and wrote the 
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 Introduction 5.1
Oxidative metabolites of PUFA are an important class of lipid mediators. 
Particularly, the conversion of ARA by cyclooxygenases (COXs) and 
lipoxygenases (LOXs) to highly potent eicosanoids governing a multitude of 
biological functions has been intensively studied. Recent years have seen the 
discovery of a large number of eicosanoids and oxidation products of other 
PUFA, generally referred to as oxylipins. The routes of formation are diverse 
comprising in addition to the LOX and COX pathways conversion by 
cytochrome P450 enzymes and non-enzymatic (aut)oxidation [1]. The initially 
formed products can in turn be further converted by a multitude of other specific 
enzymes, such as prostaglandin synthases or soluble epoxide hydrolase 
leading to a large number of ARA-derived oxylipins [2]. 
OH-FAs are a main group of products, and are formed in all branches of the 
ARA cascade. In the conversion of ARA by COX-2, 15-hydroxy eicosatetraenoic 
acid (HETE) results as site product [3]. 5-LOX conversion of ARA leads to 5-
hydroperoxy eicosatetraenoic acid (HpETE), 12-LOX conversion to 12-HpETE 
and 15-LOX conversion to 15-HpETE which can be further converted e.g., to 
leukotrienes or are reduced to 5-HETE, 12-HETE and 15-HETE [1]. Other 
important mediators formed from ARA, either by LOX action or by acetylated 
COX-2 after treatment with acetyl salicylic acid are the anti-inflammatory 
multihydroxylated lipoxins [4, 5]. Also, other PUFAs are substrates for these 
reactions, e.g., conversion of linoleic acid (C18:2n6, LA) and alpha-linolenic 
acid (C18:3n3, ALA) to 13-hydroxy octadecadienoic acid (HODE) and 13-
hydroxy octadecatrienoic acid (HOTrE), respectively [6], or conversion of 
docosapentaenoic acid (C22:5n6, DPA) to 17-hydroxy-DPA or 10,17-dihydroxy-
DPA which have been characterized as anti-inflammatory lipid mediators [7, 8]. 
In an analogous manner, OH-FAs result from reduction of hydroperoxides 
formed via autoxidation of PUFAs [9, 10]. Aside from analgesic and anti-
inflammatory epoxy-FA formation by CYP2 isoforms [11, 12], the CYP branch of 
the ARA cascade can give rise to a diverse spectrum of OH-FAs. CYP4 
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enzymes catalyze predominantly hydroxylation at ω or ω-1 position, yielding 20-
HETE and 19-HETE, or the corresponding metabolites of other PUFA. 20-HETE 
has direct biological activity, acting as vasoconstrictor among other functions 
[13]. Moreover, CYP enzymes catalyze further hydroxylation of PUFA to several 
metabolites, such as 11-HETE, 12-HETE and 13-HETE [14].  
The n3 PUFAs, particularly EPA and DHA are also efficiently metabolized by 
the pathways described above [2], thus adding a large number of OH-FAs with 
potential biological activity to the OH-FA lipidome. The formation of important 
OH-FAs derived from ARA, EPA and DHA is summarized in Fig. 5.1. Several of 
the EPA- and DHA-derived OH-FAs, such as 18-hydroxy eicosapentaenoic acid 
(HEPE), 17-hydroxy docosahexaenoic acid (HDHA) and 14-HDHA, are 
precursors of potent multiple hydroxylated lipid mediators such as resolvins, 
protectins and maresins [4, 15]. Of these, particularly for the 15-LOX-derived 
17-HDHA, there are data indicating direct anti-inflammatory properties [8], 
comparable to the multihydroxylated resolvins [16-19]. 
 
Fig. 5.1: Simplified overview about the formation routes of OH-FAs from ARA (red), EPA 
(green) and DHA (blue) analyzed in this study. Shown are the 5, 12, and 15 lipoxygenase 
pathways leading to OH-FAs via an intermediate formation of a hydroperoxide. Moreover, a 
large number of OH-FAs can be formed by (aut)oxidation shown on the right. Note: The CYP4 
mediated ω and ω-1 hydroxylations leading e.g. to 20-HETE are not included in the figure. 
Quantification of OH-FAs can, therefore, be used to assess and understand the 
activity of multiple lipid metabolite formation pathways, e.g. to analyze LOX 
enzyme pathways, instead of analyzing the instable initially formed 
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hydroperoxides. In this context, reliable quantification methods for the 
determination of OH-FAs are indispensable. Several methods for the 
quantification of OH-FAs in biological matrices have been developed. In the 
past, gas chromatography mass spectrometry (GC-MS) following extraction and 
derivatization was used [20]. Though, this technique is still a powerful analytical 
tool [21], nowadays liquid chromatography mass spectrometry (LC-MS) is 
predominantly used for the quantitative analysis of a large number of oxylipins, 
such as OH-FAs. Some of these methods cover a large number of OH-FAs, 
e.g., 37 [22], 21 [23], 17 [24, 25] or 15 [26] among other oxylipins making a 
targeted metabolomics analysis of OH-FA formation feasible. However, with 15-
26 min runtimes, these methods are rather long for modern ultra-high 
performance LC [22, 23, 26]. This impedes sample throughput and thus 
mechanistic studies on the formation and biological role of OH-FAs. In order to 
allow quantification of a comprehensive set of OH-FAs in a large number of 
samples, the aim of the present study was, therefore, the development of a 
rapid LC-MS method with automated sample preparation. The performance of 
the method was thoroughly characterized and the method was validated for 
direct analysis of plasma and cell culture samples. The applicability is 
demonstrated by the comparison of the OH-FA pattern in four different human 
and one murine cell line, formed upon incubation with PUFA ethyl esters. The 
results of this study provide new interesting insights in the OH-FA generation in 
cell lines, which warrants further investigation 
 Experimental 5.2
5.2.1 Chemicals and Biological Materials 
Dulbecco’s modified Eagle’s medium (DMEM), fetal calf serum (FCS) and all 
other cell culture reagents were purchased from Biochrom (Berlin, Germany). 
LC-MS grade acetonitrile (ACN), acetic acid (HAc) and methanol (MeOH) were 
from Fisher Scientific (Nidderau, Germany). Oxylipin standards and internal 
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standards (Table 5.1) were purchased from Cayman Chemicals (local 
distributor: Biomol, Hamburg, Germany). All other chemicals were purchased 
from Sigma Aldrich (Schnelldorf, Germany). HCA-7 cells were from the 
European Collection of Cell Cultures (ECACC, Salisbury, United Kingdom) and 
all other cell lines were from the German Collection of Microorganisms and Cell 
Cultures (DSMZ, Braunschweig, Germany). Pooled human EDTA plasma was 
obtained from healthy male volunteers. 
5.2.2 LC-MS analysis 
Quantification of OH-FAs was carried out by LC-MS with automated sample 
preparation by online-SPE in backflush mode (Fig. 5.2) as described [27]. Two 
binary Agilent 1290 pumps and an Agilent 1290 column oven (Agilent, 
Waldbronn, Germany) equipped with a high-pressure six-port two-position valve 
(valve 1, Fig. 5.2) were used. Samples were kept at 4 °C in an xt-PAL 
autosampler (CTC Analytics, Zwingen, Switzerland) with an injection loop of 20 
µL and a 100 µL syringe; wash solution 1 was 0.1% HAc in water and wash 
solution 2 was ACN. The complete setup is shown in Fig. 5.2. At the beginning 
of each analysis, 5 µL of the sample was transferred through a 0.3 µm SS frit 
(1.3 µL) inlet filter (Agilent part number 5067-4638) and valve 1 to the 1 x 20 
mm Oasis-HLB SPE column (particle size 25 µm, Waters, Eschborn, Germany) 
with a flow of 3.5 mL min-1 0.1% aqueous HAc (solvent A) delivered by pump 1 
(Fig. 5.2). After 30 s, the six-port valve 1 (Fig. 5.2) was switched and the 
analytes were eluted in reversed direction (backflush) with the LC flow (0.5 mL 
min-1) of pump 2. The valve was switched back after 1.5 min. Separation of 
hydroxy-FAs was achieved on a 50 x 2.1 mm Kinetex RP-C18 column filled with 
1.3 µm fused core particles with 100 Ǻ pores (Phenomenex, Torrance, CA USA) 
equipped with a Crude Catcher inlet filter (Phenomenex). The outlet of the 
analytical column and the waste line of the SPE-column were connected to a 
Valco six-port two-position valve (valve 2, Fig. 5.2) implemented in the MS. 
Valve 2 was switched after 1.5 min allowing the separate collection of the 
aqueous waste and reducing contamination of the MS source. 
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For pump 1, solvent A was 0.1% HAc and solvent B was 95/5 ACN/water 
acidified with 0.1% HAc (v/v). Gradients and flow rates are depicted in Fig. 5.2. 
Separation was carried out by the isocratic flow of pump 2 which comprised of 
55% solvent B (800/150/1 ACN/MeOH/HAc v/v) and 45% solvent A 
(water/solvent B 95/5, v/v, acidified with 0.1% HAc). After the separation is 
completed at 5.0 min, the column is cleaned for 0.6 min with 100% solvent B 
(~2 void volumes) and equilibrated at 55% B for 0.3 min as well as during the 
next injection cycle and the SPE extraction (~4 void volumes). 
Mass spectrometric detection was carried out on an AB Sciex 6500 QTRAP 
instrument (AB Sciex, Darmstadt, Germany) in selected reaction monitoring 
(SRM) mode following negative electrospray ionization. The instrument was 
operated with the following parameters: ion spray voltage -4.5 kV, entrance 
potential -10 V, curtain gas 35 psi, gas 1 and gas 2 both 60 psi, temperature 
500 °C. The collision-activated dissociation (CAD) gas was set to high (12 psi) 
and declustering potential (DP), collision energy (CE) and collision cell exit 
potential (CXP) were optimized for each transition as shown in Table 5.1. 
Nitrogen was used as nebulizer, desolvation and collision gas. The instrument 
was operated in scheduled SRM mode with a detection window of ± 12.5 s 
around the expected retention time and a maximum cycle time of 0.5 s. 
Quantification was performed by an external calibration using 4 deuterated 
internal standards (IS, Table 5.1). For calibration, the analyte to IS area ratios 
were linearly fitted reciprocally weighted by concentration. Instrument controlling 
was performed with Analyst 1.6.1 and data analysis was carried out with 
Multiquant 2.2 (AB Sciex). 
Table 5.1:  Parameters of the online-LC-ESI(-)-MS/MS method for the determination of the 
concentration of hydroxy-fatty acids in biological samples. Shown are all analytes covered by 
the current method, the mass transition used for quantification in scheduled SRM mode, the 
electronical MS parameters declustering potential (DP), collision energy (CE), collision cell exit 
potential (CXP), the internal standard (IS), the retention time and its standard deviation (SD), 
peak width (full width at half maximum height (FWHM)), limit of detection (LOD, s/n > 3) and 
limit of quantification (LLOQ, s/n > 9, accuracy ±15%). It should be noted, that the actual 
dynamic range for the quantification in the sample matrix depends on the dilution (2-4 fold for 
plasma and media) during sample preparation. 
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Table 5.1: 
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A breakthrough of OH-FAs was analyzed by connecting the outlet of the SPE 
column (Fig. 5.2) to the MS (split 1:10) and injecting 5-20 µL of a 40 nM 
standard in ACN while keeping the flow at 3.5 mL min-1 100% 0.1% acetic acid 
for 1 min. The transfer time to elute the analytes from the SPE column was 
assessed by removing the analytical column from the setup (Fig. 5.2) and 
directly monitoring the eluate of the SPE column by the flow delivered from 
pump 2. 
Carry over was determined by injecting the highest standard (500 nM of OH-
FAs except for 2000 nM of HODEs) and a subsequent injection of MeOH. Carry 
over was calculated based on the peak area observed in the MeOH injection. 
5.2.3 Sample preparation 
The only sample preparation step carried out was mixing the sample with IS 
solution yielding a final IS concentration of 20 nM followed by centrifugation at 
20 000 xg at 4 °C for 5 min. Cell culture medium samples and plasma samples 
were either mixed with IS solution in ACN 1:1 (v/v; 50 µL+50 µL; 200 µL+200 
µL) or 1:4 (v/v; 25 µL+75 µL). For determination of accuracy and precision, 
DMEM (supplemented with 10% FCS, glutamine, penicillin and streptomycin 
(see below)) and human plasma spiked with a low, medium and high (10, 30, 
100 nM) concentration of the analytes were analyzed as quality control 
samples. The recovery of the OH-FAs was calculated based on the determined 
concentrations in the quality control samples after subtraction of the determined 
concentration in non-spiked matrix samples. Three independently prepared 
samples were analyzed within one batch, and the three samples were analyzed 
in three different batches on three different days. 
5.2.4 Cell culture 
HCA-7, HCT-116, SW480 and HT-29 cells were cultured in DMEM with 10% 
FCS, 2 mM glutamine, penicillin (100 IU mL-1) and streptomycin (100 µg mL-1) 
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in a humidified 37 °C incubator with 5% carbon dioxide. Stock cultures were 
split at a confluence of 70-80% by using trypsin/EDTA and seeded in 6-well 
plate dishes at a density of 500 000 cells/well (HCA-7) and 750 000 cells/well 
(HCT-116, SW480 and HT-29), respectively (8.96 cm2 growth area per well). 
Balb/c 3T3 cells were cultured accordingly using Dulbecco’s modified Eagle’s 
medium/Hams F12 1:1 (DMEM Hams F12) with 5% FCS, 2 mM glutamine, 
penicillin (100 IU mL-1) and streptomycin (100 µg mL-1) and were seeded in 6-
well plate dishes at a density of 250 000 cells/well. 24 h after seeding, the 
medium was removed and replaced by 2 mL medium freshly supplemented with 
a stock solution of ARA, EPA or DHA ethyl ester (EE) (50 mM in ethanol) 
yielding a concentration of 50 µM. The same incubations were carried out with 
and without cells. Medium was sampled before and after 24 hours of incubation 
and all experiments were carried out in quadruplicates. 
 Results and Discussion 5.3
5.3.1 Online-SPE-LC-MS 
A central aim of our study was the development of a LC-MS method for the 
rapid quantification of the major OH-FAs from all the biologically relevant 
PUFAs: LA, ALA, ARA, EPA and DHA. In order to allow high throughput, the 
analysis time was kept short and the manual sample preparation was 
minimized. As demonstrated for the analysis of epoxy-FAs and dihydroxy-FAs 
[28], sample preparation in oxylipin analysis can be reduced by means of 
online-SPE. Similar to this study, online-SPE was carried out with a basic 
backflush set-up (Fig. 5.2) using an SPE column filled with large particles at 
high flow rates [28-30]. The setup was extended by a second six-port valve 
allowing the separate collection of aqueous from organic waste thus preventing 
contamination of the MS-source by directing the void volume of the analytical 
column to waste (Fig. 5.2) [27]. 
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The OH-FAs were fully extracted by the online-SPE using Oasis HLB material 
(Waters) which is commonly used for the offline SPE of oxylipins [25, 26]. No 
breakthrough was detected following injections of standards in ACN up to an 
injection volume of 20 µL. Thus, it can be assumed that the analytes are 
robustly and efficiently extracted following injection of 5 µL biological samples 
containing less organic solvent. After switching of the six-port valve 1 (Fig. 5.2), 
the analytes were rapidly eluted from the SPE column by the flow of pump 2 
and transfer of all OH-FAs was completed after 1.2 min. The six-port valve 
could, therefore, be switched back at 1.5 min before the elution and detection of 
the OH-FAs.  
 
Fig. 5.2: Online-SPE-LC-MS setup (left). Following addition of IS solution and centrifugation the 
crude samples are directly injected. The samples are transferred onto the SPE column by the 
flow of pump 1. The flow rate and gradient of pump 1 are depicted on the right. After 0.5 min 
the six-port valve 1 is switched and the analytes are transferred from the SPE to the separation 
column and separated by the isocratic flow of pump 2. The second valve further prevents 
contamination of the MS source and allows collecting the aqueous waste separately from the 
organic waste. 
The used separation column combines the high chromatographic resolution of 
an efficient mass transfer and high surface area of small particles with equal 
distribution of diffusion paths of fused core particles [31]. Indeed the separation 
efficiency of the OH-FAs was high, leading to narrow peaks with a full width at 
half maximal height (FWHM) of about 3 s corresponding to a high number of 
theoretical plates, e.g., 19 x105 for 8-HETE (Fig. 5.3C; Table 5.1). The 
structurally similar analytes eluted in a short retention time window of 1.8 min 
between 1.8 and 3.6 min total analysis time (Fig. 5.3). The best separation was 
obtained using isocratic conditions for transfer and separation. 
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Despite the application of online-SPE, narrow peaks (small FWHM) were 
obtained for HODEs, HOTrEs, HETEs and HEPEs. Also, the stronger retained 
HDHAs showed only low or moderate tailing. Only for 4-HDHA, eluting more 
than 0.5 minutes later than all other OH-FAs, significant tailing was observed, 
which was with a FWHM of 3.6 sec still acceptable (Fig. 5.3). 
 
Fig. 5.3: Separation efficiency of the developed method. Shown are the SRM signals used for 
quantification following injection of a multianalyte standard (20 nM). A: LA derived HODEs, B: 
ALA derived HOTrEs, C: ARA derived HETEs, E: EPA derived HEPEs and F: DHA (22:6) 
derived HDHAs. The critical separation pair 12-/9-HETE is shown superimposed in panel D. 
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As a result of the separation efficiency, the OH-FA regioisomers were well 
resolved. For example, 5 of the 7 analyzed HETEs and 4 out of 5 analyzed 
HEPEs were (almost) baseline separated (Fig. 5.3). Nevertheless, several 
regioisomers eluted together. Almost perfect co-elution occurred for 8-HETE 
and 12-HETE as well as 10-HDHA and 14-HDHA, whereas regioisomers of 
HODEs and HOTrEs as well as 12-HETE and 9 HETE, 12-HEPE and 8-HEPE 
and different HDHAs were not fully separated (Fig. 5.3). Moreover, the OH-FAs 
of the different PUFA coeluted. 
Regarding these limitations, it should be noted that even methods using longer 
separation columns (with more theoretical plates), slower gradients and thus 
longer runtimes do not allow to fully resolve the structurally so similar OH-FAs 
chromatographically. For example, in the method of Yang et al. [24, 25] and 
Strassburg et al. [26], using a 150 x 2.1 mm column with 1.8 µm or 2.7 µm 
particles and gradients of 21-25 min, co-elutions occurred. Likewise, the 
retention times of the method used by Gomolka et al. on a 150 x 2.1 mm 
column with 3.5 µm particles were similar, indicating the co-elution of several 
OH-FAs [23]. Also, after derivatization to N-(4-aminomethylphenyl) pyridinium 
amides – improving ESI(+) detection sensitivity – co-elutions occurred, e.g., of 
11-HETE and 12-HETE [32]. Overall it has to be concluded that reversed phase 
chromatography alone is not sufficient for a specific detection of OH-FAs. Since 
regioisomers have the same (exact) mass (Table 5.1), detection in selected 
reaction monitoring, based on the different fragmentation of the regioisomers is 
indispensable to specifically quantify the OH-FAs independently from one 
another by means of LC-MS. 
Similar to previous LC-MS methods [22, 25, 26, 33, 34], detection was carried 
out following negative ESI ionization based on the fragment resulting from β-
cleavage of the carbon-carbon-bond adjacent to the hydroxyl group. Taking 
localization of the negative charge at the carboxyl group into account, the 
dominant fragment ions with chain lengths according to the position of the 
hydroxyl group (n) or n-1 were used for quantification (Table 5.3). Only for 11-
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HDHA, 17-HDHA and 20-HDHA different transition ions were used as described 
[23]. 
Following injection of standard mixtures, multiple peaks were observed in the 
signals of several transitions (Fig. 5.3). For example, the transition m/z 
319167 (9-HETE) yielded a signal for 9-HETE, 12-HETE and 15-HETE and 
m/z 319179 (12-HETE) for 12-HETE and 9-HETE (Fig. 5.3). Moreover, in the 
transition of m/z 343121 (11-HDHA) a strong signal is observed for 17-HDHA 
(Fig. 5.3, App. Fig. 9.2.1). Thus, SRM detection of OH-FAs is – as well known 
for other oxylipins [25] – far away of being fully specific and analysis of OH-FAs 
requires an efficient chromatography. 
In the presented method, only one critical separation pair [25], with interfering 
SRM transitions and incomplete chromatographic separation, was identified: 12-
HETE and 9-HETE (Fig. 5.3). MS/MS analysis of both compounds failed to 
deduce a fragment which was exclusively formed by one of the two analytes 
allowing a more specific detection. All dominant fragments formed from the [M-
H]- ion of 9-HETE resulted also from 12-HETE fragmentation (see fragmentation 
pattern in [35]). Nevertheless, the separation was sufficient for reproducible 
integration yielding good accuracy and precision of both HETEs (see below). 
The limit of detection (LOD) for the different OH-FAs, defined as signal/noise 
ratio (s/n) = 3, was determined as 0.1-2 nM (Table 5.1) corresponding to 0.5-10 
fmol on column. With this performance, the method is more sensitive or 
comparable to state of the art targeted metabolomics LC-MS methods of 
oxylipins with LODs of 0.2-4.2 nM [26], 0.01-0.21 ng (~30-600 fmol) [23], 10-30 
pg (~30-90 fmol) [36], 0.1-1 pg (~0.3-3 fmol) [22], 10-20 pg (~30-60 fmol) [33] 
and 0.2-10 pg (~0.6-30 fmol) on column [32] or reported lower limits of 
quantification (LLOQs) of 0.1-5 nM [25].  
Using four deuterated OH-FAs as IS at a concentration of 20 nM, an excellent 
linear correlation of the signal was obtained (R2>0.997). The LLOQ, defined as 
s/n = 9 and ±15% accuracy of the calibration curve, ranged for the OH-FAs 
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between 0.25-5 nM. This sensitivity allows the quantification of a large number 
of OH-FA in cell culture samples (see below). However, the low concentration of 
several OH-FA in plasma and serum samples [6, 37] might require a pre-
concentration on the SPE column and thus higher injection volumes than tested 
in this study. For all analytes, the upper limit of quantification was not reached 
by the highest standard injected indicating a dynamic range of more than three 
orders of magnitude. Despite the use of SPE, carry over was found to be 
negligible, being highest for the strongest retained 4-HDHA with 0.11±0.01% 
(n=3) and lowest for the polar 9-HOTrE with 0.05±0.001% (n=3). 
The performance of the method for the quantitative analysis of OH-FAs in 
biological samples was characterized oriented on the Guideline on bioanalytical 
method validation of the European Medicine Agency 2011 
(EMEA/CHMP/EWP/192217/2009). For this purpose, matrix samples were 
spiked at low (10 nM), medium (30 nM) and high analyte levels (100 nM) and 
analyzed within one batch and in different batches.  Two types of biological 
matrices were used: (i) cell culture medium (DMEM) with 10% FCS 
representing the matrix of the samples from cell culture analyzed below and (ii) 
human plasma as matrix containing more protein, lipids and other potentially 
interfering matrix compounds.  
Table 5.2: Recovery of IS in cell culture medium and plasma. Recovery was determined based 
on the peak area of the IS relative to the IS peak area in a matrix-free standard of the same 
concentration (20 nM). Shown are mean and SD of quadruplicate injections of 24 independently 
prepared samples per matrix. 
 sample:IS d6-20-HETE d4-9-HODE d8-12-HETE d8-5-HETE 
cell 
medium 
1:1 80 ± 9 80 ± 5 76 ± 10 76 ± 10 
1:4 96 ± 12 98 ± 8 94 ± 12 93 ± 12 
plasma 
1:1 80 ± 9 80 ± 5 76 ± 10 76 ± 10 
1:4 100 ± 10 83 ± 5 92 ± 10 92 ± 11 
The only sample preparation step was mixing the sample with IS 1:1 or 1:4 
followed by centrifugation. As shown in Table 5.2, the recovery rates of the 
internal standards obtained in both matrices were higher than 75% indicating 
efficient extraction from the matrix and low ion suppression. It is interesting that 
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these levels exceed by far the IS recovery rates for OH-FAs described for 
classical offline SPE using the same Oasis HLB material [26]. 
For the analysis of cell culture samples, the accuracy for all spike-levels was 
good (within 100±15%, Table 5.3). Similarly, high intra-batch and inter-batch 
precisions of better than 15% were found. As expected, the variation increased 
getting close to the LLOQ. Thus, the OH-FAs with a better, i.e., lower LLOQ 
were determined in the low spiked levels at higher precision (Table 5.3). No 
apparent differences were observed for mixing IS 1:1 or 1:4 (v/v), indicating 
dilution integrity and thus efficient removal of potentially interfering matrix from 
cell culture medium by the online-SPE step. 
For the analysis of plasma mixed 1:1 (v/v) with IS solution, the matrix influenced 
the signals of the OH-FAs. For the early eluting HEPEs, 13-HODE and 13-
HOTrE using 2H4-9-HODE as IS slightly too high recovery rates (120-130%) 
were observed. This could be caused by a higher ion suppression at the IS 
retention time of 2.4 min compared to the slightly different retention time window 
of the analytes (Table 5.1). At a higher dilution with IS (1:4, v/v), acceptable 
recovery rates (100±15%) were observed and thus matrix effects could be 
diluted out. This supports the assumption that the higher than supposed levels 
at 1:1 dilution are caused by ion suppression/ion enhancement effects of the 
matrix. All other OH-FAs were determined with good accuracy in spiked quality 
control plasma at both dilutions, except for few outliers (8-HETE, 12-HETE and 
9-HETE with still tolerable recovery rates of about 72-80%). Overall intra- and 
inter-batch precision was high and better than 15% (Table 5.3). However, for 
1:1 dilution of plasma, few analytes such as 20-HETE or 17-HDHA were 
determined at low concentrations with low precision. This high variation might 
be problematic for the analysis of biological samples by masking physiological 
effects. 
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Table 5.3: Accuracy and precision of the method. Cell culture medium including 10% FCS and 
human plasma were spiked at low, medium and high concentration (10, 30, 100 nM) of the OH-
FAs. The samples were either prepared by mixing 1:1 (v/v) or 1:4 (v/v) with IS solution as 
indicated in the rows. Recovery (accuracy) and SD (variation) were determined for 3 
independent samples analyzed within one batch (intra batch accuracy & precision) and within 3 
batches on 3 different days (inter batch accuracy & precision). 
    LA ALA ARA 
 
   
13- 
HODE 
9- 
HODE 
13- 
HOTrE 
9- 
HOTrE 
20- 
HETE 
15- 
HETE 
11- 
HETE 
8- 
HETE 
12- 
HETE 
9- 
HETE 
5- 
HETE 
p
la
s
m
a
 
1:1 
in
tr
a
 10 78 ± 7 97 ± 7 135 ±4  101 ± 1 108 ± 16 105 ± 8 102 ± 3 78 ± 5 76 ± 2 80 ± 12 96 ± 3 
30 94 ± 16 100 ± 7 134 ±6  106 ± 3 107 ± 7 107 ± 0 107 ± 3 79 ± 3 78 ± 2 92 ± 4 105 ± 6 
100 97 ± 1 96 ± 2 123 ±1  100 ± 4 99 ± 6 98 ± 1 100 ± 1 73 ± 1 72 ± 3 82 ± 6 100 ± 3 
in
te
r 
10 91 ± 26 98 ± 14 143 ±7  107 ± 4 112 ± 45 93 ± 9 110 ± 11 77 ± 4 84 ± 7 81 ± 19 96 ± 6 
30 91 ± 21 97 ± 3 134 ±5  104 ± 6 108 ± 4 106 ± 13 111 ± 1 82 ± 3 82 ± 7 90 ± 7 106 ± 7 
100 93 ± 14 98 ± 2 125 ±4  101 ± 4 100 ± 9 102 ± 8 102 ± 5 75 ± 7 76 ± 6 88 ± 1 101 ± 5 
1:4 
in
tr
a
 10 109 ± 2 96 ± 1 118 ±17  102 ± 2 94 ± 2 102 ± 2 104 ± 6 73 ± 23 81 ± 2 89 ± 6 96 ± 4 
30 102 ± 7 93 ± 10 110 ±14  104 ± 3 92 ± 12 97 ± 8 106 ± 2 76 ± 13 80 ± 6 97 ± 23 100 ± 2 
100 94 ± 1 95 ± 1 108 ±2  105 ± 1 99 ± 4 99 ± 3 101 ± 3 83 ± 1 79 ± 2 80 ± 7 92 ± 3 
in
te
r 
10 111 ± 3 95 ± 3 108 ±18  112 ± 16 97 ± 19 108 ± 10 100 ± 3 72 ± 3 79 ± 8 79 ± 10 92 ± 5 
30 103 ± 4 93 ± 5 114 ±2  108 ± 9 111 ± 22 100 ± 13 109 ± 3 77 ± 7 80 ± 3 90 ± 9 99 ± 2 
100 96 ± 2 97 ± 2 111 ±1  109 ± 3 99 ± 7 105 ± 8 106 ± 4 79 ± 5 78 ± 3 80 ± 4 99 ± 6 
c
e
ll
 m
e
d
iu
m
 
1:1 
in
tr
a
 10 99 ± 3 100 ± 4 103 ±5  100 ± 2 99 ± 9 106 ± 5 110 ± 7 107 ± 5 101 ± 7 101 ± 7 103 ± 2 
30 95 ± 3 97 ± 3 96 ±5  97 ± 2 97 ± 0 101 ± 4 97 ± 4 97 ± 4 95 ± 5 97 ± 5 99 ± 2 
100 88 ± 3 88 ± 2 87 ±3  87 ± 2 87 ± 3 96 ± 1 93 ± 2 96 ± 5 91 ± 2 89 ± 5 91 ± 3 
in
te
r 
10 101 ± 7 101 ± 3 104 ±5  94 ± 5 104 ± 12 109 ± 11 111 ± 3 107 ± 9 104 ± 3 96 ± 3 102 ± 2 
30 95 ± 3 97 ± 3 97 ±2  97 ± 2 100 ± 5 102 ± 1 104 ± 6 103 ± 5 104 ± 7 97 ± 7 100 ± 1 
100 88 ± 2 89 ± 3 89 ±2  89 ± 3 88 ± 3 96 ± 8 91 ± 5 95 ± 6 93 ± 8 94 ± 3 91 ± 2 
1:4 
in
tr
a
 10 97 ± 5 96 ± 4 93 ±6  92 ± 5 109 ± 13 105 ± 6 104 ± 4 100 ± 7 105 ± 5 99 ± 4 105 ± 1 
30 93 ± 3 95 ± 3 91 ±4  90 ± 2 102 ± 6 100 ± 3 99 ± 4 103 ± 4 96 ± 7 92 ± 9 97 ± 5 
100 89 ± 5 92 ± 4 86 ±4  87 ± 3 89 ± 2 95 ± 3 95 ± 5 95 ± 4 95 ± 4 90 ± 5 91 ± 2 
in
te
r 
10 98 ± 2 99 ± 2 99 ±2  94 ± 7 93 ± 11 108 ± 5 105 ± 0 102 ± 10 101 ± 0 93 ± 6 107 ± 3 
30 94 ± 3 95 ± 3 90 ±1  90 ± 3 101 ± 7 102 ± 4 101 ± 1 103 ± 4 98 ± 5 101 ± 6 102 ± 1 
100 87 ± 4 89 ± 10 87 ±2  86 ± 2 88 ± 5 98 ± 6 95 ± 4 96 ± 5 97 ± 2 94 ± 4 94 ± 0 
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Table 5.3: Continued. 
    EPA DHA 
 
   
18- 
HEPE 
15- 
HEPE 
8- 
HEPE 
12- 
HEPE 
5- 
HETE 
17- 
HDHA 
14- 
HDHA 
7- 
HDHA 
4- 
HDHA 
p
la
s
m
a
 
1:1 
in
tr
a
 
10 131 ± 3 125 ± 2 131 ± 6 123 ± 5 124 ± 3 81 ± 10 90 ± 10 88 ± 3 90 ± 3 
30 134 ± 2 125 ± 4 125 ± 3 121 ± 5 123 ± 3 90 ± 4 98 ± 3 89 ± 3 92 ± 6 
100 122 ± 3 121 ± 3 117 ± 2 113 ± 3 115 ± 2 83 ± 1 91 ± 3 81 ± 3 87 ± 3 
in
te
r 
10 132 ± 5 122 ± 9 127 ± 6 123 ± 6 118 ± 4 119 ± 41 99 ± 2 83 ± 3 89 ± 5 
30 129 ± 5 123 ± 5 122 ± 6 119 ± 7 120 ± 5 98 ± 8 92 ± 7 87 ± 4 93 ± 4 
100 120 ± 3 120 ± 5 116 ± 2 115 ± 3 114 ± 1 85 ± 2 88 ± 9 82 ± 4 87 ± 3 
1:4 
in
tr
a
 
10 115 ± 2 108 ± 10 113 ± 4 114 ± 7 104 ± 7 107 ± 6 100 ± 8 93 ± 8 90 ± 2 
30 110 ± 5 115 ± 3 110 ± 3 112 ± 3 106 ± 2 92 ± 14 96 ± 2 93 ± 6 90 ± 2 
100 110 ± 1 108 ± 2 105 ± 2 105 ± 1 102 ± 2 93 ± 0 96 ± 4 88 ± 2 85 ± 2 
in
te
r 
10 112 ± 8 112 ± 12 107 ± 2 108 ± 3 101 ± 8 96 ± 9 91 ± 11 84 ± 3 85 ± 4 
30 110 ± 2 112 ± 6 107 ± 2 109 ± 5 104 ± 3 103 ± 1 96 ± 13 91 ± 8 89 ± 7 
100 108 ± 5 106 ± 5 104 ± 5 104 ± 5 102 ± 7 101 ± 13 100 ± 3 89 ± 4 84 ± 7 
c
e
ll
 m
e
d
iu
m
 
1:1 
in
tr
a
 
10 102 ± 2 102 ± 3 99 ± 3 92 ± 1 99 ± 3 95 ± 14 108 ± 16 92 ± 7 96 ± 3 
30 96 ± 3 93 ± 6 95 ± 3 93 ± 3 94 ± 4 92 ± 10 94 ± 2 88 ± 6 93 ± 3 
100 86 ± 3 86 ± 3 87 ± 2 86 ± 2 87 ± 1 96 ± 7 93 ± 2 83 ± 1 88 ± 2 
in
te
r 
10 102 ± 3 102 ± 3 98 ± 3 93 ± 2 97 ± 1 92 ± 7 106 ± 16 83 ± 3 93 ± 2 
30 92 ± 4 92 ± 5 91 ± 2 89 ± 5 92 ± 5 93 ± 7 88 ± 4 87 ± 4 90 ± 3 
100 85 ± 2 85 ± 1 86 ± 1 85 ± 2 85 ± 1 86 ± 5 89 ± 7 82 ± 4 87 ± 5 
1:4 
in
tr
a
 
10 99 ± 6 97 ± 8 94 ± 10 91 ± 2 97 ± 6 104 ± 21 104 ± 11 98 ± 12 101 ± 2 
30 90 ± 4 92 ± 3 90 ± 3 89 ± 2 91 ± 1 96 ± 9 101 ± 5 97 ± 6 96 ± 2 
100 88 ± 5 88 ± 3 87 ± 5 88 ± 5 87 ± 3 91 ± 7 97 ± 4 92 ± 3 91 ± 4 
in
te
r 
10 101 ± 4 103 ± 4 97 ± 8 89 ± 6 97 ± 8 110 ± 15 106 ± 7 104 ± 7 93 ± 14 
30 91 ± 2 92 ± 3 90 ± 4 88 ± 3 87 ± 6 94 ± 9 101 ± 6 100 ± 5 95 ± 3 
100 85 ± 3 87 ± 4 86 ± 6 87 ± 3 85 ± 5 97 ± 6 95 ± 6 92 ± 4 90 ± 4 
Based on these method characteristics, it is concluded that the developed rapid 
analysis method allows the sensitive determination OH-FAs in crude medium 
and plasma samples with good accuracy and precision. With the simultaneous 
detection of 26 analytes the developed method allows determining a 
comprehensive pattern of enzymatically and non-enzymatically formed OH-FAs. 
This makes a targeted metabolomics analysis of the pathways of the ARA 
cascade easily feasible. Only the method described by Dennis and Coworkers 
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[22] covers with 37 more OH-FAs, whereas other targeted metabolomics 
methods of the ARA cascade provide only quantitative information on fewer 
OH-FAs, e.g., 21 [23], 17 [24, 25] 15 [26] and 14 [33]. With a total analysis time 
of 6.5 min, the developed method is at the same time faster and can compete 
with all other approaches in terms of sensitivity, accuracy and precision (see 
above). Only the method of Miller is with 6 min equally fast, but covers only 3 
OH-FAs [34]. Most importantly, the developed method allows the direct injection 
of samples after IS addition and centrifugation due to automated sample 
preparation by online-SPE. All other LC-MS-based targeted metabolomics 
approaches for the analysis of OH-FAs utilize classical (offline) SPE impeding 
sample throughput. Since sample preparation and analysis time is fast, our 
approach allows the analysis of about 200 samples per day by a single 
operator. This makes – for the first time – a detailed analysis of the formation of 
OH-FAs as lipid mediators and pathway markers in the ARA cascade in large 
sample sets, e.g., from cell cultures, feasible. 
5.3.2 Analysis of OH-FA pattern in cell culture 
Cell culture of cell lines from different human tissues has become the standard 
tool for the mechanistic investigation of cellular pathways and regulatory 
networks. Surprisingly few information is available on the oxylipin pattern 
formed by these models [35, 38-40]. This may be explained by the long 
runtimes and laborious sample preparation of today´s LC-MS-based targeted 
metabolomics methods.  
In order to demonstrate that our rapid approach is well-suited for mechanistic 
studies of lipid mediator formation in cell culture, we investigated 4 human colon 
carcinoma cell lines and a murine fibroblast cell line after incubation with the 
ethyl ester of either ARA, EPA or DHA (50 µM). Before incubation, no or very 
low OH-FA levels (<10 nM) were detected in the cell supernatant media. 
Similarly, in non-supplemented medium no relevant formation of OH-FAs 
(<10 nM) was found. By contrast, following 24 h incubation of cell culture 
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medium with 50 µM PUFA-EE a strong formation of OH-FAs was observed in 
HCA-7, SW-480 and Balb/c 3T3 cells (Fig. 5.4), whereas HT-29 and HCT-116 
cells showed no product formation compared to cell free controls (App. Fig. 
9.2.2).  
 
Fig. 5.4: Formation of OH-FAs in cell culture medium. HCA-7 (A), SW480 (B) and BALB/c 3T3 
(C) were incubated with PUFA ethyl esters (50 µM) for 24 hours. Shown is the concentration of 
an incubation with (dark grey) and without cells (light grey) reflecting formation by hydrolysis 
and autoxidation. Incubations for every cell line were carried out with ARA, EPA and DHA. The 
concentrations in the media before incubation and in incubations without addition of PUFA were 
below 10 nM (not shown). All results are given as mean±SD (n=4). 
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Incubation of HCA-7 cells with ARA-EE led to a dominant formation of 15-HETE 
(567±100 nM) followed by about 200 nM of 11-HETE, 8-HETE and 12-HETE 
(Fig. 5.4A, left column). In presence of EPA-EE 18-HEPE was detected at 
highest concentration (218±48 nM) followed by 15-HEPE, 8-HEPE, and 12-
HEPE with about 60 nM. DHA-EE was converted by the HCA-7 cells to a 
diverse pattern of HDHAs with highest concentration for 20-HDHA (357±131 
nM) and 8-HDHA (383±137 nM), followed by 17-HDHA (259±98 nM) and 14-
HDHA (194±78 nM), whereas for 16-HDHA, 13-HDHA, 10 HDHA, 11-HDHA 
and 7-HDHA a concentration of about 100 nM was found. SW480 cells 
produced overall the same pattern and concentration of HETEs and HDHAs 
following incubation with ARA-EE and DHA-EE respectively (Fig. 5.4B). 15-
HETE as well as 20-HDHA and 8-HDHA were formed dominantly. Interestingly, 
the conversion of EPA by SW480 cells was much lower compared to HCA-7 
cells (Fig. 5.4B, middle). A similar low conversion of EPA was observed for the 
fibroblasts Balb/c 3T3 which only exceeded the control incubations without cells 
for 18-HEPE and 8-HEPE (Fig. 5.4C middle). For Balb/c 3T3, the conversion 
rate of DHA was also about five fold lower than for the two colon cell lines (Fig 
5.4C, bottom). However, the overall pattern of metabolites formed was 
consistent: All HDHAs were generated except for 4-HDHA with a dominant 
formation of 20-HDHA, 8-HDHA and 17-HDHA. Generation of HETE from ARA 
EE was also slightly lower; however, with 417±28 nM 15-HETE was formed in 
the same range as with the other cell lines. The overall similar pattern of OH-
FAs generated by these three cell lines implies a rather unspecific formation, or 
common pathways in the two colon cell lines and the fibroblast cell line. 
Nevertheless, when assaying the colon carcinoma cell lines HT-29 and HCT-
116 under the same conditions, no or only slightly elevated concentrations of 
OH-FAs compared to the control could be detected. This indicates that 
formation of OH-FA is highly cell line-dependent. For all incubations, high 
standard deviations (>35%) in the determined OH-FA concentrations were 
observed, e.g. 8-HDHA and 20-HDHA (Fig. 5.4). Because the precision in 
spiked medium (see above) was generally ≤15% (Table. 5.3) it is concluded 
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that these high variations are based on differences in the incubations rather 
than low performance of the analytical method. 
Regarding the control incubations of culture media without cells, high 
concentrations of OH-FAs were detected; particularly of 15-HETE, 5-HETE, 18-
HEPE, 5-HEPE and 4-HDHA. Thus, relevant hydrolysis of the PUFA-EE to 
PUFA and hydroxylation occurs directly in the medium (Fig. 5.4). This might 
primarily be triggered by components of the fetal calf serum added to the cell 
culture media, and could be due to auto-oxidation processes in this context. 
However, levels in the presence of the HCA-7 cells discussed above exceeded 
the concentration in the controls by at least a factor of 2-3. Thus, dominant 
routes of formation for the OH-FAs observed with this cell line and for HDHAs 
as well as 11-, 8- and 12-HETE by SW480 and Balb/c 3T3 seem to be 
absorption of PUFA-EEs in the cell, enzymatic hydrolysis and conversion to 
OH-FAs with subsequent release to the cell culture medium. 
It is interesting that the concentrations of 5-LOX products, i.e., 5-HETE, 5-HEPE 
and 4-HDHA were slightly lower (3-20%) in the presence of the cells compared 
to control incubations without cells. It is reasonable to assume that these OH-
FAs are also formed in the media during incubation with cells. The initially 
formed 5-HETE, 5-HEPE and 4-HDHA are probably then absorbed and 
converted by the HCA-7, SW-480 and Balb/c 3T3 cells instead of being 
released to the medium. Different fates of the OH-FAs in the cells can be 
considered, ranging from esterification and incorporation into lipids [37], 
conjugation to glucuronic acid (phase II metabolism) [41, 42] or processing to 
further lipid mediators, e.g., multihydroxylated PUFA [5]. For 5-HETE further 
oxidation to 5-oxo-ETE by 5-hydroxyeicosanoid dehydrogenase (5-HEDH) [43] 
as well as hydroxylation by 15-LOX to 5,15-DiHETE [44] are well-characterized 
pathways. The n3-PUFAs EPA and DHA may undergo similar conversions, e.g., 
to oxo metabolites [45] or multiple hydroxylated derivatives which are in part 
potent inflammation resolving mediators [5]. As incorporation in lipids and 
conjugation are usually rather unspecific for the different OH-FAs, the clearance 
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of the 5-LOX products from the cell culture media might indicate a further 
processing of 5-HETE, 5-HEPE and 4-HDHA to new oxylipins in the cell lines 
tested. 
12-HETE, 12-HEPE and 14-HDHA are formed by HCA-7, SW-480 and Balb/c 
3T3 cells (Fig. 5.4). However, the formation of these OH-FAs does not dominate 
over the formation of other OH-FAs indicating only low 12-LOX activity in the 
cells. The dominant formation of 15-HETE and 17-HDHA could indicate that the 
cell lines express active 15-LOX. However, HCA-7 cells overexpress COX-2 
[46, 47] and it is well known that COX-2 has a side activity to generate 15-HETE 
[3], which might explain part of the 15-HETE formation by HCA-7. Using the 
OH-FA levels released to the cell culture medium as LOX pathway marker, the 
FA-OH pattern does not suggest specifically high activity of LOX enzymes in 
any of the cell lines tested. This is consistent with reports about expression of 
LOX enzymes in the cell lines without any activation, showing no 15-LOX 
activity for HCT-116 [48] and low expression of 5-, 12- and 15-LOX by SW-480 
cells [49]. However, significant expression of 15-LOX in HT-29 [49] as well as 5-
LOX expression in HCT-116, HT-29 and HCA-7 has been described [50-52] and 
for HT-29 and HCT-116 even the formation of leukotriene B4 – a downstream 5-
LOX product – could be shown [52]. In Balb/c 3T3 significant formation of 9-
HODE and 13-HODE was observed upon epidermal growth factor hormone 
stimulation which was attributed to LOX activity [40].  
Since two of the active (HCA-7 and SW480) and both inactive (HT-29 and HCT 
116) were human cell lines originating from colorectal adenocarcinomas [46, 49, 
52], this shows that the capability to generate OH-FAs can vary strongly even in 
cell lines derived from the same tissue and species. Further research will have 
to address lipid metabolite profiles in direct samples from human colorectal 
cancer. 
Dennis and coworkers carried out incubations with ARA, EPA and DHA and 
found an impressive pattern of oxylipins in stimulated RAW264.7 macrophages 
[38]. Consistent with our observations, they found a strong elevation of 20-
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HDHA, 16-HDHA and 8-HDHA in Toll-like receptor 4 activated 264.7 cells. 
Interestingly, no increase in 18-HEPE following EPA treatment was observed. 
However, it is questionable if these studies are comparable (different cell lines, 
stimulation vs. no stimulation). 
Overall it is striking that 18-HEPE and 20-HDHA are formed most dominantly in 
three different cell lines. While some authors indicate 18-HEPE as CYP 
metabolite [38], no detailed information about an enzymatic route of formation is 
available for this compound. Regarding the formation by radical chain reaction 
during autoxidation, these OH-FAs are most likely formed via an initial 
abstraction of a proton at the bisallylic carbon (ω-5) of the fatty acid chain of 
both n3-PUFA, i.e the bisallylic proton located closest to the ω end of the fatty 
acid chain. Interestingly, the dominantly formed OH-FA of the n6-PUFA ARA is 
15-HETE, which is initially also formed by abstraction of the proton at the 
bisallylic carbon at position 13 which is closest to the ω-end of the fatty acid 
chain. Because of the mesomeric stabilization of the intermediately formed 
radical, protons are preferentially abstracted at bisallylic carbons in radical chain 
reactions during autoxidation and 11-HpETE and 15-HpETE are the dominating 
primary products of autoxidation of ARA [9]. Accordingly, for EPA initial 
abstraction of protons at C7, C10, C13 or C16 occurs [10]. Thus, the formation 
of 18-HEPE and 20-HDHA is consistent with the expected preferred 
autoxidation products of the PUFA. Nevertheless, an enzymatic conversion 
cannot be ruled out because particularly 18-HEPE is formed dominantly 
compared to other expected metabolites in HCA-7 and Balb/c 3T3 cells. In 
order to address these questions, the OH-FA pattern of more cell lines should 
be evaluated and compared with the pattern observed in tissues. With the help 
of different responses in different cell lines and other molecular biological study 
approaches, e.g., using expression analysis and co-incubations with inhibitors, 
the formation pathways of these oxylipins could probably be elucidated in more 
detail. The rapid LC-MS method described here provides an excellent tool for 
these studies. 
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 Conclusion 5.4
A new rapid LC-MS method for the targeted metabolomics analysis of OH-FA 
formation within the ARA cascade has been developed and validated for 
biological samples. With the parallel determination of 26 analytes, the method 
allows the determination of a comprehensive pattern of OH-FAs. Being equally 
or more sensitive, the method is with a runtime of 6.5 min, significantly faster 
than previous methods. Most importantly, the method allows the direct analysis 
of crude samples after IS addition and centrifugation, thus making the analysis 
of large sample sets at low cost per sample feasible.  
Among the five cell lines tested, two did not release OH-FA after incubation with 
ARA, EPA and DHA (HT-29 and HCT-116), as compared to media-only control 
experiments. It is noteworthy, however, that incubation of cell culture medium 
containing FCS with PUFA-EE alone (without cells present) led to a formation of 
relevant concentrations of OH-FAs–therefore, media-only control experiments 
are necessary in order to correctly assess the cellular component of metabolite 
formation. A significant formation of OH-FA was found for three out of five cell 
lines, the colon cancer cell lines HCA-7 and SW480, as well as the fibroblast 
cell line Balb/c 3T3. The dominantly formed OH-FA metabolites were 15-HETE 
from ARA, 18-HEPE from EPA and 20-HDHA from DHA. 
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6 Chapter 6 
Modulation of the Endogenous Omega-3 Fatty Acid and 
Oxylipin Profile in vivo – A Comparison of the fat-1 
Transgenic Mouse with C57BL/6 Wildtype Mice on an 
Omega-3 Fatty Acid Enriched Diet* 
Dietary intervention and genetic fat-1 mice are two models for the investigation 
of effects associated with omega-3 polyunsaturated fatty acids (n3-PUFA). In 
order to assess their power to modulate the fatty acid and oxylipin pattern, we 
thoroughly compared fat-1 and wild-type C57BL/6 mice on a sunflower oil diet 
with wild-type mice on the same diet enriched with 1% EPA and 1% DHA for 0, 7, 
14, 30 and 45 days. Feeding led after 14-30 days to a high steady state of n3-
PUFA in all tissues at the expense of n6-PUFAs. Levels of n3-PUFA achieved by 
feeding were higher compared to fat-1 mice, particularly for EPA (max. 1.7% in 
whole blood of fat-1 vs. 7.8% following feeding). Changes in PUFAs were 
reflected in most oxylipins in plasma, brain and colon: Compared to wild-type 
mice on a standard diet, arachidonic acid metabolites were overall decreased 
while EPA and DHA oxylipins increased with feeding more than in fat-1 mice. In 
plasma of n3-PUFA fed animals, EPA and DHA metabolites from the 
lipoxygenase and cytochrome P450 pathways dominated over ARA derived 
counterparts. Fat-1 mice show n3-PUFA level which can be reached by dietary 
interventions, supporting the applicability of this model in n3-PUFA research. 
However, for specific questions, e.g., the role of EPA derived mediators or 
concentration dependent effects of (individual) PUFA, feeding studies are 
necessary. 
* Ostermann AI, Waindok P, Schmidt MJ, Chiu C-Y, Smyl C, Rohwer N, 
Weylandt KH and Schebb NH. 2017. Submitted for publication. 
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 Introduction 6.1
It has long been suggested that dietary intake of long-chain n3 polyunsaturated 
fatty acids (n3-PUFA), especially of eicosapentaenoic acid (C20:5 n3, EPA) and 
docosahexaenoic acid (C22:6 n3, DHA), is associated with beneficial health 
effects [1, 2]. Strong evidence exists for an improvement of cardiometabolic 
health by lowering blood trigylceride levels and cardiovascular outcomes, such 
as sudden cardiac death [2]. Furthermore, anti-inflammatory [1, 2] and anti-
angiogenic [3, 4] effects have been described and DHA plays an important role 
in neurodevelopment [5]. Part of the effects might be explained by direct 
physiological actions of n3-PUFA. They have been shown to act directly on 
membrane ion channels, or to reduce expression of inflammatory genes via 
nuclear factor-kappaB (NFκB), e.g. by interacting with peroxisome proliferator-
activated receptor gamma (PPARγ) [1, 2]. Moreover, n3-PUFA serve as 
substrates in the arachidonic acid (C20:4 n6, ARA) cascade. In this signaling 
cascade, ARA is converted via three enzymatic pathways and autoxidation to 
oxidative metabolites, called oxylipins, several of which are biologically highly 
active: (I) Cyclooxygenase (COX) conversion of ARA yields series-2 
prostanoids, like the potent prostaglandin (PG) E2 which is involved in the 
regulation of pain, fever and inflammation or thromboxane (Tx) A2 which is 
involved in platelet aggregation [6-8]. (II) Lipoxygenase (LOX) action on ARA 
leads to multiple biologically active classes of lipid mediators via hydroperoxy 
intermediates, such as leukotrienes (LT), e.g. LTB4, involved in the chemotaxis 
of neutrophils, lipoxins with anti-inflammatory properties or hydroxy-fatty acids 
(OH-FA) [6-8]. (III) Finally, cytochrome P450 (CYP) enzymes can convert ARA 
to OH- and epoxy-FA (Ep-FA). For instance, ω-hydrolase activity of CYP 
enzymes can yield the vasoconstrictory 20-hydroxyeicosatetraenoic acid (20-
HETE) formed by members of the CYP4A or 4F family [6, 8, 9]. Conversion of 
ARA by CYP2C and 2J, e.g., leads to vasodilatory, anti-inflammatory, analgesic 
and angiogenic acting Ep-FA [6, 8-11] which are further metabolized to less 
potent dihydroxy-FA (DiH-FA) by the soluble epoxide hydrolase [6, 8, 12]. The 
effect of n3-PUFA on this important signaling cascade is multifaceted. On the 
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one hand, by competing with ARA for conversion, the formation of potent ARA 
derived mediators, such as pro-inflammatory PGE2 and LTB4 is reduced, while 
their EPA derived counterparts, PGE3 and LTB5 have been shown to be less 
potent [1, 8]. On the other hand, enzymatic conversion of EPA and DHA can 
yield highly potent lipid mediators: CYP catalyzed epoxidation leads, e.g., to 
anti-arrhythmic acting 17(18)-epoxy eicosatetraenoic acid (EpETE) from EPA 
and 19(20)-epoxy docosapentaenoic acid (EpDPE) from DHA [13]. Interestingly, 
while these Ep-FA share the anti-inflammatory action of the corresponding ARA 
oxylipins [3], 19(20)-EpDPE has been shown to inhibit angiogenesis in contrast 
to ARA derived Ep-FA [4]. Moreover, multiple hydroxylation leads to highly 
potent, specialized pro-resolving lipid mediators (SPM) such as resolvins and 
protectins [14, 15]. 
Regarding the clinical relevance of n3-PUFA in different diseases the results of 
epidemiological and intervention studies are conflicting [1, 2, 16]. Moreover, 
molecular modes of action for individual effects of n3-PUFA have not been fully 
unveiled, and dose dependencies remain largely unclear [1, 2]. In order to 
address these questions, appropriate experimental models allowing a defined 
modulation of the endogenous n3-PUFA and oxylipin profile are required. 
In humans and other mammals EPA and DHA can be synthesized 
endogenously by combined elongation (ELOVL2 and 5 (human gene name 
indicated)), desaturation (delta 5 (FADS1) and delta 6 (FADS2) desaturase) and 
β-oxidation reactions from the essential n3-PUFA alpha linolenic acid (C18:3 
n3, ALA) [17, 18]. However, conversion rates are low on a diet rich in linoleic 
acid (C18:2 n6, LA), as it is the case for a typical western diet (soy, corn and 
sunflower oil based) [17]. Additionally, mammals lack an n3 desaturase for the 
endogenous conversion of n6 to n3-PUFA [18]. Therefore, EPA and DHA have 
to be directly supplied, either by consumption of n3-PUFA rich food, like fish, 
algae or krill [19] or by ingestion of supplementation products [20]. In in vivo 
studies, animal diets are often enriched with EPA and DHA containing oils to 
modulate the endogenous n3-PUFA profile. This approach has been used in 
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different disease models for the investigation of n3-PUFA associated biology, 
e.g. in inflammatory diseases, such as colon inflammation [21, 22], arthritis [23, 
24], hypertension [25], liver injury [26] or Parkinson’s Disease [27]. 
Another approach to investigate physiological effects of elevated endogenous 
n3-PUFA concentrations is the use of the fat-1 transgenic mouse model. The 
DNA of these mice has been edited to carry the fat-1 gene of the nematode 
Caenorhabditis elegans encoding an n3 fatty acid desaturase catalyzing the 
conversion of n6 to n3 fatty acids [28]. This leads to a massively decreased 
endogenous n6/n3-ratio in fat-1 mice fed with a standard n6-PUFA rich diet 
compared to wild type (WT) animals, e.g. from 46.6 (WT) to 2.9 (fat-1) in 
erythrocytes [28]. Therefore, fat-1 mice have been used in many studies for the 
investigation of n3-PUFA associated effects, e.g. in inflammation, including 
colitis [29, 30], hepatitis [31], pancreatitis [32], different types of cancer, such as 
liver [33], colitis-associated colon cancer [34, 35] and melanoma [36] as well as 
Parkinson’s Disease [37] or chemically induced diabetes [38]. 
In most studies using fat-1 mice, selected FA and/or (variations of) the n6/n3-
PUFA ratio in tissues are used as biomarker of the endogenous n3-PUFA 
status [29-39]. Only little attention has been paid to the modulation of n3- and 
n6-PUFA oxylipins in fat-1 compared to wild type mice. In disease models a 
focus was set on selected oxylipins, such as PGE and/or PGD from ARA and/or 
EPA [29, 30, 34, 36, 38], SPMs [30], precursor thereof [33] and few others [30, 
34, 38]. A comprehensive set of free oxylipins in fat-1 mice has only been 
described in plasma [40] and total (free and esterified) OH-FA have been 
described in plasma and tissues [39]. Almost no data is available on the 
differences in fatty acids and oxylipins in between fat-1 versus WT mice after 
dietary supplementation with n3-PUFA. The only available study compares the 
effects of nine weeks of feeding on selected oxylipins and fatty acids in kidney 
tissue [41]. Therefore, in the present study we thoroughly investigated the 
modulations of both, the total fatty acid and oxylipin profile in fat-1 vs. WT mice 
on standard, sunflower oil based diet and the same diet enriched with n3-PUFA 
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(1% EPA and 1% DHA). Not only is a comprehensive set of tissues and blood 
(including plasma and blood cells) analyzed, we also show the time course of 
effects occurring on a diet enriched with n3-PUFA over a feeding period of 7-45 
days. This study provides fundamental insights on the breadth of effects on the 
lipidome caused by the insertion of the fat-1 gene into the murine DNA in the 
context of a diet high in n6-PUFA compared to an n3-PUFA dietary intervention 
as well as the time dependency of nutrition induced changes. 
 Experimental 6.2
6.2.1 Chemicals 
Acetic acid and methanol (Optima LC/MS Grade) as well as acetonitrile (HPLC-
MS grade) were obtained from Fisher Scientific (Schwerte, Germany) and 
ammonium acetate (p.a.) was purchased from Merck (Darmstadt, Germany). 
Methyl tert-butyl ether and n-hexane (HPLC grade) were obtained from Carl 
Roth (Karlsruhe, Germany). Methyl tricosanoate (FAME C23:0) was obtained 
from Santa Cruz Biotechnology (Heidelberg, Germany). Oxylipin and deuterated 
oxylipin standards were purchased from Cayman Chemicals (local distributor: 
Biomol, Hamburg, Germany). Further oxylipin standards (Epoxy 
octadecadienoic acids (EpODEs) and dihydroxy octadecadienoic acids 
(DiHODEs)) were a kind gift from the laboratory of Bruce Hammock (UC Davis, 
CA, USA). Ethyl acetate, methyl formate and all other chemicals were 
purchased from Sigma Aldrich (Taufkirchen, Germany).  
6.2.2 Feeding experiment 
Pellets for the feeding experiment were based on a standard experimental diet 
from ssniff (product number: E15051; ssniff Spezialdiäten GmbH, Soest, 
Germany) with 10% fat. The fat used for the standard diet was refined sunflower 
oil (Henry Lamotte Oils, Bremen, Germany) enriched with 0.2% (w/w) 
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tocopherol mix (Covi-Ox T 70 EU, BASF, Ludwigshafen). The n3-PUFA rich diet 
was the same diet containing 1% EPA and 1% DHA as ethyl esters. The fatty 
acid concentrations of the chow and details on the actual fatty acid composition 
of the diets can be found in the supplementary information (App. Table 9.3.1). 
Animals were cared for in accordance with the institution’s guidelines for 
experimental animals. The animal protection committee of the local authorities 
approved all experiments. Transgenic fat-1 mice were generated as described 
[28] and phenotyping (ratio of n6/n3-PUFA) from tails was carried out using gas 
chromatography. For the feeding experiment female C57BL/6 WT and fat-1 
mice of 9-10 weeks of age were used (n=6). Before the experiment, mice were 
kept on a diet with 3.3% fat (1.8% LA, 0.23% ALA in the diet, App. Table 9.3.2) 
with water and food supply ad libitum. WT mice were kept on the experimental 
diets for 7, 14, 30 and 45 days. Fat-1 mice were kept on the standard sunflower 
diet for 30 days. One group of WT and fat-1 animals was sacrificed on day 0. 
Animals were killed by cervical dislocation and organs (liver, kidney, spleen, 
brain and colon) as well as blood (by cardiac puncture) were collected. 10 µL of 
whole blood were directly diluted with 50 µL of deionized water. For plasma and 
blood cell generation, blood was directly centrifuged (800 xg, 10 min, 4 °C). 
Plasma was collected and blood cells were washed once with phosphate 
buffered saline (containing 1.5 mg/mL ethylenediaminetetraacetic acid (EDTA)) 
and reconstituted to the original blood volume in phosphate buffered saline. All 
samples were stored at -80 °C until further analysis 
6.2.3 Fatty acid analysis 
Fatty acid composition was analyzed in all collected blood fractions (60 µL 
diluted whole blood, 50 µL plasma and 100 µL reconstituted blood cells) and 
tissues (30-35 mg) as described [42 (see Chapter 3)]. Briefly, blood and tissues 
were extracted with methanol/ methyl tert-butyl ether (1:2, v/v) and derivatized 
to fatty acid methyl esters (FAME) with methanolic hydrogen chloride 
(acetylchloride in methanol (1:10, v/v)). FAMEs were analyzed by means of gas 
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chromatography with flame ionization detection (GC-FID) on a 6890 series 
instrument (Agilent Technologies, Waldbronn, Germany) equipped with a 30 m 
x 0.25 mm FAMEWAX column (0.25 µm film) and a 5 m x 0.25 mm deactivated 
guard column of intermediate polarity (Restek GmbH, Bad Homburg, Germany), 
using FAME C23:0 as internal standard. Peak integration was performed with 
Chemstation B01.03 (Agilent). For the calculation of the relative pattern and 
absolute fatty acid concentrations response factors were used [42 (see Chapter 
3), 43]. Results are presented as mean ± standard error of the mean (SEM). 
6.2.4 Oxylipin analysis 
Extraction and analysis of oxylipins from plasma (200 µL) and colon (50±5 mg) 
was carried out as described [44 (see Chapter 4), 45]. Brain (50±5 mg) was 
homogenized following addition of internal standards and antioxidant solution 
[44 (see Chapter 4), 45] in 750 µL ethyl acetate and 500 µL water (pH 6) by a 
ball mill using two 3 mm metal beads (25 Hz, 5 min, Retsch, Haan, Germany). 
Following homogenization and centrifugation (20 000 xg, 5 min, 4 °C), the 
organic phase was collected and the sample extracted with another 750 µL 
ethyl acetate. The combined organic phases were evaporated using a vacuum 
centrifuge (Christ, Osterode am Harz, Germany) and the dried lipid extract was 
reconstituted in 300 µL methanol. All samples were diluted to 6 mL with water 
and acidified with acetic acid (to pH 3) directly before extraction. The acidified 
samples were brought onto a C18 solid phase extraction cartridge (500 mg, 
Macherey-Nagel, Düren, Germany) and eluted using methyl formate [44 (see 
Chapter 4), 45]. Oxylipins were quantified by liquid chromatography-mass 
spectrometry (LC-MS) following negative electrospray ionization on a 
QTrap6500 mass spectrometer (Sciex, Darmstadt, Germany) operated in 
scheduled selected reaction monitoring mode [44 (see Chapter 4), 45]. Analyst 
1.6.2 (Sciex) was used for data acquisition and Multiquant 2.1.1 (Sciex) was 
used for data analysis. Hemolytic plasma samples and samples with high TxB2 
and 12-HETE – indicating improper anticoagulation – were excluded from 
analysis. Results are presented as mean ± SEM. 
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 Results 6.3
6.3.1 Behaviour and bodyweight 
During the experiment, no differences in animal behavior were observed. 
Bodyweight means of the groups ranged from 17.9 to 21.7 g. Compared to 
baseline, groups on a standard sunflower based, n6-PUFA rich diet (WT-STD) 
showed a slight decrease in bodyweight, whereas groups on a sunflower based 
diet enriched with n3-PUFA (WT-STD+n3) did not show a consistent trend. Fat-
1 mice at baseline were a little lighter than WT mice and their bodyweight did 
not change during the feeding period (App. Fig. 9.3.1). These results indicate no 
differences in feeding behavior between the groups. 
6.3.2 Fatty acid profile 
Fig. 6.1 and Table 6.1 show the relative pattern of selected FA as well as the 
FA profile grouped as saturated fatty acids (SFA), monounsaturated fatty acids 
(MUFA) and n6- and n3-polyunsaturated fatty acids (PUFA) during the course 
of the feeding time. The full FA profile of blood and tissues is found in the 
Appendix (App. Table 9.3.3A+B). 
After 30 days on a sunflower oil based diet, low in n3-PUFA (WT-STD, App. 
Table 9.3.1), EPA was <0.05% in most investigated tissues and blood, except 
for whole blood (Fig. 6.1, Table 6.1). DHA levels ranged from 0.73% (colon) to 
7.4% (kidney) and were higher in brain (17%, Fig. 6.1, Table 6.1). ARA levels 
increased over the feeding period slightly in most tissues reaching 20-23% in 
whole blood, plasma, blood cells, kidney and spleen (Fig. 6.1, Table 6.1). 
Lowest levels were found in colon (5.7%), the only tissue in which ARA 
decreased over the feeding time (Table 6.1, App. Table 9.3.3B). Interestingly, 
ALA levels in all tissues and blood decreased over the feeding period in all 
groups (App. Table 9.3.3B) due to the low ALA content of sunflower oil (0.29-
0.34% of ALA in all diets, App. Table 9.3.1). 
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Fig. 6.1: Relative amounts of EPA, DHA and ARA as well as the relative distribution of n3- and 
n6-PUFA, MUFA and SFA in transgenic fat-1 mice and wild type animals (WT-STD) after 30 
days on a sunflower oil based diet, as well as in wild type mice on the same diet enriched with 
EPA and DHA (WT-STD+n3) during the course of the feeding period (45 days) in (A) whole 
blood, (B) plasma and (C) blood cells. Analytes that were below the limit of quantification are 
marked with a white filling in the diagram. 
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Feeding of a diet enriched in n3-PUFA (1% EPA and 1% DHA as ethyl ester, 
WT-STD+n3, App. Table 9.3.1) led to a massive increase in the relative and 
absolute concentrations of these FA in blood and all investigated tissues (Fig. 
6.1, Table 6.1, App. Fig. 9.3.2). The fatty acid pattern changed most during the 
first seven days of supplementation and no further increase of n3-PUFAs was 
found in plasma (Fig. 6.1). Constant levels (steady state) were reached after 14-
30 days of feeding in brain, spleen as well as kidney (Table 6.1) and after 30 
days in blood cells as well as whole blood (Fig. 6.1). For liver and colon tissue, 
relative amounts of EPA and DHA varied more between the different time 
points, however, the data also suggests that a steady state was reached at 
least after 30 days of feeding (Table 6.1). When comparing the levels of EPA 
and DHA after 30 days of n3-PUFA supplementation to levels in tissues and 
blood of mice at the beginning of the feeding experiment, changes in EPA were 
more pronounced (App. Fig. 9.3.2): While the mean %difference [(c(FA)WT-
STD+n3, D30 - c(FA)WT, D0)/c(FA)WT, D0*100] in DHA was about 100% (except in 
colon and brain, with an increase of at most 35%), EPA was increased by about 
2000-5000% in whole blood, blood cells, plasma, liver, kidney and spleen. 
Again, changes in colon and brain were lower (400% and 1200%, respectively). 
Relative increases in the elongation product of EPA, n3 docosapentaenoic acid 
(C22:5n3, n3-DPA), ranged from 160% (colon) to 480% (liver, App. Fig. 9.3.2). 
In response to n3-PUFA supplementation, SFA and MUFA changed only 
slightly (Fig. 6.1, Table 6.1, App. Fig. 9.3.3), while n6-PUFA levels were 
uniformly decreased. For instance, ARA as a major n6-PUFA, showed a 40-
85% decrease in all tissues and blood, except brain (App. Fig. 9.3.2). It should 
be noted that due to the high content in the experimental sunflower based diets, 
the other main n6-PUFA, LA, was slightly higher compared to baseline in most 
tissues of the feeding groups. 
Over all groups (fat-1, WT-STD and WT-STD+n3) the sum of SFA and MUFA 
was comparable (Fig. 6.1, Table 6.1, App. Fig. 9.3.3), ranging between 50-60% 
in most investigated tissues and blood. In colon and brain the sums of SFA and 
MUFA were slightly higher (62-70%, Table 6.1). 
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Table 6.1: Relative amounts of EPA, DHA and ARA as well as the sum of n6-PUFA, n3-PUFA, 
MUFA and SFA in liver, kidney, spleen, colon and brain tissue in WT (WT-STD) and fat-1 mice 
after 30 days on a standard sunflower oil based diet and in WT mice on the same diet enriched 
with EPA and DHA (WT-STD+n3) during the course of the feeding period (day7-45). 
  
EPA DHA ARA n6-PUFA n3-PUFA MUFA SFA 
Liver 
 
  
 
  
  
  
 
  
   
  
 
  
   
   
WT-STD Day 30 <LOQ 3.7 ± 0.2 15.9 ± 0.9 39.5 ± 0.8 3.8 ± 0.2 24 ± 2 33 ± 1 
fat-1 Day 30 0.16 ± 0.02 6.8 ± 0.5 13.2 ± 0.7 36.7 ± 0.6 7.2 ± 0.5 24 ± 2 32 ± 1 
WT-STD+n3 Day 7 6.1 ± 0.4 14.7 ± 0.3 7.8 ± 0.2 26.8 ± 0.6 22.3 ± 0.6 13.5 ± 0.5 37.4 ± 0.3 
 
Day 14 4.4 ± 0.2 11.1 ± 0.4 5.9 ± 0.4 27 ± 1 17.0 ± 0.6 21 ± 1 35.1 ± 0.8 
 
Day 30 5.4 ± 0.4 14.1 ± 0.8 5.1 ± 0.2 26.3 ± 0.5 21 ± 1 19 ± 2 34.7 ± 0.5 
 Day 45 4.2 ± 0.5 12.5 ± 0.5 6.1 ± 0.2 29 ± 1 18.1 ± 0.9 18.9 ± 0.6 34.4 ± 0.5 
Kidney                      
WT-STD Day 30 0.015 ± 0.002 7.4 ± 0.6 22 ± 2 38.8 ± 0.7 7.7 ± 0.6 16 ± 2 38.0 ± 0.6 
fat-1 Day 30 1.01 ± 0.07 12.1 ± 0.3 20.3 ± 0.6 35.5 ± 0.5 13.9 ± 0.4 12.1 ± 0.5 38.5 ± 0.3 
WT-STD+n3 Day 7 4.6 ± 0.1 14.9 ± 0.7 12.9 ± 0.8 27.8 ± 0.3 20.6 ± 0.8 13 ± 1 39.1 ± 0.3 
 
Day 14 5.2 ± 0.2 16.3 ± 0.7 10.9 ± 0.6 25.7 ± 0.2 22.6 ± 0.8 13 ± 1 38.7 ± 0.2 
 
Day 30 6.3 ± 0.3 18.0 ± 0.5 10.3 ± 0.4 24.6 ± 0.2 25.5 ± 0.6 11.0 ± 0.7 39.0 ± 0.2 
 Day 45 6.2 ± 0.2 16.5 ± 0.7 9.5 ± 0.5 25.2 ± 0.3 23.9 ± 0.9 13 ± 1 38.1 ± 0.4 
Spleen                      
WT-STD Day 30 0.035 ± 0.007 2.6 ± 0.1 20.4 ± 0.8 39 ± 1 3.0 ± 0.1 16 ± 2 42.8 ± 0.5 
fat-1 Day 30 1.6 ± 0.2 4.9 ± 0.6 14 ± 1 31.2 ± 0.2 9 ± 1 18 ± 3 41 ± 1 
WT-STD+n3 Day 7 3.58 ± 0.07 9.8 ± 0.3 10.5 ± 0.5 25.7 ± 0.4 17.8 ± 0.4 13.3 ± 0.9 43.2 ± 0.2 
 
Day 14 4.0 ± 0.1 10.3 ± 0.2 8.3 ± 0.4 23.4 ± 0.4 18.7 ± 0.4 14.8 ± 0.7 43.0 ± 0.3 
 
Day 30 4.3 ± 0.1 11.2 ± 0.2 7.7 ± 0.2 23.2 ± 0.2 20.1 ± 0.5 13.1 ± 0.7 43.6 ± 0.3 
 Day 45 3.8 ± 0.2 10.5 ± 0.6 6.9 ± 0.5 23.6 ± 0.2 19 ± 1 16 ± 2 42.1 ± 0.9 
Colon                      
WT-STD Day 30 0.048 ± 0.010 0.73 ± 0.13 5.7 ± 1.0 35.5 ± 0.8 0.96 ± 0.15 35 ± 1 29.0 ± 0.8 
fat-1 Day 30 0.65 ± 0.22 1.5 ± 0.5 4.7 ± 1.4 32 ± 1 2.9 ± 0.8 35 ± 2 31 ± 1 
WT-STD+n3 Day 7 1.8 ± 0.3 3.5 ± 0.4 2.8 ± 0.8 28.8 ± 0.6 6.7 ± 0.7 32 ± 2 32.9 ± 0.8 
 
Day 14 2.8 ± 0.4 5.0 ± 0.5 3.6 ± 0.6 26.0 ± 0.6 9.2 ± 0.8 30 ± 1 34.6 ± 0.7 
 
Day 30 2.0 ± 0.2 4.5 ± 0.3 1.8 ± 0.4 27.5 ± 0.6 7.7 ± 0.5 30.5 ± 0.9 34.2 ± 0.6 
 Day 45 3.0 ± 0.4 5.7 ± 0.2 3.5 ± 0.4 27.4 ± 0.5 10.2 ± 0.6 27.4 ± 0.8 35.0 ± 0.3 
Brain                      
WT-STD Day 30 <LOQ 17.1 ± 0.3 11.3 ± 0.2 15.5 ± 0.3 17.2 ± 0.3 20.5 ± 0.6 46.8 ± 0.2 
fat-1 Day 30 0.066 ± 0.005 16.3 ± 0.9 9.8 ± 0.8 14.0 ± 0.9 16.5 ± 0.9 25 ± 3 45 ± 1 
WT-STD+n3 Day 7 0.15 ± 0.02 16.7 ± 0.4 10.3 ± 0.3 14.3 ± 0.4 17.1 ± 0.4 23 ± 1 46.0 ± 0.4 
 
Day 14 0.14 ± 0.01 17.4 ± 0.3 10.6 ± 0.2 14.6 ± 0.3 17.9 ± 0.3 20.9 ± 0.7 46.6 ± 0.3 
 
Day 30 0.18 ± 0.01 19.0 ± 0.3 9.5 ± 0.2 13.2 ± 0.2 19.6 ± 0.3 21.2 ± 0.5 46.0 ± 0.2 
 
Day 45 0.16 ± 0.01 17.4 ± 0.5 8.8 ± 0.2 15.8 ± 0.4 15.8 ± 0.6 20 ± 1 48.7 ± 0.3 
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After 30 days of feeding a standard sunflower oil based diet, level of EPA in 
blood in tissues of fat-1 mice ranged from 0.066±0.005% (brain) to 1.7±0.2% 
(whole blood, Fig. 6.1, Table 6.1). EPA level in WT mice on the same diet (WT-
STD) were <0.05% in most tissues and blood (Fig. 6.1, Table 6.1). 30 days of 
n3-PUFA supplementation led to EPA levels which were about 200-600% 
higher (and up to 1500% and 3300% in plasma and liver, App. Fig. 9.3.4) as 
compared to fat-1 mice and ranged from 2.0±0.2% (colon) to 9.5±0.8% (plasma, 
Fig. 6.1, Table 6.1). EPA level in brain was 0.18±0.01% (Table 6.1). In fat-1 
mice n3-DPA level ranged from 0.14±0.03% (plasma) to 2.7±0.3% (spleen, 
App. Table 9.3.3B). Levels of n3-DPA in WT mice on the same diet were much 
lower with highest amounts found in blood cells (0.38±0.10%, App. Table 
9.3.3B). After 30 days of feeding a chow enriched in n3-PUFA to WT mice, 
large differences in n3-DPA levels compared to fat-1 mice were observed in 
plasma and liver (App. Fig. 9.3.4), yet, levels were roughly in the same range, 
yielding 0.42±0.01% (brain) to 1.90±0.02% (blood cells, App. Table 9.3.3B). 
Spleen showed a high level of n3-DPA with 4.6±0.1%. DHA levels in fat-1 mice 
were 2- to 42-fold (and 250-fold in brain) higher than EPA concentrations and 
were found in the range of 1.5±0.5% (colon) to 16.3±0.9% (brain, Fig. 6.1, Table 
6.1). Except for brain, DHA level in tissues and blood of WT animals on the 
same diet were about twofold lower in comparison to fat-1 mice, while DHA 
level after 30 days of n3-PUFA supplementation were in roughly twofold higher 
compared to DHA in fat-1 mice (mean %difference of about 100%, App. Fig. 
9.3.4), ranging between 4.5±0.3% (colon) and 19.0±0.3% (brain, Fig. 6.1, Table 
6.1). In brain, DHA levels differed least between the groups (Table 6.1). ARA 
levels in fat-1 mice were lowest in colon (4.7±1.4%) and highest in whole blood, 
blood cells, plasma and kidney (18-20%, Fig. 6.1, Table 6. 1). In WT mice on 
the same diet ARA level were slightly higher (Fig. 6.1, Table 6.1). After n3-
PUFA supplementation, ARA levels were roughly 40-60% lower compared to 
fat-1 mice (App. Fig. 9.3.4) and ranged from 1.8±0.4% (colon) to 10.3±0.4% 
(kidney, Fig. 6.1, Table 6.1). 
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The n6/n3 ratio in blood and tissues as well as the sum of %EPA and %DHA 
(%EPA+DHA) in blood cells, a modification of the omega-3 index [46], as 
marker for the endogenous n3-PUFA status after 30 days of EPA and DHA 
supplementation in comparison to fat-1 and WT animals on the standard 
sunflower oil based diet are presented in Fig. 6.2. The ratios during the feeding 
course and data on the tissues are shown in the appendix, Table 9.3.4. Massive 
differences were found in the n6/n3 ratio in the same tissue between the 
different groups. The ratios in different tissues and in blood within the same 
feeding group, however, were comparable, with the exception of colon and 
brain (Fig. 6.2A+B). Of other tissues and blood, highest n6/n3 ratios were found 
in WT animals on the STD diet with 5.1-20, compared to 2.5-6.9 in fat-1 mice, 
thus, exceeding levels in fat-1 mice approximately 2- to 3.5-fold (Fig. 6.2A+B). 
With EPA and DHA supplementation, the n6/n3 ratio decreased below two 
throughout all tissues (except colon and brain). Compared to fat-1 mice, feeding 
thus led to 2.6- to 4.5-fold lower n6/n3 ratios, and compared to WT mice on the 
STD diet to 5.4- to 13-fold lower n6/n3 ratios. Colon tissue showed remarkably 
high n6/n3 ratios (Fig. 6.2B), however, relative changes between feeding 
groups were comparable to other tissues. In brain, the n6/n3 ratio was below 
one in all groups. It was only slightly modulated by n3-supplementation (Fig. 
6.2B). Compared to WT mice on the STD diet (3.93±0.08%), %EPA+DHA in 
blood cells of fat-1 mice was about twofold higher (7.4±0.2%) and fourfold 
elevated in STD+n3 fed WT animals, reaching 17.4±0.2% (Fig. 6.2C). 
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Fig. 6.2: n6/n3 ratio in blood (A) and in tissues (B), as well as %EPA+DHA in blood cells (C) 
in transgenic fat-1 mice and wild type animals (WT-STD) on a standard sunflower oil based diet, 
as well as in wild type mice on the same diet enriched with EPA and DHA (WT-STD+n3) after 
30 days of feeding. The n6/n3 ratio was calculated as Ʃ%(C18:2 n6, C18:3 n6, C20:3 n6, C20:4 
n6, C22:4n6)/ Ʃ%(C18:3 n3, C20:5 n3, C22:5 n3, C22:6 n3). 
6.3.3 Oxylipin pattern 
Oxylipins were analyzed in selected tissues, i.e. plasma, colon and brain. 
Concentrations of all oxylipins covered by the LC-MS method in all feeding 
groups in plasma, colon and brain are presented in the appendix, Table 9.3.5. 
Since a steady state in the nutrition induced changes in fatty acids (see above) 
was reached after 30 days, the differences between the groups are highlighted 
for this time point in Fig. 6.3 for selected oxylipins from EPA, DHA and ARA in 
plasma, brain and colon.  
Feeding of a diet enriched with n3-PUFA (1% EPA and 1% DHA as ethyl 
ester, WT-STD+n3) led to high changes in the oxylipin pattern of plasma, brain 
and colon already in the first seven days of supplementation. Thereafter, 
concentrations remained almost constant showing only minor trends towards a 
further increase (App. Table 9.3.5). However, the levels of several oxylipins, 
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such as OH-FA of EPA and DHA in plasma, varied strongly, showing no clear 
trend between day 7 and 45 of feeding (App. Table 9.3.5). After 30 days of 
feeding, EPA metabolites showed the highest change of all oxylipins derived 
from EPA, DHA and ARA with a mean %increase of over 500% for many 
compounds in plasma, brain and colon as compared to baseline (App. Fig. 
9.3.6). Increases in DHA oxylipins were also massive e.g., mean %difference of 
>500% for HDHAs in plasma and EpDPEs in colon, however, for other analytes 
more moderate in comparison to EPA oxylipins (App. Fig. 9.3.6). Most ARA 
derived eicosanoids decreased in plasma and the investigated tissues (up to 
about 90% for 12-HETE in colon, App. Fig. 9.3.6). For few analytes, a slight 
increase was found, e.g. TxB2 (41%) or 12-HETE (140%) in plasma (App. Fig. 
9.3.6). As observed for the parent FA, ALA metabolites decreased massively. 
This trend was also found for ALA metabolites in WT and fat-1 animals on the 
STD diet (App. Table 9.3.5). 
After 30 days of feeding a standard n6-PUFA rich sunflower oil based diet, 
concentrations of EPA metabolites in plasma of fat-1 mice were overall in the 
low nM range with highest concentrations found for 17(18)-DiHETE (5.3±0.8 
nM, Fig. 6.3, App. Table 9.3.5). In comparison to WT animals after 30 days on 
the same diet, concentrations in plasma of fat-1 animals were highly elevated 
(up to 15-fold for 12- hydroxy eicosapentaenoic acid (12-HEPE)) and many 
analytes were found which were not detectable in STD fed WT animals, e.g. 
17(18)-EpETE, 5-HEPE or 18-HEPE (Fig. 6.3). Compared to fat-1 animals, WT 
mice on a diet enriched with n3-PUFA showed massively higher concentrations 
of EPA derived oxylipins (up to 7000% for 12-HEPE, Fig. 6.3, App. Fig. 9.3.7). 
After n3-PUFA feeding, highest concentrations were found for OH-FA (6.3-240 
nM) followed by DiH-FA (1.5-14 nM) and Ep-FA (0.94-1.1 nM, Fig. 6.3, App. 
Table 9.3.5). Resolvins were below the limit of quantification (<LOQ) in plasma 
of the feeding groups and the only EPA derived prostanoid found in detectable 
concentrations was TxB3 in animals on the STD+n3 diet (Fig. 6.3). 
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Fig. 6.3: Concentrations of oxylipins in plasma of transgenic fat-1 mice and wild type animals 
(WT-STD) on a sunflower oil based diet, as well as in wild type mice on the same diet enriched 
with EPA and DHA (WT-STD+n3) after 30 days of feeding. Shown are concentrations of 
selected prostanoids, 5-LOX, 12-LOX, 15-LOX, CYP4 and CYP2 products of ARA, EPA and 
DHA as well as 18-HEPE in (A) plasma, (B) brain and (C) colon. The lower limit of quantification 
(LLOQ) for the analyte is indicated in case it was not exceeded in >50% of the samples per 
group. 
MODULATION OF THE ENDOGENOUS N3-PUFA AND OXYLIPIN PATTERN IN MICE 
 
119 
 
Comparing the ratio of precursor PUFA and their oxidative products in all three 
groups, an almost linear correlation (R2>0.8) resulted for CYP and LOX 
metabolites (Fig. 6.4) which was also observed for DHA metabolites. The slope 
of >2 indicates that moderate changes in the concentrations of EPA or DHA led 
to a more pronounced change in the concentrations of their oxylipins. 
 
Fig. 6.4: Correlation between plasma n3-PUFA/n6-PUFA oxylipins and the ratio of their 
precursor fatty acids: The ratio of CYP metabolites (sum of epoxy-FA and dihydroxy-FA) from 
EPA (A) and DHA (B) and the respective ARA metabolites are plotted against the ratio of their 
precursor PUFA. In panel C-D the same correlation is shown for selected 12-LOX metabolites 
(12-HETE and 14-HDHA). The slope of the linear regression and the correlation coefficient were 
calculated based on all feeding groups of the experiment. 
In brain, only few EPA derived oxylipins were found in fat-1 animals and mice 
on the STD diet, whereas all OH-FA, some Ep-FA, 19(20)-DiHDPE, TxB3 and 
PGD3 were found in mice supplemented with n3-PUFA, though in low nmol/kg 
concentrations (up to 17±5 nmol/kg for 12-HEPE, Fig. 6.3, App. Table 9.3.5). In 
colon tissue, differences observed between fat-1 mice and WT animals on the 
STD diet were massive, e.g. 74-fold higher concentrations for 17(18)-EpETE 
and 27-fold higher levels for 18-HEPE while differences between fat-1 and n3 
supplemented animals were more moderate (on average 2-4 fold higher in WT-
STD+n3, Fig. 6.3). Overall, concentrations of EPA oxylipins in colon were much 
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higher compared to plasma and brain and ranged in fat-1 and n3-PUFA 
supplemented animals from DiH-FA, dominantly found in low nmol/kg 
concentrations (0.65-8.6 nmol/kg; except 17,18-DiHETE), to Ep-FA (9-100 
nmol/kg) and OH-FA (3.3-430 nmol/kg) to prostanoids in the high nmol/kg range 
(60-830 nmol/kg, Fig. 6.3, App. Table 9.3.5). Interestingly, resolvin (Rv) E2 was 
found in colon tissue of n3-supplemented mice (1.7±0.2 nmol/kg) while no other 
resolvin could be detected in the other assayed tissues (App. Table 9.3.5). 
All DHA metabolites covered by the method (except RvD1) were found in 
plasma of all feeding groups. Concentrations in fat-1 mice ranged up to 9.3±1.4 
nM for 19(20)-dihydroxy docosapentaenoic acid (DiHDPE) and were on 
average two- to threefold higher than in WT mice on the same diet (Fig. 6.3, 
App. Table 9.3.5). WT mice after n3-PUFA feeding showed about fourfold 
higher concentrations than fat-1 mice for DiH-FA and Ep-FA (mean %difference 
of about 300%), while OH-FA, were elevated up to 2800% (14-hydroxy 
docosahexaenoic acid (14-HDHA), App. Fig. 9.3.7). Highest concentrations in 
DHA metabolites after n3-PUFA feeding were found for HDHAs (2.7-190 nM) 
followed by DiHDPEs and EpDPEs (1.6-31 nM, Fig. 6.3, App. Table 9.5.5). DHA 
metabolites in brain were in the low nmol/kg range in all groups (1-24 nmol/kg, 
Fig. 6.3, App. Table 9.3.5), with most DiHDPEs being <LOQ. While DHA levels 
in all groups were similar, differences in DHA docosanoids between fat-1 and 
n3-PUFA fed mice were pronounced, being with a mean% difference of 220-
230% highest for 7-HDHA and 19(20)-DiHDPE (Fig. 6.3, App. Fig. 9.3.7). As 
observed for EPA metabolites, amounts of DHA oxylipins in colon were higher 
compared to plasma and brain, reaching high nmol/kg concentrations for some 
HDHAs (up to 850±200 nmol/kg for 14-HDHA in fat-1 mice, App. Table 9.3.5). 
By contrast, most DiHDPEs, except 19,20-DiHDPE, were found in low nmol/kg 
concentrations (up to 8.6±0.4 nmol/kg for 4,5-DiHDPE in WT-STD+n3 mice, 
App. Table 9.3.5). Levels in fat-1 mice compared to WT mice on the STD diet 
were on average twofold higher and WT mice supplemented with n3-PUFA 
showed again two to threefold higher concentrations as compared to fat-1 mice 
(Fig. 6.3). Concentration differences for some HDHAs were higher (mean 
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%difference of up to 780% for 22-HDHA, App. Fig. 9.3.7). Interestingly, 17-
HDHA concentrations in colon were comparable between the three groups and 
14-HDHA was lowest in n3 supplemented mice (Fig. 6.3).  
Except for 12-HETE, concentrations of ARA metabolites in plasma were low 
(between 0.060±0.008 nM for PGE2 in WT-STD+n3 mice and 6.3±0.9 nM for 
5(6)-epoxy eicosatrienoic acid (EpETrE) in WT-STD mice) in all three feeding 
groups on day 30 (Fig. 6.3, App. Table 9.3.5). It is notable that compared to 
EPA and DHA derived LOX and CYP products, ARA products were much lower 
in plasma of WT mice after n3-PUFA supplementation while the product pattern 
was dominated by ARA derived eicosanoids in WT mice on the standard 
sunflower oil based diet (Fig. 6.3). Concentrations of most ARA derived 
eicosanoids in n3-PUFA fed animals, except TxB2 and 12-HETE, were about 
50-60% lower as compared to fat-1 mice (App. Fig. 9.3.7) and differences 
between fat-1 and WT-STD mice were in the same range (Fig. 6.3, App. Table 
9.3.5). In brain of all feeding groups at day 30, diH-FA of ARA were found in low 
nmol/kg concentrations (0.51-1.3 nmol/kg), followed by ep-FA (10-81 nmol/kg) 
and OH-FA (2.9-150 nmol/kg). Prostanoids were found in concentrations up to 
750±40 nmol/kg (PGD2, WT-STD, Fig. 6.3, App. Table 9.3.5). Highest change 
between the groups was found for TxB2 (with a factor of 2.7) between WT-STD 
and fat-1 mice (Fig. 6.3). It is interesting that concentrations of most ARA 
derived eicosanoids were slightly higher in WT-STD+n3 mice compared to fat-1 
mice (Fig. 6.3, App. Table 9.3.5). ARA eicosanoid levels in colon reached 
µmol/kg concentrations for some prostanoids, e.g. PGE2 and PGD2, and 
HETEs, such as 11-HETE and 15-HETE (Fig. 6.3), while diH-ARA were found 
in low nmol/kg concentrations (0.8-11 nmol/kg, App. Table 9.3.5). Changes 
between the groups (WT-STD vs. fat-1 vs. WT-STD+n3) were comparable, 
roughly twofold for most analytes (Fig. 6.3). 
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 Discussion 6.4
A low dietary content of n3-PUFA has been implicated in a variety of 
pathophysiological processes and could impair human health. However, neither 
the breadth of biological effects of n3-PUFA nor the underlying molecular 
mechanisms are completely understood. Therefore, predictive (animal) models 
are needed which allow investigating the biology of n3-PUFA and their 
metabolites. In recent years, a transgenic mouse model with high endogenous 
levels of n3-PUFA has been established which is in addition to feeding studies, 
providing n3-PUFA with the diet, frequently used for this purpose and has 
shown beneficial effects of increased endogenous n3-PUFA levels in a wide 
variety of disease models [29-36, 38]. The aim of the present study was to 
thoroughly characterize and compare the power of the transgenic model and a 
feeding approach to modulate the endogenous fatty acid and oxylipin profile.  
Feeding of n3-PUFAs EPA and DHA with the diet led to massively higher 
concentrations of respective fatty acids in blood and tissues compared to WT 
mice on a standard sunflower oil based diet as reported earlier in rodents [13, 
21-24]. In men, similar observations were made following EPA+DHA 
supplementation, however, changes were more moderate caused by lower 
supplementation levels of n3-PUFA [47-52]. After 14-30 days of feeding a 
sunflower oil based diet enriched with 1% EPA and 1% DHA, levels of both FA 
reached a maximum steady state. This data suggests that studies aiming to 
investigate the effect of n3-PUFA need to implement a pre-feeding period of at 
least 14-30 days to elicit the full effects of n3-PUFA. 
Fat-1 mice showed lower concentrations of n3-PUFA as compared to 
supplemented WT mice which was most pronounced for EPA, being 2.7-34 fold 
lower in blood and tissues, while DHA concentrations were at most threefold 
lower at maximum steady state at 30 days and thereafter (Fig. 6.1, Table 6.1). 
This can be explained by the genetic background of these animals. In the fat-1 
mouse model the fat-1 gene of the roundworm C. elegans was introduced into 
the DNA of C57BL/6 wildtype mice. As a consequence, homo- and 
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heterozygote animals can biosynthesize n3- from n6-PUFA [28]. In C. elegans, 
different n6-PUFA, such as LA, C20:3 n6 and ARA are converted by the n3 
desaturase, encoded by the fat-1 gene, resulting in ALA, C20:4 n3 and EPA, 
respectively [53]. The roundworm lacks further elongase activity. Therefore, the 
biosynthetic fatty acid pathway stops at EPA, being the most abundant PUFA in 
the worm [53]. By contrast, in mammals EPA is further elongated to n3-DPA 
which in turn is converted via C24:5 n3 to DHA (conversion by elongase and 
delta-6 desaturase with subsequent β-oxidation in peroxisomes) [17, 18]. These 
reactions occur at high rates, e.g. 63% (EPA to n3-DPA) and 37% (n3-DPA to 
DHA) in humans [54]. EPA biosynthesis in mammals from the essential ALA, 
however, is low – caused by the rate limiting desaturation of ALA to C18:4 n3 in 
combination with high dietary LA and low ALA consumption [17, 18]. This 
results in low endogenous EPA levels compared to DHA, being <0.05% in WT 
mice on a standard sunflower oil based diet in most tissues and blood (Fig. 6.1, 
Table 6.1) or two- to tenfold lower than DHA in blood of non-supplemented 
humans [47-52]. 
Due to n3 desaturase activity in fat-1 mice, endogenous EPA formation is 
higher compared to WT mice. However, further metabolism by mammalian 
enzymes again resulted in high DHA concentrations compared to EPA e.g., 
6.8% (DHA) vs. 0.16% (EPA) in liver, which is consistent with previous results 
[31]. Thus, n3 desaturase activity led to high DHA levels in fat-1 while EPA 
levels were in the low range. 
Levels of intermediary formed n3-DPA were in the same range as EPA levels in 
fat-1 mice, supporting higher conversion rates of EPA to n3-DPA than of n3-
DPA to DHA as observed in humans [54]. This finding is also supported by 
levels of n3-DPA in STD fed WT mice, which were higher compared to EPA 
levels in all investigated tissues and blood cells. However, it should be noted, 
that n3-DPA is not only formed as intermediate in the conversion of EPA to 
DHA, but also in the process of DHA retroconversion: Following a single dose of 
3 mg [13C]22:6-triacylglycerol to male rats (300 g), retroconversion was found to 
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be 9% of the total plasma [13C]22:6 n3 (estimated by [13C]22:5 n3+[13C]20:5 n3 
in plasma lipids) [55]. 
The n6/n3 ratio, a frequently used marker to describe the endogenous n3-PUFA 
status [21, 27, 30, 31, 34, 36, 56] was reduced in fat-1 compared to WT animals 
on a standard diet. Although calculated slightly different, the observed n6/n3 
ratios were comparable, however, a little higher than ratios observed by Kang et 
al. [28]. This reduction in the n6/n3 ratio observed in fat-1 mice has been 
associated with protection in different disease models, including colon 
inflammation and hepatitis [29-36, 38]. Feeding of WT animals with a diet 
enriched with 1% EPA and 1% DHA led to notably lower n6/n3 ratios. It remains 
to be determined if this is also associated with a higher degree of protection. In 
a model of Parkinson’s Disease this seems to be the case: Fat-1 mice did not 
show a neuroprotective effect [37], while n3-PUFA supplementation did [27]. 
The lack of efficiency in the fat-1 mouse model might be due to a lower 
modulation of the endogenous n3 and n6 PUFA profile compared to 
supplementation, as discussed by Bousquet et al. [37]. 
The %EPA+DHA in blood cells for the description of the endogenous n3-PUFA 
status is a modification of the omega-3 index which is discussed as a risk factor 
for cardiovascular diseases in humans [46, 57]. In fat-1 mice, %EPA+DHA in 
blood cells was 7.4±0.2%. Translating from mouse to men, these levels were in 
the range of an omega-3 index that has been shown to be correlated with a 
lower cardiovascular risk, e.g. for an acute coronary syndrome event or for 
mortality from coronary heart disease (omega-3 index >8%, [46, 57]). 
%EPA+DHA in blood cells of fat-1 mice was also comparable to the omega-3 
index observed in healthy volunteers following supplementation (0.46-1.6 mg/d 
EPA and 0.38-1.1 g/d DHA for up to 12 weeks) which ranged from 8.4-11% 
(calculated from the means presented for EPA and DHA as %of total FA [47, 
49, 50]). However, the ratio of DHA to EPA in fat-1 mice was seven while in 
humans after supplementation this ratio was on average two [47, 49, 50]. Thus, 
individual level of EPA and DHA were differently modulated in fat-1 mice 
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compared to n3-PUFA supplementation with almost equal amounts of EPA and 
DHA. Keeping in mind that EPA and DHA effects might be different (e.g. 
EpDPEs were more effective in reducing pain than EpETEs in a model of pain 
associated with inflammation [58]), care must be taken when directly 
transferring results obtained from the fat-1 mouse model to humans. By 
contrast, using feeding approaches, experiments can be designed with defined 
treatment regimens and optimized n3-PUFA concentrations mimicking dietary 
ingestion of n3-PUFAs in humans. 
In response to higher endogenous level of n3-PUFA induced by 
supplementation or insertion of the fat-1 gene, the share of n6-PUFA, such as 
ARA and related FA, was decreased which is consistent with previous findings 
in n3-PUFA fed animals on a dietary background high in LA [13, 23, 24] and fat-
1 mice [29-31, 33-38]. Thus, EPA and DHA supplementation directly led to a 
notable displacement of ARA, which is a common explanation for their anti-
inflammatory action [1-3]. This theory is based on the assumption that most 
ARA derived oxylipins act pro-inflammatory and that n3-PUFA compete for 
conversion by the same enzymes yielding, e.g., less potent, EPA derived PGE3 
or LTB5 [1, 8]. Our study supports this replacement of ARA by n3-PUFA on the 
level of oxylipins, reflecting the changes observed for PUFA (Fig. 6.3): While 
oxylipin levels in WT animals on a standard diet – in line with the high ARA level 
– were dominated by ARA derived oxylipins, the pattern shifted to n3-PUFA 
derived ones in fat-1 and n3-PUFA fed animals. This is consistent with previous 
results, showing similar trends for free oxylipins [40] and esterified OH-FA [39] 
in fat-1 mice as well as for esterified CYP metabolites in plasma and tissues of 
rodents [13] and for free and/or esterified oxylipins in plasma of humans [47-52]. 
It should be noted that in general the modulation of the oxylipin pattern was 
more pronounced for n3-supplemented than for fat-1 mice compared to WT 
mice on the standard diet. As a result, n3-PUFA feeding led overall to higher 
concentrations of n3-PUFA derived oxylipins and lower ARA derived 
eicosanoids (except in brain) compared to fat-1 mice. This was most 
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pronounced in plasma for EPA metabolites, thereby reflecting the high 
difference in EPA between fat-1 and n3-PUFA fed mice. 
As shown in Fig. 6.3 for exemplary oxylipins, the product patterns of the LOX (5, 
12 and 15) and CYP (hydroxylation and epoxygenation) pathways in plasma 
after n3-PUFA feeding were dominated by EPA and DHA oxylipins. This is 
somewhat remarkable, since ARA remained a dominating PUFA (6.7% ARA vs. 
9.5% EPA vs. 11% DHA in plasma of WT-STD+n3 mice, Fig. 6.1) and indicates 
a preferred formation of n3-PUFA oxylipins over ARA derived ones. The ratio of 
substrates and products for CYP and LOX (Fig. 6.4), found in this study 
suggests that a preference of the enzymes could explain part of the effect. 
However, the moderate preference of, e.g., epoxygenating and hydroxylating 
CYP enzymes for DHA or EPA over ARA (ARA:EPA:DHA 1:4:1.5 for CYP2J2) 
[13, 59] alone seems not to sufficiently explain the massive difference observed 
in the overall pattern of oxylipins in plasma. Interestingly, in tissues, the 
dominance of LOX and CYP derived n3-PUFA oxylipins was less pronounced 
and concentrations were mostly in a similar range as ARA derived eicosanoids 
which indicates a tissue specific regulation. Nevertheless, our findings once 
more show that a moderate shift in the fatty acid pattern causes a pronounced 
increase in their oxidation products. 
In contrast, only a slight shift in ARA derived eicosanoids to n3-PUFA oxylipins 
was observed for COX products in plasma and tissues. While absolute 
concentrations of COX derived ARA metabolites were similarly decreased as 
LOX and CYP products, EPA metabolite concentrations in fat-1 and n3-PUFA 
fed mice were still very low compared to their ARA derived counterparts. This 
can be explained by the low conversion rate of n3-PUFA by COX [60] leading 
on the one hand to low EPA-product formation and on the other hand to 
inhibition of ARA conversion by COXs. 
It is interesting that, compared to plasma and brain, the highest concentrations 
of oxylipins from all three branches of the ARA cascade were found in colon, 
although the share of n3-PUFA among all FA in colon was lowest in all 
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investigated tissues and blood. Particularly COX metabolites were found in high 
concentrations, indicating an important role in homeostasis. Distinct differences 
in the oxylipin pattern were found between fat-1 and WT mice on the STD diet 
in colon. While relative changes in ARA and DHA metabolites were moderate, 
EPA metabolites from all enzymatic pathways were massively increased in fat-1 
compared to WT-STD mice. This high increase may in part explain the 
effectiveness of the fat-1 model in colitis and colitis-associated colon cancer 
[29, 30, 34, 35]. Not only were pro-inflammatory ARA derived metabolites, such 
as COX products, decreased (see above) but also were most EPA derived 
mediators elevated. While specialized pro-resolving mediators (SPM) derived 
from EPA were not found in colon tissue of fat-1 mice, 18-HEPE, as anti-
inflammatory pathway indicator and precursor for E series resolvins [61] with 
unclear formation pathway, was highly increased. Since RvE1 has previously 
been found in the same concentration range as PGE3 in inflamed colon of fat-1 
mice [30], this might indicate elevated resolvin formation in case of an 
inflammation. Also, 17(18)-EpETE, precursor to the potent anti-inflammatory 
mediator 12-OH-17,18-EpETE [62], was elevated. Although 12-OH-17,18-
EpETE was not found in colon tissue, it might as well be formed upon 
inflammatory stimuli. 
In brain, only slight modulations in the overall fatty acid profile were found 
between the groups compared to the other tissues investigated. In comparison 
to WT mice on the STD diet, DHA concentrations were slightly lower in fat-1 
after 30 days on the same diet and slightly higher after 30 days of n3-PUFA 
supplementation. This low modulation of DHA in adult mice with a developed 
brain [63] is consistent with previous findings in adult rats. Bourre et al. showed 
that neither feeding an n3-PUFA deprived diet for seven months to adult rats 
[64] nor eight weeks of feeding a diet containing 1.5% fish oil altered the brain 
DHA level [65]. However, with higher concentrations of fish oil in the diet, the 
DHA content in brain increased [65]. It should be noted that in contrast to slight 
changes in DHA concentrations, DHA oxylipins were elevated about twofold 
between WT-STD/fat-1 and fat-1/WT-STD+n3. On the one hand, a higher 
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substrate availability from plasma, a main source of brain DHA [66] might have 
led to the observed increase. On the other hand, oxylipins formed in other 
tissues might have been transported to the brain tissue. However, it should be 
noted that the animals were not perfused before collection of organs and 
residual blood might have been present in the tissue analyzed, although highest 
care was taken during sample preparation. Thus, the observed modulation in 
brain oxylipins may have resulted from residual blood in the tissue. 
Nonetheless, the pronounced effect on brain oxylipin levels by n3-PUFA 
warrants further investigation. 
Overall, the fatty acid and oxylipin pattern in fat-1 mice and n3 supplemented 
mice were modulated to higher concentrations of n3-PUFA and their 
metabolites in blood and tissues compared to WT mice on a standard sunflower 
diet, which is associated with a protection against different diseases. In general, 
the modulation in fat-1 mice was lower compared to n3-PUFA supplementation. 
The applicability of the fat-1 mouse model to investigate n3-PUFA associated 
effects, however, has been demonstrated in various disease models, e.g. colon 
inflammation or hepatitis [29-36, 38]. Since levels of EPA+DHA in blood cells of 
fat-1 mice were comparable to humans after supplementation, this model 
mimics n3-PUFA concentrations readily achievable with dietary 
supplementation. However, levels of the individual FA, particularly EPA were 
different, which might result in different physiological effects. An advantage of 
the fat-1 mouse model in comparison to feeding of n3-PUFA is the possibility of 
using one standard diet for the experimental groups. Therefore, confounding 
factors which might be introduced by the use of different experimental diets [56] 
or degradation of oxidation prone PUFA to potentially bioactive compounds [67] 
are reduced. However, for several questions, this model might not be suitable, 
particularly for the investigation of concentration dependent effects or the 
optimization of the dietary n6/n3 ratio needed for protection against diseases 
[68]. Here, feeding studies using defined concentrations of n3-PUFA in the diet 
in combination with an effective feeding regime are the most suitable approach. 
Another drawback of the fat-1 mouse model is that a discrimination between 
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individual effects derived from DHA and EPA is not possible while the diet for 
feeding studies can be modulated accordingly.  
Given the large amount of biologically relevant effects observed in studies using 
fat-1 mice, these results indicate that efficacy of n3-PUFA, and their derived 
oxylipins, might thus be found already in the context of rather low endogenous 
levels of n3-PUFA which could be easily achieved – and even surpassed – by 
dietary interventions. However, for some questions, e.g. the in depth and 
concentration dependent effects of (individual) n3-PUFA in vivo, feeding studies 
remain the model of choice. 
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7 Chapter 7 
A Diet Rich in Omega-3 Fatty Acids Enhances 
Expression of Soluble Epoxide Hydrolase in Murine 
Brain* 
Several studies suggest that intake of omega-3 polyunsaturated fatty acids (n3-
PUFA) beneficially influence cognitive function. However, effects on the adult brain 
are not clear. Little is known about the impact of dietary intervention on the fatty acid 
profile in adult brain, the modulation in the expression of enzymes involved in fatty 
acid biosynthesis and metabolism as well as changes in resulting oxylipins. These 
questions were addressed in the present study in two independent n3-PUFA feeding 
experiments in mice. Supplementation of eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA, 1% each in in the diet) for 30 days to adult NMRI and 
C57BL/6 mice led to a distinct shift in the brain PUFA pattern. While n3-PUFAs EPA, 
n3-docosapentaenoic acid and DHA were elevated, many n6-PUFAs were 
significantly decreased (except, e.g. C20:3 n6 which was increased). This shift in 
PUFAs was accompanied by immense differences in concentrations of oxidative 
metabolites derived from enzymatic conversion of PUFAs, esp. arachidonic acid 
which products were uniformly decreased, and a modulation in the activity and 
expression pattern of delta-5 and delta-6 desaturases. In both mouse strains a 
remarkable increase in the soluble epoxide hydrolase (sEH) activity (decreased 
epoxy-fatty acids (FA) concentrations and epoxy-FA to dihydroxy-FA–ratios) as well 
as sEH expression was observed. Taking the high biological activity of epoxy-FA, 
e.g. on blood flow and nociceptive signaling into account, this finding might be of 
relevance for the effects of n3-PUFAs in neurodegenerative diseases. On any 
account, our study suggests a new distinct regulation of brain PUFA and oxylipin 
pattern by supplementation of n3-PUFAs to adult rodents 
* Ostermann AI, Reutzel M, Hartung N, Franke N, Kutzner L, Schoenfeld K, 
Weylandt KH, Eckert GP and Schebb NH. 2017. Submitted for publication. 
Author contributions: AIO: Designed research, performed experiments, and wrote manuscript; 
RM, NH, FN, LK, KS: Performed experiments; KHW: Contributed to research design; GPE, 
NHS: Designed research and wrote the manuscript. 
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 Introduction 7.1
The dietary intake of long chain (LC) n3 polyunsaturated fatty acids (n3-PUFA), 
especially of eicosapentaenoic acid (C20:5 n3, EPA) and docosahexaenoic acid 
(C22:6 n3, DHA) is associated with beneficial effects on human health [1, 2]. 
Aside from blood triglyceride and blood pressure lowering as well as anti-
inflammatory effects, improvement of cognition in adults by dietary n3-PUFA is 
intensively discussed [3, 4] and the importance of n3-PUFA, especially DHA, in 
neurodevelopment is well established [3, 5]. Moreover, several studies suggest 
that intake of LC n3-PUFA in adults may prevent neuronal degradation and thus 
contribute to the maintenance of normal brain function and cognition in elderly 
people [5, 6]. DHA is the main n3-PUFA in brain [5, 7] and most effects of n3-
PUFA have been attributed to this FA, however evidence exists that other n3-
PUFA, such as EPA or n3 docosapentaenoic acid (C22:5 n3, n3-DPA) also 
show distinct effects in the brain [7]. 
Aside from incorporation into the membranes, PUFA can be metabolized in the 
brain (Fig. 7.1). Though endogenous synthesis of n3-PUFA in the brain is low 
compared to the uptake from plasma unesterified fatty acid pool [8], brain tissue 
possesses all enzymes to convert one PUFA into another. Reactions involved in 
the biosynthesis of DHA from alpha-linolenic acid (C18:3 n3, ALA) include 
conversion by delta 5 and delta 6 desaturase (FADS1 and FADS2), elongases 
in the endoplasmatic reticulum (ELOVL2 and 5) and β-oxidation in peroxisomes 
[9]. LC-n3-PUFA in brain tissue are dominantly found in phospholipids and can 
be converted in the arachidonic acid (ARA) cascade to eicosanoids and other 
oxylipins upon liberation by phospholipases. Several of the originating lipid 
mediators are implicated in brain (patho)physiology [7, 10]. Oxylipins are formed 
via three enzymatic pathways as well as autoxidation [11, 12]: Constitutively 
expressed cyclooxygenase (COX) 1 and COX2, the latter of which is induced 
e.g. during inflammation, give rise to prostaglandins (PG). Conversion by 
lipoxygenases (LOX) leads to hydroxperoxy FA, which can be further 
metabolized to, e.g., leukotrienes or hydroxy-FA. Cytochrome P450 enzymes 
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can act either as ω-hydroxylases, yielding e.g. terminally hydroxylated PUFA, or 
as epoxygenases, yielding epoxy-FA [13]. The latter act anti-inflammatory, 
vasodilatory and analgesic [13, 14] and are inactivated by the soluble epoxide 
hydrolase to dihydroxy-FA [15]. In addition multiple hydroxylated n3-PUFA, so 
called specialized pro-resolving lipid mediators (SPM) such as resolvines, 
maresines and protectins are described as potent oxylipins (Fig. 7.1). 
 
Fig. 7.1: Biosynthesis of long chain n3-polyunsaturated fatty acids from LA and ALA and 
selected oxygenation reactions of ARA, EPA and DHA within the ARA cascade.  Elovl – 
elongases; HpETE – hydroperoxy eicosatetraenoic acid; HETE – hydroxy eicosatetraenoic acid; 
Lx – lipoxin; LT – leukotriene; EpETrE – epoxy eicosatrienoic acid; DiHETrE – dihydroxy 
eicosatrienoic acid; HpEPE – hydroperoxy eicosapentaenoic acid; HEPE - hydroxy 
eicosapentaenoic acid; EpETE – epoxy eicosatetraenoic acid; DiHETE – dihydroxy 
eicosatetraenoic acid; HpDPA – hydroperoxy docosahexaenoic acid; HDHA – hydroxy 
docosahexaenoic acid; Mar – maresin, PD – protectin; RvD – D series resolvins. 
Despite the tremendous interest of n3-PUFA supplementation on brain 
physiology and cognitive function, only little information is available on the 
modulation of PUFA metabolizing enzymatic pathways in the brain. Therefore, 
in the present study we investigated the modulation of key enzymes from the 
fatty acid biosynthesis (Fads1, Fads2) and metabolism (Ptgs-2 (COX2), EPHX2 
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(sEH)) after dietary intervention with n3-PUFA in murine brain based on activity 
markers quantified by means of targeted oxylipin and fatty acid metabolomics. 
 Experimental 7.2
7.2.1 Chemicals 
Acetic acid and methanol (Optima LC/MS Grade) as well as acetonitrile (HPLC-
MS grade) were from Fisher Scientific (Schwerte, Germany) and ammonium 
acetate (p.a.) was purchased from Merck (Darmstadt, Germany). Methyl tert-
butyl ether, n-hexane (HPLC grade) and sodium acetate (p.a.) were obtained 
from Carl Roth (Karlsruhe, Germany). Oxylipin and deuterated oxylipin 
standards were obtained from Cayman Chemicals (local distributor: Biomol, 
Hamburg, Germany). Methyl pentacosanoate, ethyl acetate, methyl formate, 
and all other chemicals were purchased from Sigma Aldrich (Taufkirchen, 
Germany). 
7.2.2 Feeding experiment 
Diets were obtained from ssniff GmbH, Soest, Germany. A standard diet 
(product number: E15051) with 10% fat from refined sunflower oil (Henry 
Lamotte Oils, Bremen, Germany) enriched with 0.2% tocopherol mix (Covi-Ox T 
70 EU, BASF, Ludwigshafen) was used as control (STD). The same diet 
containing 1% EPA and 1% DHA as ethyl esters was used as n3-PUFA rich diet 
(STD+n3). For the feeding experiments, female C57BL/6 and NMRI mice 
(Charles River, Sulzfeld, Germany) of 9-10 weeks of age were used (n=6-8) and 
kept on the standard sunflower oil (STD) or the n3-PUFA enriched diet 
(STD+n3) for 30 days. The animals had access to food and water ad libitum. 
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7.2.3 Fatty acid and oxylipin analysis 
Lipids were extracted from brain tissue (15±2 mg) using methanol/methyl tert-
butyl ether (1:2, v/v) and (trans-)esterified to fatty acid methyl esters (FAME) 
with methanolic hydrogen chloride as described [16 (see Chapter 3)]. The 
method was extended to cover C20:3 n9, C22:5 n6 (n6-DPA) and 20:4 n3 
allowing to calculate wt %n3 and wt %n6 in HUFA. FAMEs were analyzed by 
means of gas chromatography with flame ionization detection [16 (see Chapter 
3)] and quantified using methyl pentacosanoate as internal standard. For 
oxylipin analysis, brain from C57BL/6 mice (50±5 mg) was homogenized 
following addition of internal standards and antioxidant solution [17 (see 
Chapter 4), 18] in 750 µL ethyl acetate and 500 µL water (pH 6). Brain tissue 
was homogenized in a ball mill using two 3 mm metal beads (25 Hz, 5 min, 
Retsch, Haan, Germany). Following centrifugation (20 000 xg, 5 min, 4 °C), the 
organic phase was collected and the sample was extracted with another 750 µL 
ethyl acetate. The dried lipid extract was reconstituted in 300 µL methanol, 
diluted with water to 6 mL and acidified with acetic acid (to pH 3). Extraction 
was carried out on C18 material (500 mg, Macherey-Nagel, Düren, Germany) 
as described [17 (see Chapter 4), 18] using methyl formate as eluent. Brain 
tissue from NMRI mice was pulverized in liquid nitrogen in a mortar and 50±5 
mg were homogenized, after addition of internal standards and antioxidant 
solution [17 (see Chapter 4), 18], in acidified methanol (0.2% formic acid) using 
a ball mill (15 Hz, 8 min, see above). After centrifugation (20 000 xg, 5 min, 4 
°C), the supernatant was diluted with 1 M sodium acetate (pH 6.0) to 3 mL and 
extracted on an unpolar (C8)/anion exchange mixed mode material (Bond Elut 
Certify II, 200 mg, Agilent) using ethyl acetate/n-hexane (75:25 v/v) with 1% 
acetic acid as eluent [17 (see Chapter 4)]. Oxylipins were quantified by liquid 
chromatography-mass spectrometry (LC-MS) following negative electrospray 
ionization on a QTrap6500 mass spectrometer (Sciex, Darmstadt, Germany) 
operated in scheduled selected reaction monitoring mode [17 (see Chapter 4), 
18]. All results are presented as mean ± standard error of the mean (SEM). 
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7.2.4 Transcription analysis by quantitative real-time PCR (qRT-PCR) 
For qRT-PCR analysis, cerebrum cortex tissue from NMRI mice was used. Due 
to limitations of cerebrum tissue, tissue from the cerebellum of C57BL/6 mice 
had to be used for qRT-PCR analysis. Brain tissues were stabilized with 
RNAlater (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions and stored at -80 °C. Total RNA was isolated from brain tissue (~20 
mg) using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
instructions. Quantification of RNA and assessment of purity was conducted 
using a NanoDropTM 2000 c spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA, USA). To remove residual genomic DNA, total RNA was treated 
with TURBO DNA-freeTM Kit according to the manufacturer‘s instructions 
(Thermo Fisher Scientific). First strand cDNA was synthesized from total RNA 
(1 µg) using the iScipt cDNA synthesis kit (BioRad, Munich, Germany) 
according to the manufacturer‘s instructions. qRT-PCR was performed on a CfX 
96 TouchTM real time PCR detection system (BioRad). All Primers were 
received from Biomol (Biomol, Hamburg, Germany) except EPHX2 (BioRad). 
Oligonucleotide primer sequence, product sizes and primer concentrations for 
qRT-PCR are displayed in Table 7.1. DNA for qRT-PCR was diluted 1:10 with 
RNase free water (Qiagen) before use and experiments were performed in 
triplicates. qRT-PCR cycling conditions for Fads2 were 95 °C for 3 min followed 
by 50 cycles of 95 °C for 10 s, 58 °C for 45 s and 72 °C for 29 s. q-PCR 
conditions for Ptgs2 were 95 °C for 3 min followed by 45 cycles  95 °C for 10 s, 
56 °C for 30 s and 72 °C for 29 s. qRT-PCR cycling conditions for Fads1 were 
were 95 °C for 3 min followed by 50 cycles of  95 °C for 10 s, 58 °C for 45 s and 
72 °C for 29 s. qRT-PCR conditions for EPHX2 were 95 °C for 3 min followed 
by 40 cycles of  95 °C for 10 s, 56 °C for 30 s and 72 °C for 29 s. Gene 
expression was analysed using the 2(-ΔΔCq) method using BioRad Cfx 
manager (BioRad) and Biogazelle qbase+ (Biogazelle, Zwijnaarde, Belgium) 
and normalized to the levels of β2 microglobulin (B2M) and phosphoglycerat 
kinase 1 (PGK1). 
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Table 7.1: Oligonucleotide primer sequences, product sizes and primer concentrations for qRT-
PCR. 
Gene Primer Sequence Product size (bp) Primer conc. (nm) 
EPHX21 N/A N/A sixfold dilution (6x) 
Fads1 
5’-aagcacatgccatacaacca-3’ 
5’-cagcggcatgtaagtgaaga-3’ 
177 200 
Fads2 
5’-aaagagcctgcatgtgtttg-3’ 
5’-gatgccgtagaaagggatgt-3’ 
250 100 
Ptgs2 
5’-tgatcgaagactacgtgcaa-3’ 
5’-gtgagtccatgttccaggag-3’ 
229 100 
bp base pairs, conc. Concentration                
1
commercial primer, no information available (N/A) 
 Results and Discussion 7.3
The aim of this study was the investigation of the effect of n3-PUFA 
supplementation on the activity of PUFA metabolizing enzymes in murine brain. 
Utilizing targeted oxylipin metabolomics and fatty acid analysis accompanied by 
qRT-PCR, changes in the product patterns of the enzymes were correlated to 
their transcription levels in brain.  
During the feeding experiments, no differences in feeding and animal behavior 
were observed. Feeding of a diet containing 1% EPA and 1% DHA as ethyl 
esters led to slight changes in the overall fatty acid pattern (Fig. 7.2 I). However, 
changes in the brain PUFA composition of the animals were distinct (Fig. 7.2 II). 
In C57BL/6 mice, concentrations of most ALA downstream products, covered 
by the method, were increased compared to baseline (from 6.1±0.5 to 6.9±0.4 
µg/mg for DHA, from <0.002 to 0.084±0.005 µg/mg for EPA and from 
0.037±0.003 to 0.18±0.01 µg/mg for n3-DPA, respectively, Fig. 7.2 IIA, App. 
Table 9.4.1), while concentrations of arachidonic acid (C20:4 n6, ARA) were 
decreased (from 4.6±0.4 to 3.9±0.3 µg/mg, Fig. 7.2 IIA, App. Table 9.4.1). 
Consequently, downstream products of ARA, C22:4 n6 and n6 
docosapentaenoic acid (C22:5 n6, n6-DPA) formed from ARA by elongation 
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(C22:4 n6) with subsequent desaturation and β-oxidation in peroxisomes (n6-
DPA)[19] were also found at significantly lower concentrations (Fig. 7.2 IIA). 
Interestingly, levels of C20:3 n6 (dihomo gamma-linolenic acid, DGLA), 
precursor of ARA in the fatty acid biosynthesis, were increased (Fig. 7.2 IIA), 
indicating elevated conversion of linoleic acid (C18:2 n6, LA) to longer chain 
PUFA, which is further supported by the D6D index (Fig. 7.2 IVA, see below). 
The desaturation product of LA, gamma-linolenic acid (C18:3 n6, GLA) was 
below the limit of detection in both feeding groups (Fig. 7.2 IIA, STD and 
STD+n3), suggesting that this FA is quickly further metabolized. This is 
consistent with previous results, reporting that the first step in the conversion of 
LA/ALA (the desaturation of LA/ALA by delta-6 desaturase (Fads2)) [19, 20] to 
longer chain PUFA is rate limiting. An independent feeding experiment (new 
batch of n3-PUFA chow, different animal facility, different mouse strain (NMRI)) 
led to same effects (Fig. 7.2 B), though absolute PUFA concentrations were 
slightly lower. Changes observed in the absolute fatty acid pattern were 
reflected in relative levels (App. Fig. 9.4.1, Table 9.4.2). 
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Fig. 7.2: Fatty acid concentrations in brain tissue of of C57BL/6 (A) and NMRI-mice (B) fed 
with a standard sunflower oil based diet (STD) or the same diet enriched with n3-PUFA 
(STD+n3). Shown are (I) relative amounts of saturated (SFA), monounsaturated (MUFA), n3 
and n6 polyunsaturated fatty acids (PUFA) as well as (II) selected n3- and n6-PUFA. n9-PUFA 
are not shown in (I) due to relative amounts below 0.2 % of total FA. The LOQ for an analyte is 
indicated as dashed line in case it was not exceeded in >50% of the samples per group.  (III) 
wt%n3 and wt%n6 in HUFA (highly unsaturated fatty acids) were calculated as follows, modified 
from [21] (C20:3 n9 not quantified): %n3 in HUFA = 100*(C20:5 n3 + C22:5 n3 + C22:6 
n3)/(C20:3 n6 + C20:4 n6 + C22:4 n6 + C22:5n6 + C20:5 n3 + C22:5 n3 + C22:6 n3); %n6 in 
HUFA = 100*(C20:3 n6 + C20:4 n6 + C22:4 n6 + C22:5n6)/(C20:3 n6 + C20:4 n6 + C22:4 n6 + 
C22:5 n6 + C20:5 n3 + C22:5 n3 + C22:6 n3). (IV) Desaturase indices of the delta-5 desaturase 
(D5D) and delta-6desaturase (D6D) were calculated according to [29]: D5D=C20:4 n6/C20:3 n6 
and D6D=C20:3 n6/C18:2. Statistical differences were determined with a two-tailed t-test for 
unpaired samples (* p<0.05, ** p<0.01, *** p≤0.0001). No t-test was performed for C 18:3 n3 
and C20:5 n3. Results are shown as mean ± SEM. 
In both models, feeding of the n3-PUFA enriched diet massively changed the 
%n3 and %n6 in HUFA ratio (modified from [21]) in the cerebral tissue (Fig. 7.2 
III). The changes in PUFAs in cerebrum are consistent with previous studies in 
rodents: Following three weeks of feeding an almost identical (~1% EPA and 
DHA) diet to rats (four weeks of age), Arnold et al. found an increase from 16% 
to 20% DHA and a decrease in ARA (13% to 11%) and n6-DPA (2.7% to 0.9%), 
while EPA levels (0.1%) were not altered [22]. However, Bourre et al. found 
almost no increase in DHA (12.1% vs 12.3%) and no change in EPA in 190-200 
g rats after a feeding period of 8 weeks with 1.5% fish oil in the diet, while other 
downstream products of LA/ARA pathways were similarly modulated as 
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observed here (slight increase in DGLA and n3-DPA, decrease in ARA, n6-DPA 
and 22:4 n6) [23]. With a higher concentration of fish oil in the diet, the FA 
pattern, including DHA and EPA, was stronger modulated [23]. When looking at 
observed the effects, one could argue that the low ALA (and other n3-PUFA) 
content in the control diet (sunflower oil) led to a depletion of n3-PUFA in the 
brain of the control group causing the differences to the DHA/EPA feeding 
group. Indeed, Joffre et al. demonstrated that 4 months old C57BL/6 mice 
growing up on an n3-PUFA deficient diet had lower DHA and EPA brain levels 
than animals on a balanced n6/n3 diet [24]. However, Bourre et al. found that 
feeding a diet low in ALA over 7 months did not affect brain DHA content of 
adult rats [25]. Our experiment was carried out in grown up mice, aged 9-10 
weeks, when the brain development is almost finished [26]. Thus, it is 
somewhat remarkable that the rather short DHA and EPA supplementation (30 
days) could significantly change brain PUFA pattern. These findings are 
consistent with our recent study in old (24 month) mice, showing that fish oil 
supplementation by oral gavage for 21 days significantly increased DHA but not 
EPA levels in the brain [27]. Extrapolating from mice to men, this indicates that 
brain lipid composition may be directly and rapidly influenced by diet in adult 
age. This is consistent with the improved cognition in healthy subjects following 
n3-PUFA supplementation demonstrating a direct effect on brain physiology [5, 
6]. 
The change in PUFA levels in brain compelled us to ask the question how 
PUFA metabolizing enzymes in brain are modulated by n3-PUFA 
supplementation. This is of particular importance in the context that the index of 
delta-5 desaturase (D5D) activity significantly increased in blood/plasma of 
human subjects supplemented with fish oil, whereas the index of delta-6 
desaturase (D6D) activity decreased post-supplementation [28, 29]. Utilizing the 
product/substrate ratios of FA as marker for D5D and D6D activity (FAMEs 
C20:4 n6/C20:3 n6 as marker of D5D activity and C20:3 n6/C18:2 n6 for D6D 
[29]), we evaluated the effect of n3-PUFA feeding on these key enzymes in 
PUFA synthesis. In both mouse strains the brain PUFA composition indicated a 
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massive change in the activity of the two desaturases. The D6D index was 
highly increased. This is consistent with the finding that feeding of EPA/DHA 
significantly induced gene transcription of Fasd1 in cerebrum cortex tissue 
isolated from NMRI mice (Fig. 7.3 e), indicating that the increase in D6D activity 
was at least partly due to elevated enzyme levels. The D5D index however, was 
significantly decreased, while expression analysis of Fads1 (D5D) showed an 
increase similar to Fads2 (D6D, Fig. 7.3). In the cerebellum of C57BL/6 mice 
D5D and D6D activity indices were similarly modulated compared to NMRI 
mice, while expression of both desaturase genes was barely influenced in the 
cerebellum, with a slight tendency to an upregulation in Fads2 (Fig. 7.3 a,b).  
 
Fig. 7.3: Relative normalized mRNA (a, b, c, d, e, f, g, h) expression from C57BL/6 (a-d) and 
NMRI (e-h) mice of delta-5-desaturase (a, e), delta-6-desaturase (b, f),cyclooxygenase 2 
(COX2, c, g) and epoxide hydrolase 2 (EPHX2; d, h) in brain homogenate determined using 
quantitative real-time PCR; mRNA expression of LA is 100 %; n= 7-8; mean ± SEM; unpaired t-
test with *P < 0.05; **P < 0.01; ***P < 0.001; mRNA expression is normalized to the expression 
levels of β2 microglobulin (B2M) and phosphoglycerat kinase 1 (PGK1). 
In Fads2-null mice fed a high n6/n3-PUFA diet, Fads1 mRNA levels were 
significantly higher in liver tissue. However, diet and genotype had little effect on 
brain PUFAs in those mice [30]. Feeding rats an n3-PUFA deficient diet up-
regulated D6D activity and mRNA levels in the liver but neither D5D nor D6D 
activity nor gene expression were changed in the brain [31]. Expression levels 
of Fads2 decreased in growing finishing pigs when DHA was introduced into the 
diet [32]. Mice fed EPA-rich vegetable or fish oils showed lower Fads1 mRNA 
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levels in liver tissue. Fads2 mRNA levels were only enhanced by the EPA-rich 
camelina sativa seed oil lacking any DHA [33]. Moreover, it was shown in rats 
that dietary intervention, in form of n3-PUFA deprivation, led to an increased 
elongase (2 and 5) and desaturase (delta5- and delta-6) expression in liver, 
while no effect on brain was found [34]. These results suggest that higher levels 
of, e.g. DGLA leading to a higher D5D activity as observed in NMRI and 
C57BL/6 mice might also be a result of an increased expression or activity of 
Fads2 in liver. The observed modulation in brain PUFA and the D5D/D6D 
indices might thus be a result of changed PUFA supply from the plasma rather 
than from changes in brain enzyme activities. However, NMRI mice clearly 
showed a modulation of mRNA level between animals on a standard sunflower 
oil based diet and mice supplemented with n3-PUFA. While D6D activity as well 
as Fads1 and Fads2 expression levels were elevated, D5D activity was 
decreased. However, there is evidence from gene expression data that Fads2 
correlates with Fads1 brain expression in human and mice [35] and it has been 
shown that in Fads1-null mice PUFA levels determined in brain and liver 
reflected decreased D5D and normal D6D activity [36]. Keeping in mind that the 
plasma unesterified fatty acid pool is the main source for brain PUFA, the 
discrepancy between the D5D index (estimated by the ratio of C20:4 n6 to 
C20:3 n6) and elevated Fads1 expression levels, could be a result of a 
depletion of ARA in plasma in response to n3-PUFA supplementation, as shown 
previously in plasma of rats on an almost identical diet (see above) [22].  
Evidence exists that fatty acid uptake from plasma is not selective, i.e. EPA and 
DHA are transported similarly into the brain [37]. However, consistent with 
previous findings [22-24], EPA level in brain were very low in comparison to 
DHA level. It has been shown that EPA in brain is quickly metabolized, with β-
oxidation playing an important role [37, 38]. Although conversion of EPA to DHA 
plays a minor role in the metabolism of EPA (radioactivity found in DHA was 
only 0.064% of a single injection of 10 µCi 14C-EPA into rat brain [38]), 
increased Fads2 level might be a response to sub-chronical (30 days) exposure 
to high plasma level of EPA. However, this question warrants further 
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investigation. In this context, it will be important to investigate the effect of EPA 
alone on the expression of fatty acid metabolizing enzymes. 
The effect of n3-PUFA feeding on selected enzymes of the AA cascade was 
investigated by quantitative targeted metabolomics utilizing the tissue 
concentration of selected oxylipins as pathways markers (Fig. 7.4). For COX 
activity, the concentrations of PGE2, PGD2, PGF2α and 6-keto-PGF1α 
(prostacyclin (PGI2) hydrolyzation product) as well as thromboxane (Tx) B2 were 
evaluated. In both models n3-PUFA feeding massively decreased the brain 
levels of these prostanoids. This is consistent with a previous study, showing 
that n3-PUFA feeding (17 weeks) to 70 weeks old rats led to decreased level of 
PGE2, PGD2 and PGF2α in brain cortex [39]. mRNA levels of Ptgs2 encoding for 
COX2 indicate that expression changes were not responsible for decreased 
levels in prostanoids: Feeding of EPA/DHA had no effect on gene expression of 
Ptgs2 encoding for COX2 in cerebrum cortex tissue isolated from NMRI mice 
(Fig. 7.2 g) and in the cerebellum of C57BL/6 mice Ptgs2 expression was 
significantly enhanced (Fig. 7.2 c) which might reflect a compensatory up-
regulation of COX2 gene expression. Another explanation for the observed 
lower concentrations of ARA prostanoids might be a lower substrate availability, 
since ARA levels were slightly decreased in brain following n3-PUFA 
supplementation. Moreover, EPA can be converted in the COX pathway of the 
ARA cascade to series 3 PGs, at conversion rates much lower compared to 
ARA[40], thereby reducing level of potent, inflammation mediating ARA 
metabolites, like PGE2, which is a common explanation for the anti-
inflammatory effects of n3-PUFA [1, 2]. Concentrations of most EPA derived 
oxylipins were low, probably because of low EPA concentrations in combination 
with low conversion rates (Fig. 7.4). However, the slight change in substrate 
availability might not compensate for the massive decrease observed in ARA 
eicosanoids. As discussed for PUFA, changes in peripherally formed 
prostanoids, which might pass the blood-brain barrier, as shown exemplary for 
PGE1 in rats [41] and PGD2 in mice [42], might account for part of the observed 
changes in prostanoid concentrations. However, uptake of PG from plasma was 
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low [41, 42]. Since the expression of 15-hydroxyprostaglandin dehydrogenase, 
an important enzyme in the inactivation of PGs, is low in adult brain tissue and 
PGs are deprotonated at physiological pH, indicating low diffusion rates [43], an 
active transport, e.g. via organic anion transporter 3 (Oat3) or multidrug 
resistance-associated protein 4 (Mrp4) [43] through the blood-brain barrier is 
likely. Thus, decreased concentrations of PG observed in this study could be a 
result from increased efflux. 
 
Fig. 7.4: Concentrations of AA derived COX products PGE2, TxB2, PGD2, 6-keto-PGF1α and 
PGF2α in (A) C57BL/6 mice and (B) NMRI mice fed with a standard sunflower oil based diet 
(STD) or the same diet enriched with n3-PUFA (STD+n3). From all EPA derived prostanoids 
covered by the LC-MS method, only PGD3 and TxB3 could be quantified in STD+n3 fed mice. 
Concentrations were 3.1 ± 0.3 nmol/kg and 0.96 ± 0.08 nmol/kg in C57BL/6 mice and 2.7 ± 0.2 
nmol/kg and 0.8 ± 0.1 nmol/kg in NMRI mice for PGD3 and TxB3, respectively. Statistical 
differences were determined using a two-tailed t-test for unpaired samples (* p<0.05, *** 
p≤0.001). (II) Comparison of 5-LOX products (5-HETE, 5-HEPE, 4- and 7-HDHA), 12-LOX 
products (12-HETE, 12-HEPE, 14-HDHA) and 15-LOX products (8- and 15-HETE, 8- and 15-
HEPE, 10- and 17-HDHA) of ARA, EPA and DHA in the STD and STD+n3 feeding groups of (A) 
C57BL/6 and (B) NMRI mice. EPA derived 5-LOX and 15-LOX products were <LOQ (5-HEPE: 
0.5; 8-HEPE: 0.63 and 15-HEPE: 1.25 nmol/kg) in C57BL/6 mice of the STD feeding group. 
EPA derived 5-LOX and 12-LOX products were <LOQ (5-HEPE: 0.5 and 12-HEPE: 0.63 
nmol/kg) in NMRI mice of the STD feeding group and 15-LOX products were <LOQ (8-HEPE: 
0.63 and 15-HEPE: 1.25 nmol/kg) in NMRI mice of both feeding groups. 
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The LOX products of EPA and DHA increased in C57BL/6 mice following n3-
PUFA supplementation (Fig. 7.2), while ARA derived LOX products decreased 
in both models as described in previous studies in plasma and serum of men 
[44-47]. Consistently, feeding of n3-PUFAs (17-weeks) to 70 weeks old rats let 
to increases in EPA and DHA derived LOX products, while ARA lox products 
were not altered [39]. However, the levels of the LOX products did not show a 
consistent trend regarding a modulation of LOX activity in the two mouse strains 
(Fig. 7.4).  
Changes in the activity of the “third branch” of the ARA cascade were evaluated 
using the levels of epoxy-FA and dihydroxy-FA as marker (Table 7.2). 
Exceeding the commonly observed replacement of n6-PUFA derived epoxy-FA 
by n3-epoxy-FA in plasma or serum of men [45-47] or in plasma and tissues of 
rats (however not in cerebral cortex showing elevated epoxy-ARA) [22], the 
overall sum of epoxy-FA levels in brain as well as the epoxy-FA/dihydroxy-FA 
ratios (in NMRI mice) were markedly reduced (Table 7.2). This indicates a 
higher activity of the soluble epoxide hydrolase (sEH), i.e. EPHX2. Using the 
tissue concentration of epoxy-FA and the ratio of epoxy- to dihydroxy-FA from 
LA as a sensitive marker for sEH activity [48], decreased concentrations in 
epoxy-FA levels were observed in both models, being statistically highly 
significant in NMRI mice. Consistently, all ARA derived epoxy-FA in C57BL/6 
and NMRI mice and corresponding epoxy/diol ratios in NMRI mice were 
decreased. In C57BL/6 mice, concentrations of DHA derived epoxy-FA (13(14)-, 
16(17)-, 19(20)- epoxy docosapentaenoic acid (EpDPE)) and dihydroxy-FA 
(19,20- dihydroxy docosapentaenoic acid (DiHDPE)) were elevated in response 
to n3-PUFA supplementation. This can be explained by the higher enzyme 
specificity towards n3-PUFA, e.g. ARA:EPA:DHA 1:4.2:1.5 of CYP2J2, a PUFA-
epoxygenase [13, 22], in combination with a slight shift in the brain PUFA 
pattern (decrease in ARA, increase in DHA). Nonetheless, the ratio of the main 
DHA metabolite 19(20)-EpDPE/19,20-DiHDPE also reflected the increased sEH 
activity. In NRMI mice, the levels of DHA epoxy-FA were even decreased 
following n3-PUFA supplementation indicating a massively higher sEH activity, 
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which is additionally supported by an increase in the hydrolyzation product of 
19(20)-EpDPE, 19,20-DiHDPE. Though not all epoxy-FA and epoxy/dihydroxy-
FA ratios showed a statistically significant reduction in response to n3-PUFA 
treatment, level of LA, ARA and DHA metabolites clearly indicated that n3-
PUFA treatment increased sEH activity in the brain in both models.  
Table 7.2: Concentrations of epoxy-fatty acids (Ep-FA), dihydroxy-FA (DiH-FA) as well as the 
ratio of the corresponding Ep-FA/DiH-FA in brain tissue of (A) C57BL/6 mice and (B) NMRI 
mice fed with STD-diet and n3-PUFA enriched STD diet. Additionally, selected sums of Ep-FA 
and DiH-FA along with their respective ratios are shown. Enzymatically formed products of LA 
(EpOME/DiHOME), ARA (EpETrE/DiHETrE), and DHA (EpDPE/DiHDPE) are presented. Due to 
chemical instability, 5(6)-EpETrE, and 4(5)-DiHDPE were not evaluated. Statistical differences 
were determined with a two-tailed t-test for unpaired samples. Results are shown as mean ± 
SEM. 
A) C57BL/6 
  STD STD+n3 t-test 
FA  
precursor 
isomer Ep-FA DiH-FA ratio EP-FA DiH-FA ratio Ep-FA DiH-FA ratios 
LA 9,10 8.0 ± 1 1.9 ± 0.2 4.5 ± 0.9 6.3 ± 1.2 1.3 ± 0.1 4.8 ± 0.7 n .s. <0.01 n .s. 
 
12,13 8.8 ± 2 3.5 ± 0.2 2.6 ± 0.5 7.1 ± 1.3 2.2 ± 0.2 3.1 ± 0.4 n .s. <0.01 n .s. 
 
sum 17 ± 3 5.4 ± 0.4 3.2 ± 0.6 13 ± 2 3.5 ± 0.3 3.7 ± 0.5 n .s. <0.01 n .s. 
ARA 8,9 22 ± 4 <0.5
*
  -
+
 16 ± 3 <0.5
*
  -
+
 n .s.   
 
11,12 64 ± 11 0.73 ± 0.07 86 ± 9 48 ± 11 0.56 ± 0.04 85 ± 19 n .s. n .s. n .s. 
 
14,15 39 ± 6 1.3 ± 0.1 29 ± 3 33 ± 7 1.03 ± 0.04 31 ± 6 n .s. <0.01 n .s. 
 
sum 130 ± 20 2.1 ± 0.2 57 ± 7 97 ± 21 1.59 ± 0.07 59 ± 11 n .s. <0.05 n .s. 
DHA 7,8 
 
-
#
 
 
<1
*
 -
+
 
 
- 
#
 <1
*
 -
+
 
   
 
10,11 5.3 ± 1.1 <0.25
*
 -
+
 7.2 ± 1 <0.25
*
 -
+
 n .s. 
  
 
13,14 4.3 ± 0.8 <0.25
*
 -
+
 6.4 ± 1 <0.25
*
 -
+
 n .s. 
  
 
16,17 4.1 ± 0.7 <0.5
*
 -
+
 5.9 ± 1 <0.5
*
 -
+
 n .s. 
  
 
19,20 6.3 ± 0.9 1.6 ± 0.2 3.9 ± 0.4 12 ± 3 4.8 ± 0.6 2.6 ± 0.5 n .s. <0.001 n .s. 
 
sum 20 ± 3 1.6 ± 0.2 12 ± 1 31 ± 6 4.9 ± 0.6 6.9 ± 1.3 n .s. <0.001 <0.05 
 
sum 
of all 
160 ± 20 9.1 ± 0.6 18 ± 2 140 ± 20 10 ± 1 15 ± 2 n .s. n .s. n .s. 
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Table 7.2: Continued 
B) NMRI 
  STD STD+n3  t-test  
FA  
precursor 
isomer EP-FA DiH-FA ratio EP-FA DiH-FA ratio  EP-FA DiH-FA ratios 
LA 9,10 7.1 ± 1.0 2.0 ± 0.2 3.5 ± 0.3 3.1 ± 0.4 1.7 ± 0.1 1.7 ± 0.2 <0.01 n .s. <0.01 
 
12,13 6.7 ± 0.8 2.4 ± 0.2 2.8 ± 0.3 3.2 ± 0.4 2.0 ± 0.1 1.6 ± 0.2 <0.01 n .s. <0.01 
 
sum 14 ± 2 4.5 ± 0.3 3.1 ± 0.3 6.3 ± 0.8 3.7 ± 0.3 1.7 ± 0.2 <0.01 n .s. <0.01 
ARA 8,9 54 ± 8 0.76 ± 0.09 78 ± 14 13 ± 2 <0.5*  -
+
 <0.001   
 
11,12 50 ± 8 0.98 ± 0.09 55 ± 10 14 ± 3 0.44 ± 0.02 34 ± 7 <0.001 <0.001 n .s. 
 
14,15 69 ± 9 1.8 ± 0.2 42 ± 7 27 ± 5 0.80 ± 0.03 35 ± 6 <0.001 < 0.001 n .s. 
 
sum 170 ± 20 3.4 ± 0.4 57 ± 10 55 ± 10 1.23 ± 0.04 45 ± 8 <0.001 <0.0001 n. s. 
DHA 7,8  -
#
 <1*  -
+
  -
#
  <1*  -
+
    
 
10,11 18 ± 3 0.35 ± 0.06 58 ± 10 6.3 ± 1.1 0.26 ± 0.01 24 ± 4 <0.01 n .s. <0.01 
 
13,14 10 ± 1 0.38 ± 0.07 30 ± 5 3.6 ± 0.7 <0.25
*
 
<0.5
*
 
-
+
 
-
+
 
<0.01 
  
 
16,17 8.7 ± 1.2 0.75 ± 0.11 14 ± 3 3.8 ± 0.7 <0.01 
  
 
19,20 38 ± 4 2.5 ± 0.3 17 ± 3 16 ± 2 4.8 ± 0.3 3.4 ± 0.3 <0.001 <0.001 <0.001 
 
sum 75 ± 9 3.9 ± 0.8 24 ± 4 30 ± 4 5.2 ± 0.5 5.8 ± 0.7 <0.001 n. s. 0.001 
 
sum  
of all 
260 ± 40 12 ± 1 67 ± 11 91 ± 14 10 ± 1 13 ± 1 <0.001 n. s. <0.01 
* Analyte was <LOQ in >50% of the samples of one group. In this case the LOQ is shown. 
#
  Analyte was not included in LC-MS-method. 
+
 If the concentration of either Ep-FA or DiH-FA was <LOQ in more than 50% of the samples of 
one group, or if the analyte was not included in the LC-MS method, no ratio was calculated. 
 
Consistently, a significant increase in EPHX2 mRNA levels in response to n3-
PUFA feeding was found in the cerebrum of NRMI mice and cerebellum of 
C57BL/6 (Fig. 7.2 d,h). In the rodent brain, sEH is expressed in the white matter 
mainly neuronal and not vascular or glial [49, 50]. A modulation of sEH activity 
regulating the endogenous levels of epoxy-FA in the brain is of high biological 
relevance, because epoxy-FA derived from ARA (EpETrEs, EETs) are key 
mediators in the brain [49, 50]. Similar to their action in the periphery, epoxy-
ARA regulate vascular tone and cerebral blood flow [50]. Moreover, they show 
distinct effects in the central nervous system (CNS), including astrocyte-
mediated coupling and pain processing [14, 50, 51]. It is highly remarkable that 
the analgesic action is effective in both, inflammatory as well as non-
inflammatory pain [51]. Administration of epoxy-FA or increasing epoxy-FA 
concentration, e.g., by application of potent inhibitors of sEH (sEHi), protects 
against neuronal cell death caused by ischemia [52] and higher sEH activity is 
correlated to a higher stroke risk [49, 53]. Elevation of epoxy-FA can also be 
CHAPTER 7 
 
152 
 
protective in subarachnoid hemorrhage [54]. In addition to their vasodilatory 
effects, part of this protection could be caused by the anti-inflammatory action of 
epoxy-FA leading to reduced pro-inflammatory cytokine production [55]. 
However, the anti-inflammatory efficacy in the CNS is not as established as in 
the periphery [50]. Though a large number of molecular targets of epoxy-FA 
could be uncovered, including the transient receptor potential vanilloid-4 
(TRPV4) as well as peroxisome proliferator-activated receptor (PPAR) and a 
potential G-coupled receptor, their molecular mode of action remains largely 
unclear [15, 50]. It is important to notice, that not only epoxy-ARA is biologically 
active, but also other epoxy-FA, particularly epoxy-EPA and epoxy-DHA. When 
sEHi are used to increase epoxy-FA levels, particularly in neuronal tissue – 
because of the high DHA content – epoxy-DHA is similarly elevated compared 
to epoxy-ARA [51]. With respect to nociceptive signaling, DHA epoxides were 
equally potent in reducing local pain elicited by carrageenan injection in rats as 
epoxy-ARA, while the effect of DHA metabolites lasted longer [56]. Regarding 
their vascular effects, EPA and DHA epoxides activate large-conductance 
calcium-activated potassium channels in coronary vascular smooth muscle cells 
[57, 58]. In these experiments, one DHA-epoxide was over 1000-times more 
potent than the ARA derived ones [57]. Speculating that epoxy-FA from n3-
PUFA are also more active in CNS function, the increase in sEH activity 
following n3-PUFA supplementation might be a homeostatic response to control 
action of epoxy-FA, e.g. increased vasodilation in brain. Taken the role of 
elevated/decreased sEH activity in the (patho)physiology in the CNS into 
account, the finding that n3-PUFA supplementation increases sEH activity 
warrants further investigation. In case n3-epoxy-FA are indeed more active than 
n6-epoxy-FA, this finding may also pave the route for a new pharmacological 
intervention by combined administration of sEH inhibitors with n3-PUFA, e.g. in 
prevention and treatment of a stroke or inflammatory and non-inflammatory 
pain. 
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8 Chapter 8 
Future Perspectives 
 Overall, this thesis aimed to establish sample preparation techniques and 
analytical tools to investigate the modulation of the endogenous fatty acid and 
oxylipin pattern. The methods were used to thoroughly characterize the total 
fatty acid and free oxylipin profile in tissues and blood in two frequently used 
models for the investigation of n3-PUFA related effects. Though time dependent 
changes in blood and a large number of tissues were described in detail, 
several questions remain: A large portion of oxylipins is found esterified in lipids, 
e.g. polar lipids such as phosphatidylcholine or phosphatidylserine. These 
bound oxylipins, and thus changes in their levels, were not monitored in the 
thesis. Moreover, it would be highly relevant to investigate changes in the 
different fractions of blood, i.e. lipoproteins and membranes of different types of 
blood cells. For this purpose in the future, separation of cells, membranes, 
lipoproteins and lipid classes before analysis would be highly interesting 
allowing evaluation of n3-PUFA induced changes in more detail. 
A key finding of this thesis is that the overall fatty acid profile of the adult murine 
brain is only slightly modulated by n3-PUFA, while distinct changes occurred in 
the profile of polyunsaturated fatty acids and oxylipins. The relevance of these 
findings is supported by two independent feeding experiments showing the 
same effect. Using concentrations of products and ratios of products and 
substrates as activity markers as well as transcription analysis, a significant 
increase in the expression of the soluble epoxide hydrolase, the enzyme 
hydrolyzing bioactive epoxy-FA to their less potent dihydroxy-FA, was found. 
Epoxy- ARA play an important role in the regulation of cerebral blood flow, 
vascular tone and inflammatory as well as non-inflammatory pain. Assuming a 
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similar or even a higher potency of epoxy-FA from EPA and DHA, as is the case 
in the periphery, the increase in the soluble epoxide hydrolase might be a 
compensatory mechanism to regulate epoxy-FA level.  
Based on these results, it would be highly interesting to investigate whether an 
increase in endogenous epoxy-FA from EPA and DHA in cerebral tissue, either 
by administration of potent inhibitors of the soluble epoxide hydrolase or by 
direct administration of epoxy-FA, might induce effects discussed for n3-PUFAs, 
like improvement of cognitive function and reduction of memory loss. The 
results from these experiments would additionally provide insights in the 
molecular mechanisms. 
Interestingly, increased expression of the soluble epoxide hydrolase has been 
associated with a higher risk for stroke, while dietary intake of n3-PUFA has 
been correlated with a reduced risk of stroke. Thus, it would be of high 
importance to evaluate a combined treatment with inhibitors of the soluble 
epoxide hydrolase and n3-PUFAs as a new pharmaceutical approach to 
prevent or treat stroke. 
.
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9 Summary 
Although the dietary intake of omega-3 polyunsaturated fatty acids (n3-PUFA) 
has been associated with beneficial effects in different diseases, their 
importance for human health has not been fully unveiled. Additionally, many 
questions regarding the power to modulate the endogenous profile of oxidative 
PUFA metabolites – oxylipins – remain (see Chapter 2). To answer these 
questions and for the investigation of n3-PUFA related effects, powerful 
analytical methods are needed in order to characterize modulations in the 
endogenous profile of fatty acids and oxylipins, e.g. upon dietary intervention. 
Thus, the first part of this thesis deals with the optimization of sample 
preparation procedures for the quantification of total fatty acids and free 
oxylipins in biological samples. 
An important step in the analysis of the total fatty acid profile in biological 
samples is the (trans-)esterification of lipids in order to generate fatty acid 
methyl esters which can be analyzed by gas chromatography with flame 
ionization detection. Therefore, in chapter 3, different commonly used 
derivatization techniques were compared regarding their power to efficiently 
derivatize different lipid classes found in biological samples, such as plasma 
and tissues. Using lipid standards, it was found that transesterification to methyl 
esters using methanolic hydrogen chloride was most efficient, while other 
methods showed a discrimination of specific lipid classes. In plasma, this 
resulted in distinct differences in the determined fatty acid profile. Moreover, a 
halogenated-solvent free method based on methyl tert-butyl ether and methanol 
was found to be equivalent for the extraction of lipids from small liver and 
plasma samples to a standard, chloroform/methanol based extraction 
procedure. 
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Chapter 4 and 5 describe different approaches for the extraction of free 
oxylipins from plasma and cell culture medium. For the extraction of free 
oxylipins of all different classes, including prostaglandins, epoxy- and hydroxy-
fatty acids amongst others, solid-phase extraction is commonly applied. Due to 
the low concentration of most free oxylipins in plasma, extraction of the analytes 
as well as removal of interfering matrix have to be efficient. Thus, in chapter 4, 
commonly used solid phase extraction procedures for free oxylipins were 
compared regarding their power to selectively extract free oxylipins from 
plasma. In the interpretation of the results a focus was set on extraction 
efficiency of internal standards from plasma samples and the removal of ion 
suppressing matrix. Using a mixed phase comprising of a strong anion 
exchanger and C8 material, good recoveries of internal standards and reduction 
of ion suppressing matrix was found. However, extraction of unpolar epoxy-FA 
seemed to be more efficient using a protocol based on C18 material. 
In chapter 5 a fast, online-solid phase extraction liquid chromatography-mass 
spectrometry (online-SPE LC-MS) method for the quantification of hydroxylated 
fatty acids was developed. Following minimal manual sample preparation by 
mixing the sample with a methanolic internal standard solution, extraction and 
separation of the 26 hydroxy-FA were performed within a total analysis time of 
6.5 min. The method showed good sensitivity compared to state of the art 
targeted metabolomics LC–MS methods for oxylipins, narrow peaks of about 3 
sec at half maximum height and acceptable inter- as well as intra-batch 
precision for the extraction of analytes from plasma and cell culture medium. 
The method was used to characterize the pattern of hydroxy-FA formed in 
different cell lines upon incubation with ARA, eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA). 
In the second part of the thesis the modulation of the endogenous fatty acid and 
oxylipin pattern in two common in vivo models for the investigation of n3-PUFA 
biology was thoroughly characterized by applying the methods developed in 
chapter 3 and 4: On the one hand feeding of mice with a diet enriched with n3-
PUFAs EPA and DHA and on the other hand transgenic fat-1 mice which are 
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able to endogenously convert n6- to n3-PUFA. Feeding of mice with an n3-
PUFA enriched diet (1% EPA and 1% DHA ethyl ester in the diet) led to a time 
dependent increase of EPA and DHA in blood and tissues, reaching a 
maximum steady state after 14-30 days in all investigated tissues and blood. 
Compared to wild type mice fed 30 days a standard sunflower oil based diet, 
fat-1 mice on the same diet and wild type mice on the n3-PUFA enriched diet 
showed remarkably higher amounts of EPA and DHA in blood and tissues at 
the expense of n6-PUFAs, especially ARA. However, the levels of n3-PUFAs 
following feeding were higher compared to fat-1 mice, especially EPA (7.8% 
following feeding vs. 1.7% in whole blood of fat-1 mice). Trends observed in the 
fatty acid profile were reflected in most oxylipins in plasma, colon and brain. 
Taking into account that the fat-1 mouse model has been shown to be a 
powerful model for the investigation of n3-PUFA related effects, the results 
suggest that effects of n3-PUFA might already be found at endogenous n3-
PUFA levels which are achievable by dietary intervention.  
Following feeding of a diet enriched with n3-PUFA, the oxylipin pattern in brain 
was highly modulated, while changes in the overall fatty acid pattern were low. 
This interesting finding was further investigated in chapter 7. In two independent 
feeding experiments it was found that although the overall pattern of saturated 
FA, monounsaturated FA and PUFAs was barely modulated, distinct changes 
were induced in individual PUFAs following 30 days of feeding a diet enriched 
with n3-PUFAs (1% EPA and 1% DHA ethyl ester in the diet). Moreover, in both 
models a massive shift in the pattern of oxylipins from all three enzymatic 
branches of the ARA cascade was observed. Using ratios of products and 
substrates as enzyme activity marker and transcription analysis, a distinct 
modulation of the delta-5 and delta-6 desaturases and a significant increase in 
the soluble epoxide hydrolase (sEH) was unveiled. Takng the role of epoxy-FA 
in cerebral blood flow and vascular tone as well as elevated sEH activity for the 
risk of stroke into account, this finding warrants further investigation since it 
might be important for the understanding of the role of n3-PUFA in memory loss 
or stroke. 
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10 Appendix 
9.1 Chapter 4 
Table 9.1.1: Overview of the sample preparation steps for the SPE protocols 
 
Meth. 9.1.1: LC-MS oxylipin analysis 
LC-MS oxylipin analysis 
Prior analysis, the samples were kept at 4°C in a HTS xt-PAL autosampler (CTC 
Analytics, Switzerland, local distributor: Axel Semrau, Sprockhövel, Germany) 
equipped with a 20 µL sample loop and 100 µL syringe.  
A 5 μL aliquot of the sample solution is injected in the flow of an 1290 LC System 
(Agilent, Weilbronn, Germany), on an Agilent Zorbax Eclipse Plus C-18 reversed phase 
column (dimensions 2.1 x 150 mm, particle size 1.8 μm) with a Phenomenex C-18 
SecurityGuard Ultra C18 cartridge as precolumn (cat. nr. AJ0-8782, Phenomenex, 
Torrance, CA, USA) kept in a column oven at 40 °C.  
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The oxylipins are separated by a binary solvent gradient with 0.1% acetic acid as 
solvent A and 800/150/1 (v/v) acetonitrile/methanol/acetic acid as solvent B at a flow 
rate of 0.3 mL/min: 0-0.25 min isocratic 35% B, 0.25-3.00 min linear from 35% B to 
53% B, 3.00-12.50 min linear from 53% B to 68% B, 12.50-17.50 min linear from 68% 
B to 95% B, 17.50-19.00 min isocratic 95 % B, 19.00-19.10 linear from 95% B to 35% 
followed by reconditioning for 2.40 min. Utilizing the 2-position-6-port valve build in the 
MS the eluent was directed to waste during the first 2.5 min and the last 3.5 min of 
each run to reduce contamination of the MS source. 
The detection was carried out using a 6500 QTRAP instrument (AB Sciex, Darmstadt, 
Germany) following negative electrospray ionization. The oxylipins were detected in 
scheduled selected reaction monitoring mode (App. Table 9.1.2). The detection window 
was set to ±22.5 s around the expected retention time and a maximum cycle time of 
0.5 s allowing the detection of at least 18 data points per compound. 
The optimized source settings are: Ion-spray voltage of -4500 V, 35 psi curtain gas, 60 
psi nebulizer gas (gas 1) and 60 psi drying gas (gas 2) at a temperature of 475 °C. The 
vertical axis offset of the sprayer was 0.528 cm and the horizontal 0.540 cm. Nitrogen 
was used as collision gas at 12 psi (“high”) and all transitions were monitored in unit 
resolution with an entrance potential of -10 V. Analyst Software (version 1.6.2., AB 
Sciex) was used for controlling the LC-ESI-MS system and data acquisition. Multiquant 
(version 2.1.1, AB Sciex) was used for integration and quantification. The analyte 
concentrations of the samples were calculated directly by comparison of the analyte 
peak area detected with that of the IS (App. Table 9.1.2). For calibration, the analyte to 
IS ratios were fitted in a linear way reciprocally weighted by concentration. Only those 
oxylipins were included in data analysis exceeding LOQ in >60% (e.g. 3 out of 5) of the 
samples. 
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Table 9.1.2: Parameters of the LC-ESI(-)-MS/MS method for the determination of the 
concentration of oxylipins in biological samples. Shown are all analytes covered, the mass 
transition used for quantification in scheduled SRM mode, the electronical MS parameters 
(Declustering Potential (DP), Collision Energy (CE), Collision Cell Exit Potential (CXP)), the 
internal standard (IS), the retention time and its standard deviation (SD), peak width (full width 
and full width at half maximum height (FWHM)), limit of detection and the calibration range. The 
actual dynamic range for the quantification in the sample matrix depends on the dilution or 
concentration steps (10 fold for 500 µL plasma analysis) during sample preparation. 
 
 
LOD
m/z 
(MS1)
m/z 
(MS3)
DP 
(V)
CE 
(V)
CXP 
(V)
(min)
SD
1 
(sec)
Full (s)
FWHM 
(s)
LOD 
(nM)
lower 
conc
2 
(nM)
upper 
conc
3 
(nM)
6-keto-PGF1aα 369.3 163.2 -70 -36 -6
2
H4-6-keto-PGF1α 3.18 0.69 34 18 < 0.90 0.9 361
20-COOH-LTB4 365.2 347.2 -80 -25 -8
2
H4-TxB2 3.22 1.5 17 3 0.5 1 200
ResolvinE1 349.3 195 -65 -22 -10
2
H4-TxB2 3.25 0.34 13 3 0.6 1.2 480
20-OH-LTB4 351.2 195.2 -80 -25 -8
2
H4-TxB2 3.37 0.3 14 3 0.1 0.25 200
TxB2 369.2 169.1 -60 -25 -7
2
H4-TxB2 3.69 0.19 22 3 0.25 0.63 500
PGE3 349.3 269.2 -60 -22 -6
2
H4-PGE2 4.01 0.2 7 3 0.15 0.3 120
PGD3 349.3 269.2 -60 -22 -6
2
H4-PGD2 4.22 0.26 9 3 0.5 1 200
9,12,13-TriHOME 329.2 211.1 -80 -32 -10 2H4-PGE2 4.31 0.16 22 3 0.5 1.25 1000
9,10,13-TriHOME 329.2 171.1 -80 -32 -8 2H4-PGE2 4.38 0.17 16 2 0.2 0.5 400
PGF2α 353.2 309.2 -80 -26 -7
2
H4-PGE2 4.39 0.34 13 3 0.35 0.7 281
PGE2 351.2 271.3 -60 -24 -6
2
H4-PGE2 4.58 0.15 11 3 < 0.10 0.1 200
PGE1 353.3 317.2 -60 -20 -6
2
H4-PGE2 4.71 0.17 9 2 0.13 0.33 260
PGD1 353.3 317.2 -60 -20 -6
2
H4-PGD2 4.82 0.17 13 3 0.25 0.5 200
PGD2 351.2 271.3 -60 -24 -6
2
H4-PGD2 4.85 0.29 12 3 0.5 1 200
LXA4 351.2 115.2 -60 -21 -8
2
H4-PGE2 5.25 0.18 13 3 0.09 0.18 70
11,12,15-TriHETrE 353.2 167.1 -80 -28 -10 2H4-PGE2 5.23 0.1 10 3 0.5 1 100
LTB5 333.3 195.2 -65 -22 -8
2
H4-LTB4 6.58 0.16 10 3 0.1 0.25 200
PGJ2 333.3 189.2 -60 -25 -8
2
H4-PGE2 6.56 0.16 10 3 0.8 1.6 160
PGB2 333.3 175.1 -60 -28 -8
2
H4-PGE2 6.67 0.11 16 3 <0.40 0.4 800
THF diol 353.2 127.1 -80 -32 -8 2H4-LTB4 6.77 0.19 15 3 0.13 0.25 100
15,16-DiHODE 311.2 223.2 -80 -29 -10 2H4-9,10-DiHOME 7.36 0.16 12 3 0.2 0.5 400
8,15-DiHETE 335.2 235.2 -65 -22 -4 2H11-14,15-DiHETrE 7.39 0.14 13 3 0.4 0.8 80
9,10-DiHODE 311.2 201.2 -65 -27 -10 2H4-9,10-DiHOME 7.39 0.13 20 3 <0.20 0.2 400
12,13-DiHODE 311.2 183.1 -80 -30 -8 2H4-9,10-DiHOME 7.47 0.16 14 4 1 2 400
6-trans-LTB4 335.2 195.1 -65 -23 -9
2
H4-LTB4 7.75 0.15 15 4 0.25 0.5 200
5,15-DiHETE 335.3 173.2 -60 -21 -8 2H11-14,15-DiHETrE 7.77 0.14 17 4 0.13 0.25 100
17,18-DiHETE 335.3 247.2 -65 -24 -8 2H11-14,15-DiHETrE 7.91 0.16 18 4 0.13 0.25 100
LTB4 335.2 195.1 -65 -23 -9
2
H4-LTB4 8.18 0.16 18 4 0.25 0.5 200
14,15-DiHETE 335.3 207.2 -65 -25 -10 2H11-14,15-DiHETrE 8.43 0.17 14 4 0.13 0.25 100
11,12-DiHETE 335.2 167.1 -65 -26 -5 2H11-14,15-DiHETrE 8.62 0.16 16 4 0.13 0.25 100
12,13-DiHOME 313.2 183.2 -80 -30 -8 2H4-9,10-DiHOME 8.82 0.2 28 4 0.5 1.25 1000
8,9-DiHETE 335.2 127.1 -65 -26 -5 2H4-9,10-DiHOME 8.98 0.19 15 4 0.25 0.5 100
9,10-DiHOME 313.2 201.2 -80 -29 -8 2H4-9,10-DiHOME 9.23 0.19 27 4 <0.50 0.5 1000
19,20-DiHDPE 361.2 273.2 -65 -24 -6 2H11-14,15-DiHETrE 9.89 0.21 17 4 0.5 1 100
14,15-DiHETrE 337.2 207.1 -65 -25 -10 2H11-14,15-DiHETrE 9.86 0.23 18 4 0.1 0.25 200
LTB3 337.2 195.2 -65 -22 -8
2
H4-LTB4 10.09 0.19 26 4 0.25 0.5 200
16,17-DiHDPE 361.2 233.2 -65 -24 -6 2H11-14,15-DiHETrE 10.45 0.19 16 4 0.25 0.5 100
11,12-DiHETrE 337.2 167.1 -65 -26 -8 2H11-14,15-DiHETrE 10.6 0.22 21 4 <0.25 0.25 200
13,14-DiHDPE 361.2 193.2 -65 -24 -6 2H11-14,15-DiHETrE 10.71 0.23 19 4 0.13 0.25 100
9-HOTrE 293.2 171.2 -65 -22 -8 2H4-9-HODE 10.95 0.18 18 4 0.25 0.5 100
10,11-DiHDPE 361.2 153.2 -65 -24 -6 2H11-14,15-DiHETrE 11.07 0.25 18 4 0.25 0.5 100
8,9-DiHETrE 337.2 127.1 -70 -30 -8 2H11-14,15-DiHETrE 11.22 0.23 19 4 0.25 0.5 200
Peak width
Analyte
Mass transition MS 
IS
Retention time Calibration 
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Table 9.1.2: Continued. 
 
1 
Reported retention time variance within a batch of 20 injections. Following analysis on the 
machine with different mobile phases and another column a larger retention time drift (≤0.2 min) 
was observed and the retention times in the method were adapted accordingly. 
2 
LLOQ was set 
to the lowest calibration standard injected within the sample set yielding a signal to noise ratio ≤ 
9 and an accuracy in the calibration within ±20%. ULOQ does not reflect the end of the linear 
range but the concentration of the highest calibrator. 
LOD
m/z 
(MS1)
m/z 
(MS3)
DP 
(V)
CE 
(V)
CXP 
(V)
(min)
SD
1 
(sec)
Full (s)
FWHM 
(s)
LOD 
(nM)
lower 
conc
2 
(nM)
upper 
conc
3 
(nM)
EKODE 309.2 291.1 -65 -20 -6 2H4-9-HODE 11.26 0.23 16 4 0.25 0.5 100
13-HOTrE 293.2 195.1 -70 -24 -8 2H4-9-HODE 11.3 0.32 15 4 0.3 0.6 60
5,6-DiHETE 335.2 115.2 -60 -21 -8 2H11-14,15-DiHETrE 11.71 0.24 18 5 0.13 0.25 100
15-deoxy-PGJ2 315.2 271.2 -65 -20 -6
2
H11-14,15-DiHETrE 11.76 0.24 25 5 0.5 1 400
7,8-DiHDPE 361.2 113.1 -65 -24 -6 2H11-14,15-DiHETrE 11.86 0.31 16 4 0.5 1 100
20-HETE 319.2 275.1 -80 -23 -6 2H6-20-HETE 12.04 0.25 18 5 1.3 2.6 260
15-HEPE 317.2 219.2 -60 -20 -10 2H8-12-HETE 12.04 0.25 17 5 0.63 1.25 500
5,6-DiHETrE 337.2 145.1 -70 -26 -10 2H11-14,15-DiHETrE 12.11 0.34 22 5 0.25 0.5 200
8-HEPE 317.2 155.2 -60 -20 -8 2H8-12-HETE 12.36 0.26 20 5 0.25 0.63 500
12-HEPE 317.2 179.2 -65 -20 -8 2H8-12-HETE 12.54 0.26 19 4 0.25 0.63 500
5-HEPE 317.2 115.1 -60 -20 -6 2H8-12-HETE 13.06 0.22 20 5 0.2 0.5 400
4,5-DiHDPE 361.2 229.3 -65 -24 -6 2H11-14,15-DiHETrE 13.09 0.29 16 5 1 2 100
13-HODE 295.2 195.2 -80 -26 -9 2H4-9-HODE 13.27 0.26 27 5 <1.00 1 2000
9-HODE 295.2 171.1 -80 -26 -7 2H4-9-HODE 13.38 0.27 27 5 <1.00 1 2000
15(16)-EpODE 293.3 235.2 -65 -20 -4 2H4-9(10)-EpOME 13.89 0.29 17 4 0.13 0.25 100
15-HETE 319.2 219.2 -60 -20 -8 2H8-12-HETE 13.97 0.26 22 4 0.5 1.25 1000
9(10)-EpODE 293.3 171.2 -65 -20 -8 2H4-9(10)-EpOME 14.04 0.19 18 4 0.1 0.2 80
17(18)-EpETE 317.2 215.2 -65 -20 -6 2H11-14(15)-EpETrE 14.11 0.28 16 4 0.25 0.5 100
11-HETE 319.2 167.2 -60 -23 -7 2H8-12-HETE 14.47 0.2 23 4 <0.50 0.5 1000
12(13)-EpODE 293.2 183.1 -65 -24 -8 2H4-9(10)-EpOME 14.44 0.24 16 4 0.13 0.25 100
13-oxo-ODE 293.2 195.1 -75 -20 -8 2H4-9-HODE 14.43 0.24 15 4 0.5 1 100
15-oxo-ETE 317.2 113.1 -65 -25 -8 2H8-5-HETE 14.66 0.24 11 4 0.25 0.5 100
9-oxo-ODE 293.2 185.1 -90 -28 -8 2H4-9-HODE 14.66 0.18 15 4 0.5 1 100
14(15)-EpETE 317.2 207.2 -65 -20 -6 2H11-14(15)-EpETrE 14.73 0.22 11 4 0.13 0.25 100
8-HETE 319.2 155.2 -60 -22 -6 2H8-12-HETE 14.81 0.17 16 4 1.25 2.5 1000
12-HETE 319.2 179.2 -60 -20 -8 2H8-12-HETE 14.83 0.17 16 4 <0.50 0.5 1000
11(12)-EpETE 317.2 167.2 -65 -20 -6 2H11-14(15)-EpETrE 14.87 0.15 10 4 0.25 0.5 100
8(9)-EpETE 317.2 127.2 -65 -20 -6 2H11-14(15)-EpETrE 15.01 0.23 13 3 0.5 1 100
9-HETE 319.2 167.2 -60 -23 -7 2H8-5-HETE 15.1 0.14 15 3 1.25 2.5 1000
15(S)-HETrE 321.2 221.2 -70 -23 -10 2H8-5-HETE 15.15 0.12 16 3 0.25 0.5 200
5-HETE 319.2 115.2 -60 -21 -7 2H8-5-HETE 15.33 0.11 17 3 0.5 1.25 1000
19(20)-EpDPE 343.2 241.2 -65 -20 -7 2H11-14(15)-EpETrE 15.8 0.11 10 3 0.13 0.25 100
12(13)-EpOME 295.3 195.2 -80 -23 -8 2H4-9(10)-EpOME 15.86 0.16 13 3 0.1 0.25 200
14(15)-EpETrE 319.2 219.3 -65 -20 -4 2H11-14(15)-EpETrE 15.99 0.14 15 3 0.25 0.5 100
9(10)-EpOME 295.3 171.1 -80 -23 -8 2H4-9(10)-EpOME 16.03 0.17 14 3 0.1 0.25 200
16(17)-EpDPE 343.2 233.2 -65 -20 -7 2H11-14(15)-EpETrE 16.18 0.15 19 3 0.13 0.25 100
13(14)-EpDPE 343.2 193.2 -65 -20 -7 2H11-14(15)-EpETrE 16.25 0.19 19 3 0.25 0.5 100
5-oxo-ETE 317.2 273.2 -65 -22 -6 2H4-9(10)-EpOME 16.3 0.1 10 3 1 2 100
10(11)-EpDPE 343.2 153.2 -65 -20 -7 2H11-14(15)-EpETrE 16.34 0.15 17 3 0.13 0.25 100
11(12)-EpETrE 319.3 167.2 -60 -20 -7 2H11-14(15)-EpETrE 16.44 0.1 12 3 0.25 0.5 200
8(9)-EpETrE 319.3 167.2 -60 -20 -7 2H11-14(15)-EpETrE 16.58 0.13 10 3 0.13 0.25 100
8(9)-EpETrE 2 319.2 155.2 -65 -20 -6 2H11-14(15)-EpETrE 16.58 0.2 10 3 1 2 100
5(6)-EpETrE 319.2 191.1 -60 -20 -7 2H11-14(15)-EpETrE 16.71 0.12 10 3 0.5 1 100
Peak width
Analyte
Mass transition MS 
IS
Retention time Calibration 
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Table 9.1.3: List of internal standards used and parameters of ESI(-)-MS/MS detection. Shown 
are the mass transition used for quantification in scheduled SRM mode and the electronical MS 
parameters (Declustering Potential (DP), Collision Energy (CE) and Collision Cell Exit Potential 
(CXP)). 
Analyte 
Retention 
time 
(min) 
Mass 
transition 
MS Parameters 
m/z 
(MS1) 
m/z 
(MS3) 
DP 
(V) 
CE 
(V) 
CXP 
(V) 
2H4-6-keto-PGF1α 3.18 373.3 167.1 -80 -36 -8 
2H4-TxB2 3.95 373.3 173.2 -65 -24 -8 
2H4-PGE2 4.56 355.2 275.3 -60 -25 -6 
2H4-PGD2 4.84 355.2 275.3 -60 -25 -6 
2H4-LTB4 8.12 339.2 197.2 -65 -23 -9 
2H4-9,10-DiHOME 9.15 317.2 203.4 -80 -29 -8 
2H11-14,15-DiHETrE 9.72 348.2 207.1 -65 -25 -10 
2H6-20-HETE 11.97 325.2 281.2 -70 -23 -6 
2H4-9-HODE 13.27 299.2 172.3 -80 -26 -6 
2H8-12-HETE 14.68 327.2 184.2 -65 -22 -8 
2H8-5-HETE 15.21 327.2 116.1 -60 -21 -8 
2H4-9(10)-EpOME 15.95 299.2 172.2 -80 -23 -8 
2H11-14(15)-EpETrE 15.88 330.2 219.3 -65 -20 -4 
 
 
Fig. 9.1.1: Recoveries of internal standards (IS) for the LLE protocol with addition of IS before 
the SPE-step and after the SPE-step. Shown is the mean ± SD (n=5). 
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Fig. 9.1.2: Direct comparison of recoveries of internal standards (IS) with addition of IS at the 
beginning of the sample preparation (light grey bar) and after the SPE-step (dark grey bar) for 
(A) SepPak, (B) AnionEx-strong, (C) AnionEx-weak, (D) Oasis-EA, (E) StrataX and (F) Oasis-
MeOH protocol. Shown is the mean ± SD (n=5). The same data is presented in condensed 
fashion in Fig. 4.1. 
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Table 9.1.4: Recovery rates of internal standards (IS) for the SPE protocols with addition of IS 
before (A) the SPE-step and after (B) the SPE-step. Shown are the mean±SD (n=5). 
 
  
SepPak A 70 ± 4.8 68 ± 3.1 41 ± 2.4 77 ± 3.8 85 ± 4 97 ± 6.2
B 75 ± 6.1 72 ± 7.2 42 ± 3.6 78 ± 5.5 80 ± 4.7 91 ± 5.3
AnionEx-Strong A 19 ± 3.4 22 ± 3.1 53 ± 9.3 66 ± 15 71 ± 15
B 64 ± 17 55 ± 18 67 ± 18 75 ± 22 71 ± 20 69 ± 19
AnionEx-Weak A 65 ± 2.8 76 ± 5.4 72 ± 2.7 79 ± 2.9 78 ± 3.7 78 ± 4.8
B 78 ± 3.1 81 ± 3.9 78 ± 3.3 89 ± 5 86 ± 3.3 87 ± 3.5
Oasis-EA A 70 ± 1.9 64 ± 3 65 ± 2.3 68 ± 2.9 68 ± 4.3 75 ± 2.1
B 84 ± 7.3 77 ± 4.5 76 ± 5.7 83 ± 7.7 86 ± 6 99 ± 6.5
StrataX A 70 ± 2.6 63 ± 3.2 96 ± 6.4 37 ± 3.3 88 ± 5.5 74 ± 5.6
B 76 ± 3.6 72 ± 2.2 100 ± 4.6 42 ± 1.2 97 ± 2.6 110 ± 3.7
Oasis-MeOH A 51 ± 2.1 58 ± 3 50 ± 1.9 58 ± 3.3 50 ± 1.8 58 ± 1.3
B 58 ± 3.7 63 ± 4.4 55 ± 4.9 65 ± 6.1 53 ± 3.9 67 ± 5.8
LLE A 23 ± 8.7 27 ± 11 30 ± 11 33 ± 13 36 ± 15 31 ± 11
B 30 ± 14 29 ± 14 28 ± 11 30 ± 15 29 ± 11 29 ± 7.3
SepPak A 89 ± 6.3 91 ± 7.4 72 ± 2.8 90 ± 6.2 80 ± 4.8 93 ± 6.3 74 ± 6.6
B 75 ± 5.2 70 ± 3.3 69 ± 9.8 77 ± 5.6 68 ± 5.8 91 ± 5.8 86 ± 6.7
AnionEx-Strong A 68 ± 14 69 ± 13 75 ± 14 75 ± 15 68 ± 12 77 ± 13 82 ± 16
B 64 ± 17 72 ± 16 75 ± 17 75 ± 18 68 ± 16 84 ± 18 85 ± 17
AnionEx-Weak A 74 ± 4.2 76 ± 6.1 85 ± 5.3 84 ± 6.5 74 ± 5.3 90 ± 5 91 ± 6.5
B 81 ± 4.2 86 ± 8.5 94 ± 6.2 92 ± 7.2 83 ± 6 100 ± 8.4 100 ± 8.7
Oasis-EA A 86 ± 2.9 60 ± 2.7 23 ± 1 79 ± 4.9 58 ± 2.4 48 ± 1.7 72 ± 2.6
B 99 ± 6.1 86 ± 3.2 25 ± 0.58 94 ± 3.4 69 ± 4.1 89 ± 5.1 97 ± 4.1
StrataX A 95 ± 7.7 69 ± 6.2 22 ± 0.88 81 ± 5.2 55 ± 5.2 47 ± 4.5 78 ± 7.2
B 100 ± 3.1 89 ± 2.8 24 ± 0.42 93 ± 2.1 70 ± 2.8 87 ± 2.6 93 ± 4
Oasis-MeOH A 57 ± 1.6 57 ± 2.2 22 ± 0.21 62 ± 3.7 48 ± 1.7 62 ± 1.8 68 ± 2.1
B 64 ± 5.7 64 ± 4.4 23 ± 0.79 67 ± 6.9 52 ± 3.1 70 ± 4.2 73 ± 6.5
LLE A 28 ± 7.3 29 ± 4.8 27 ± 5.9 28 ± 4.7 32 ± 9.4 32 ± 5.4 32 ± 4.7
B 27 ± 4.3 31 ± 3.2 28 ± 2.9 27 ± 2.7 28 ± 6.1 35 ± 3.6 36 ± 2.4
2H11-14(15)-
EpETrE
2H11-14,15-
DiHETrE
2H6-20-
HETE 2H4-9-HODE
2H8-12-
HETE 2H8-5-HETE
2H4-9(10)-
EpOME
2H4-6-keto-
PGF1α
2H4-TxB2
2H4-PGE2
2H4-PGD2
2H4-LTB4
2H4-9,10-
DiHOME
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Fig. 9.1.3: Ion suppression analysis of the internals standards for the different SPE protocols 
tested: (A) 
2
H4-PGE2/
 2
H4-PGE2, (B) 
2
H4-TxB2, (C) 
2
H4-LTB4, (D) 
2
H4-9-HODE, (E) 
2
H8-5-HETE, 
(F) 
2
H8-12-HETE, (G) 
2
H6-20-HETE, (H) 
2
H11-14,15-DiHETrE, (I) 
2
H1114(15)-EpETrE, (J) 
2
H4-
9,10-DiHOME. The dark grey bar indicates the retention time of the IS and the light grey bar 
indicates the retention time range of all analytes quantified with the IS. Mean intensity in the ion 
suppression (5-10 min) chromatogram was set to 100% relative intensity. 
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Fig. 9.1.3: Continued. 
 
 
 
  
APPENDIX 
 
172 
 
Fig. 9.1.3: Continued. 
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Table 9.1.5: Peak areas following extraction of 500 µL plasma of all oxylipins included in the 
LC-MS method with the different SPE-protocol tested. Shown is the mean ± SD (n=5). 
 
 
  
[1000 counts]
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
6-keto-PGF1a <LOQ <LOQ <LOQ 29.6 11.0 <LOQ <LOQ <LOQ
20-COOH-LTB4 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
RvE1 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
20-OH-LTB4 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
TXB2 31.2 1.7 <LOQ 39.2 0.7 44.3 13.9 29.2 1.2 26.0 2.0 <LOQ
PGE3 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
PGD3 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
9,12,13-TriHOME 858.0 48.3 256.3 35.0 642.7 160.5 622.7 115.0 423.7 11.3 435.0 25.6 180.3 129.9
9,10,13-TriHOME 275.0 8.2 78.5 15.5 145.8 16.3 183.8 34.7 120.5 5.7 126.0 8.4 62.9 54.0
PGF2a 8.8 0.9 <LOQ 11.4 1.4 9.9 1.5 9.7 0.5 8.0 1.3 <LOQ
PGE2 21.4 2.2 14.9 2.0 36.4 1.9 40.7 4.4 62.1 6.7 26.4 1.9 <LOQ
PGE1 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
PGD1 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
PGD2 30.4 1.7 21.8 5.0 27.2 2.1 18.4 1.6 4.9 0.9 16.3 2.2
LXA4 8.8 0.8 4.0 0.8 3.5 0.8 4.9 0.3 2.6 0.3 1.8 1.2
11,12-,15-TriHETrE <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
LTB5 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
PGJ2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
PGB2 <LOQ <LOQ <LOQ 5.5 2.0 <LOQ <LOQ <LOQ
THF diol <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
15,16-DiHODE 4306.2 270.3 3570.4 760.3 3989.1 110.3 3580.3 68.9 4440.0 217.0 3090.0 89.5 1420.3 536.6
8,15-DiHETE 135.9 7.1 72.5 14.7 70.0 3.0 73.8 3.7 88.5 3.5 57.5 5.4 20.7 9.5
9,10-DiHODE 120.5 8.3 82.4 17.4 92.1 2.8 88.8 0.8 87.5 4.5 70.7 3.7 32.4 12.2
12,13-DiHODE 74.3 8.9 55.4 14.5 <LOQ 46.3 4.5 48.9 11.2 41.7 5.0 <LOQ
6-trans-LTB4 23.8 1.3 12.2 2.8 11.4 0.4 46.0 9.3 17.0 1.1 13.6 2.5 <LOQ
5,15-DiHETE 33.8 1.1 23.6 5.0 19.9 1.3 26.7 1.2 27.3 2.0 14.5 1.6 5.7 3.0
17,18-DiHETE 228.0 18.5 197.5 41.3 213.5 4.5 215.8 6.0 241.5 15.2 155.3 8.3 76.8 27.0
LTB4 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
14,15-DiHETE 42.0 2.2 32.4 6.2 36.0 1.4 38.8 1.8 43.8 2.7 22.8 1.6 12.3 3.8
11,12-DiHETE 30.0 1.7 22.7 5.6 24.0 0.6 26.7 1.9 27.1 1.5 16.6 1.3 8.1 3.4
12,13-DiHOME 1958.0 132.2 1462.3 287.4 1573.3 47.1 1751.7 52.5 1918.0 111.8 1109.6 45.6 524.5 182.0
8,9-DiHETE 8.4 0.6 6.8 1.3 7.4 0.2 7.9 0.6 9.4 0.6 5.5 0.3 2.7 1.1
9,10-DiHOME 2183.4 138.7 1512.0 304.3 1660.8 52.5 1491.1 35.1 1360.7 82.6 1248.7 36.2 584.8 229.3
19,20-DiHDPE 234.6 15.8 196.8 38.5 210.3 6.8 200.4 6.9 232.9 11.2 172.1 7.9 77.9 26.8
14,15-DiHETrE 222.9 16.0 177.0 35.1 190.4 4.2 221.8 7.4 246.4 19.2 147.4 6.3 64.8 20.7
LTB3 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
16,17-DiHDPE 51.1 4.3 37.6 7.1 41.3 0.4 45.6 2.7 49.8 3.0 32.1 1.0 14.2 4.4
11,12-DiHETrE 143.3 11.2 111.7 22.2 121.4 2.0 100.1 4.2 102.9 6.5 89.5 3.3 42.1 15.2
AnionEX-
Strong
SepPak StrataX Oasis-MeOH LLEOasis-EA AnionEX-
Weak
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Table 9.1.5: Continued. 
  
[1000 counts]
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
13,14-DiHDPE 50.0 3.1 33.9 6.7 40.6 1.5 38.7 1.8 45.4 3.1 30.7 1.7 13.0 4.4
9-HOTrE 263.8 12.3 208.7 34.6 216.0 7.6 126.9 6.2 129.2 3.5 110.4 4.4 65.1 18.9
10,11-DiHDPE 28.7 1.2 21.9 4.4 24.0 0.5 24.6 1.4 27.0 1.3 17.1 0.8 8.9 3.2
8,9-DiHETrE 24.9 1.1 18.9 3.3 20.1 0.5 20.3 1.0 22.3 0.7 14.4 1.1 7.9 3.4
EKODE 664.0 56.8 290.3 80.1 223.9 36.1 651.2 54.7 252.3 35.8 327.1 17.7 45.3 22.3
13-HOTrE 205.7 30.7 157.4 25.7 159.8 5.3 137.9 4.3 147.0 7.3 113.4 3.3 48.5 11.9
5,6-DiHETE <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
15-deoxy-PGJ2 <LOQ <LOQ <LOQ 23.1 15.9 <LOQ <LOQ <LOQ
7,8-DiHDPE 4.5 0.6 3.5 0.9 3.8 0.4 4.7 0.6 4.2 0.4 2.6 0.5 1.5 0.7
20-HETE 29.0 5.2 21.9 3.8 27.4 2.1 23.8 1.7 24.1 1.7 22.7 2.9 9.9 3.0
15-HEPE 198.5 15.4 144.2 25.1 140.3 2.6 133.7 3.6 140.1 6.2 98.8 4.8 34.0 8.4
5,6-DiHETrE 36.7 3.0 25.7 5.2 27.1 1.0 38.0 3.1 29.4 2.4 22.1 0.5 12.6 5.2
8-HEPE 127.3 8.5 101.0 19.3 97.8 2.5 74.0 2.9 79.4 3.8 64.9 1.9 30.0 9.3
12-HEPE 223.3 13.7 426.7 87.5 350.4 14.5 128.4 3.3 118.0 5.5 107.7 4.1 43.9 11.0
5-HEPE 148.4 8.1 126.5 24.5 127.6 4.8 146.6 5.6 128.6 6.4 91.7 8.3 35.7 15.0
4,5-DiHDPE 13.4 1.0 10.4 2.2 11.0 0.2 12.3 0.4 14.0 1.0 8.9 0.9 5.2 2.1
13-HODE 5536.7 447.6 4916.2 867.9 5057.1 197.3 1508.1 56.9 1390.8 52.1 1614.9 53.0 1260.1 273.3
9-HODE 6523.8 278.1 6006.7 1092.1 6134.6 176.0 2401.6 103.5 2249.9 96.6 2463.2 109.4 1622.8 423.6
15(16)-EpODE 672.1 44.1 405.9 65.8 466.2 21.7 352.6 21.4 370.7 26.7 408.2 11.4 162.3 32.3
15-HETE 493.0 34.3 402.6 73.6 390.4 12.1 365.1 15.3 352.3 25.6 257.6 15.9 97.5 22.1
9(10)-EpODE 72.8 10.9 8.0 1.3 12.1 1.0 15.0 5.0 5.0 0.5 15.0 1.0 <LOQ
17(18)-EpETE 20.6 3.0 6.1 1.3 7.2 0.6 7.6 0.8 6.7 0.5 6.5 0.9 <LOQ
11-HETE 1369.1 91.0 1019.6 182.6 1044.7 26.8 921.6 43.5 945.4 42.6 744.4 54.3 290.1 81.4
12(13)-EpODE 88.8 11.3 25.1 5.7 29.7 2.7 26.0 3.9 17.7 1.8 34.1 2.3 12.2 2.4
13-oxo-ODE 45.9 3.4 18.2 4.1 20.4 7.2 22.2 4.7 12.6 1.4 29.3 1.2 8.0 3.9
15-oxo-ETE 97.8 8.8 116.7 20.9 128.1 6.8 151.2 8.0 149.5 16.7 108.1 8.4 34.1 7.3
9-oxo-ODE 605.4 53.2 358.1 59.4 431.3 33.3 531.4 21.0 464.5 41.9 512.4 17.5 126.0 38.2
14(15)-EpETE 27.0 6.5 <LOQ 4.9 0.6 7.4 1.5 5.8 1.0 6.4 0.7 <LOQ
8-HETE 234.7 10.6 191.8 34.9 181.2 12.8 123.5 4.7 132.3 8.7 117.1 7.4 60.2 17.4
12-HETE 576.5 20.6 861.3 175.5 741.6 38.2 368.2 28.0 323.8 18.2 325.3 18.9 137.5 34.5
11(12)-EpETE 12.8 2.1 2.6 0.4 3.5 1.0 2.9 0.9 <LOQ <LOQ <LOQ
8(9)-EpETE 2.6 0.3 <LOQ <LOQ 1.5 0.8 <LOQ 1.1 0.1 <LOQ
9-HETE 120.3 8.0 115.2 20.1 107.7 5.7 76.5 5.3 81.4 4.0 64.2 4.0 32.5 10.5
15(S)-HETrE 285.2 18.9 230.8 43.8 219.5 10.2 167.0 7.6 185.3 10.7 156.9 7.7 62.6 13.8
5-HETE 336.9 20.7 297.5 60.4 282.7 8.3 329.5 13.1 262.5 10.8 196.5 26.1 79.6 36.0
19(20)-EpDPE 56.2 8.6 14.1 2.7 16.3 0.6 17.4 2.3 12.2 0.6 18.2 0.5 4.7 1.0
12(13)-EpOME 1727.6 162.1 556.4 105.8 640.2 33.6 556.1 96.5 304.1 13.9 720.2 30.9 318.7 61.4
14(15)-EpETrE 48.3 9.3 8.8 2.0 10.2 0.9 22.8 5.8 11.0 0.6 14.8 1.5 3.8 1.0
9(10)-EpOME 1183.9 153.0 264.6 52.9 310.0 17.6 517.6 164.8 184.3 16.2 446.0 28.8 91.7 23.3
16(17)-EpDPE 37.0 8.8 3.1 0.8 4.0 0.8 7.5 2.8 4.3 0.7 8.5 0.6 <LOQ
13(14)-EpDPE 31.5 6.1 <LOQ <LOQ 6.8 3.2 <LOQ 7.0 0.8 <LOQ
5-oxo-ETE 51.9 19.3 38.4 7.4 38.0 4.1 38.9 4.6 48.0 3.0 35.6 2.2 12.8 2.9
10(11)-EpDPE 63.1 11.1 10.7 2.4 14.2 1.1 21.5 7.8 13.2 1.2 20.2 1.2 3.8 0.8
11(12)-EpETrE 41.9 7.1 6.4 1.3 6.5 0.6 29.8 12.9 8.4 0.5 14.7 1.4 1.9 0.3
8(9)-EpETrE 11.6 2.2 2.9 0.6 3.4 0.5 9.1 3.8 3.2 0.4 4.4 0.7 1.2 0.1
5(6)-EpETrE 18.6 3.4 3.8 0.4 4.5 0.3 13.7 5.2 5.9 0.8 12.9 0.7 2.2 0.6
SepPak LLEAnionEX-
Strong
AnionEX-
Weak
Oasis-EA StrataX Oasis-MeOH
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Table 9.1.6: Peak areas of all oxylipins included in the LC-MS method following extraction of 
500 µL plasma with the adjusted SepPak and AnionEx protocol, using 3 mL and 6 mL 
cartridges, respectively. Shown is the mean ± SD (n=5). 
  
[1000 counts] [1000 counts]
Mean SD Mean SD Mean SD Mean SD
6-keto-PGF1a <LOQ <LOQ EKODE 505.8 156.3 358.2 120.2
20-COOH-LTB4 <LOQ <LOQ 13-HOTrE 177.8 6.9 258.5 33.1
RvE1 <LOQ <LOQ 5,6-DiHETE <LOQ <LOQ
20-OH-LTB4 <LOQ <LOQ 15-deoxy-PGJ2 <LOQ <LOQ
TXB2 35.8 3.2 39.7 6.9 7,8-DiHDPE 4.7 0.3 5.4 1.4
PGE3 10.8 1.4 6.7 1.7 20-HETE 29.2 5.7 27.9 8.7
PGD3 20.7 3.8 19.1 2.5 15-HEPE 203.4 16.4 164.7 25.6
9,12,13-TriHOME 845.9 85.0 860.0 127.5 5,6-DiHETrE 35.0 1.7 35.2 6.0
9,10,13-TriHOME 292.9 32.9 209.3 29.5 8-HEPE 113.3 7.3 112.5 14.3
PGF2a 6.3 1.1 11.5 2.3 12-HEPE 244.4 14.6 356.7 61.0
PGE2 10.2 0.9 23.7 4.3 5-HEPE 125.8 8.3 142.5 9.8
PGE1 <LOQ <LOQ 4,5-DiHDPE 13.3 1.1 15.1 4.6
PGD1 <LOQ <LOQ 13-HODE 5953.4 387.4 7394.6 1087.9
PGD2 22.8 5.7 24.3 4.7 9-HODE 7361.8 319.6 8174.8 827.6
LXA4 5.4 0.7 5.1 2.0 15(16)-EpODE 520.7 37.1 496.3 76.5
11,12-,15-TriHETrE <LOQ <LOQ 15-HETE 525.7 37.3 506.4 59.5
LTB5 <LOQ <LOQ 9(10)-EpODE 39.6 3.3 11.5 3.0
PGJ2 <LOQ <LOQ 17(18)-EpETE 8.6 0.8 7.7 1.2
PGB2 <LOQ <LOQ 11-HETE 1387.2 50.8 1167.3 56.6
THF diol <LOQ <LOQ 12(13)-EpODE 56.3 4.7 31.4 3.1
15,16-DiHODE 4898.1 426.1 4590.9 744.7 13-oxo-ODE 27.5 2.1 23.2 4.0
8,15-DiHETE 119.3 8.2 80.0 11.2 15-oxo-ETE 52.0 23.0 135.0 12.4
9,10-DiHODE 101.2 5.1 103.4 16.4 9-oxo-ODE 557.4 19.4 443.6 54.3
12,13-DiHODE 57.9 4.9 53.8 9.7 14(15)-EpETE 9.3 0.6 4.5 0.5
6-trans-LTB4 18.1 1.9 12.2 4.8 8-HETE 248.8 13.3 185.0 31.7
5,15-DiHETE 24.6 2.8 18.5 2.9 12-HETE 659.3 47.4 677.0 91.8
17,18-DiHETE 264.2 30.2 254.2 48.9 11(12)-EpETE 6.8 0.8 <LOQ
LTB4 <LOQ <LOQ 8(9)-EpETE 1.5 0.6 <LOQ
14,15-DiHETE 45.6 4.0 43.7 8.8 9-HETE 137.2 8.6 100.9 15.3
11,12-DiHETE 27.6 2.7 28.5 9.2 15(S)-HETrE 299.6 20.7 242.6 30.6
12,13-DiHOME 2065.6 176.6 1920.7 290.9 5-HETE 344.5 41.2 304.5 32.2
8,9-DiHETE 7.2 0.5 8.4 2.0 19(20)-EpDPE 32.2 2.0 19.3 3.6
9,10-DiHOME 2113.6 153.3 2035.2 333.9 12(13)-EpOME 1258.6 67.7 733.2 78.9
19,20-DiHDPE 310.5 30.6 283.4 60.0 14(15)-EpETrE 17.2 1.7 11.7 2.3
14,15-DiHETrE 268.1 30.4 239.0 47.9 9(10)-EpOME 682.9 45.9 284.2 39.2
LTB3 <LOQ <LOQ 16(17)-EpDPE 20.0 1.4 5.5 1.4
16,17-DiHDPE 60.4 6.0 55.5 12.7 13(14)-EpDPE 19.6 2.5 <LOQ
11,12-DiHETrE 171.2 18.1 158.6 32.6 5-oxo-ETE 57.5 4.8 47.4 5.5
13,14-DiHDPE 56.0 7.4 56.5 13.2 10(11)-EpDPE 50.0 5.1 16.2 3.3
9-HOTrE 238.8 8.6 273.9 24.6 11(12)-EpETrE 21.4 1.7 8.3 0.9
10,11-DiHDPE 33.3 4.3 31.5 6.2 8(9)-EpETrE 7.2 0.7 3.9 0.9
8,9-DiHETrE 25.8 2.2 25.4 6.0 5(6)-EpETrE 11.2 0.6 4.5 0.9
SepPak -     
3 mL
AnionEx-
Weak - 6 mL
SepPak -    
3 mL
AnionEx-
Weak - 6 mL
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Table 9.1.7: Calculated concentrations for human plasma of all oxylipins included in the LC-MS 
method determined with the different SPE-protocols tested. Internal standards used for 
quantification can be found in Table 9.1.2. Shown is the mean ± SD (n=5). 
 
 
 
[nM]
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
6-keto-PGF1a <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
20-COOH-LTB4 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
RvE1 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
20-OH-LTB4 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
TXB2 0.295 0.011 0.707 0.390 0.333 0.012 0.503 0.174 0.306 0.033 0.307 0.037 0.298 0.029
PGE3 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
PGD3 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
9,12,13-TriHOME 8.279 0.668 5.086 1.066 3.356 0.812 3.642 0.652 1.665 0.156 3.348 0.097 2.256 0.850
9,10,13-TriHOME 1.579 0.126 0.927 0.236 0.454 0.048 0.640 0.119 0.282 0.023 0.577 0.026 0.456 0.246
PGF2a 0.185 0.020 <LOQ 0.130 0.016 0.127 0.022 0.083 0.007 0.134 0.021 <LOQ
PGE2 0.245 0.022 0.352 0.045 0.225 0.020 0.285 0.041 0.290 0.036 0.241 0.012 0.182 0.033
PGE1 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
PGD1 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
PGD2 0.523 0.025 0.549 0.071 0.455 0.043 0.358 0.049 0.174 0.034 0.374 0.052 <LOQ
LXA4 0.438 0.035 <LOQ 0.107 0.023 0.104 0.021 0.099 0.005 0.104 0.006 0.118 0.036
11,12-,15-TriHETrE <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
LTB5 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
PGJ2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
PGB2 <LOQ 0.063 0.007 <LOQ 0.087 0.022 <LOQ <LOQ <LOQ
THF diol <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
15,16-DiHODE 9.118 0.296 10.555 0.334 10.584 0.580 9.911 0.380 12.629 0.951 11.318 0.237 10.566 0.371
8,15-DiHETE 2.027 0.104 1.460 0.114 1.285 0.126 1.147 0.045 1.245 0.102 1.377 0.116 1.076 0.233
9,10-DiHODE 0.227 0.009 0.217 0.009 0.218 0.010 0.219 0.005 0.222 0.013 0.230 0.008 0.215 0.010
12,13-DiHODE <LOQ 0.227 0.018 <LOQ <LOQ <LOQ <LOQ <LOQ
6-trans-LTB4 0.182 0.005 0.125 0.018 0.096 0.007 0.445 0.107 0.125 0.012 0.183 0.031 0.077 0.007
5,15-DiHETE 0.468 0.026 0.440 0.040 0.339 0.040 0.386 0.018 0.356 0.033 0.322 0.029 0.270 0.083
17,18-DiHETE 0.957 0.019 1.121 0.046 1.105 0.056 0.949 0.014 0.958 0.060 1.051 0.038 1.157 0.063
LTB4 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
14,15-DiHETE 0.176 0.006 0.184 0.009 0.185 0.011 0.170 0.005 0.173 0.009 0.154 0.007 0.187 0.003
11,12-DiHETE 0.129 0.008 0.131 0.008 0.127 0.007 0.121 0.009 0.110 0.005 0.115 0.007 0.123 0.020
12,13-DiHOME 5.328 0.156 5.573 0.209 5.365 0.270 6.230 0.279 7.009 0.619 5.224 0.150 5.074 0.298
8,9-DiHETE 0.162 0.011 0.179 0.006 0.177 0.013 0.160 0.008 0.172 0.012 0.170 0.008 0.182 0.021
9,10-DiHOME 3.660 0.116 3.548 0.137 3.489 0.186 3.270 0.118 3.061 0.124 3.621 0.049 3.429 0.120
19,20-DiHDPE 2.764 0.083 3.140 0.146 3.052 0.132 2.471 0.063 2.594 0.197 3.266 0.074 3.302 0.142
14,15-DiHETrE 0.581 0.013 0.624 0.020 0.611 0.028 0.605 0.013 0.605 0.029 0.619 0.017 0.613 0.017
LTB3 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
16,17-DiHDPE 0.378 0.013 0.378 0.019 0.377 0.021 0.353 0.013 0.348 0.017 0.384 0.013 0.383 0.029
11,12-DiHETrE 0.512 0.011 0.540 0.023 0.535 0.031 0.376 0.014 0.350 0.035 0.516 0.013 0.539 0.037
Oasis-MeOHSepPak AnionEX-
Strong
AnionEX-
Weak
Oasis-EA StrataX LLE
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Table 9.1.7: Continued. 
 
[nM]
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
13,14-DiHDPE 0.280 0.009 0.257 0.012 0.279 0.011 0.226 0.008 0.239 0.015 0.276 0.015 0.263 0.009
9-HOTrE 1.803 0.115 1.360 0.065 1.243 0.077 3.127 0.079 3.408 0.217 2.896 0.101 1.299 0.086
10,11-DiHDPE 0.271 0.009 0.280 0.008 0.280 0.018 0.243 0.010 0.241 0.014 0.261 0.008 0.300 0.025
8,9-DiHETrE 0.345 0.015 0.355 0.022 0.343 0.027 0.295 0.009 0.292 0.022 0.322 0.022 0.385 0.066
EKODE 2.194 0.240 0.898 0.134 0.609 0.082 7.776 0.506 3.213 0.460 4.151 0.188 0.422 0.159
13-HOTrE 1.855 0.301 1.352 0.079 1.211 0.057 4.490 0.283 5.115 0.411 3.923 0.110 1.287 0.038
5,6-DiHETE <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
15-deoxy-PGJ2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
7,8-DiHDPE 0.160 0.021 0.166 0.016 0.165 0.021 0.172 0.018 0.141 0.014 0.150 0.025 0.193 0.033
20-HETE 0.448 0.096 0.450 0.059 0.504 0.027 0.562 0.033 0.493 0.039 0.566 0.068 0.507 0.110
15-HEPE 1.650 0.054 1.465 0.090 1.266 0.104 1.281 0.079 1.298 0.074 1.224 0.047 0.990 0.057
5,6-DiHETrE 0.370 0.010 0.350 0.015 0.338 0.027 0.402 0.042 0.281 0.013 0.360 0.007 0.448 0.055
8-HEPE 1.158 0.043 1.117 0.060 0.964 0.065 0.778 0.037 0.806 0.027 0.881 0.046 0.940 0.122
12-HEPE 1.936 0.075 4.470 0.289 3.270 0.177 1.285 0.080 1.142 0.057 1.391 0.049 1.327 0.111
5-HEPE 1.749 0.037 1.814 0.149 1.629 0.168 1.984 0.121 1.683 0.097 1.603 0.107 1.422 0.351
4,5-DiHDPE 1.101 0.032 1.153 0.107 1.115 0.070 1.064 0.032 1.086 0.065 1.181 0.122 1.507 0.234
13-HODE 28.923 2.515 24.452 1.067 22.244 1.235 28.406 1.314 27.981 1.474 32.360 0.783 19.522 0.995
9-HODE 35.678 1.490 31.266 1.135 28.277 1.573 47.400 2.275 47.431 2.594 51.716 2.023 26.114 1.202
15(16)-EpODE 2.713 0.071 2.025 0.084 1.970 0.078 2.914 0.260 3.147 0.213 2.527 0.067 2.081 0.066
15-HETE 3.473 0.100 3.455 0.162 2.977 0.188 2.961 0.181 2.762 0.169 2.702 0.101 2.407 0.108
9(10)-EpODE 0.337 0.031 0.046 0.004 0.058 0.004 0.143 0.051 0.049 0.009 0.107 0.006 0.046 0.004
17(18)-EpETE 0.369 0.027 0.100 0.013 0.105 0.007 0.143 0.018 0.115 0.009 0.129 0.015 0.099 0.013
11-HETE 2.879 0.073 2.616 0.147 2.380 0.172 2.230 0.091 2.213 0.101 2.328 0.112 2.117 0.194
12(13)-EpODE 0.326 0.021 0.113 0.006 0.115 0.009 0.197 0.035 0.137 0.014 0.193 0.011 0.144 0.011
13-oxo-ODE 0.725 0.055 0.266 0.022 0.265 0.092 1.280 0.351 0.771 0.112 1.788 0.058 0.356 0.124
15-oxo-ETE 0.916 0.065 1.315 0.032 1.313 0.111 2.017 0.026 2.119 0.158 1.774 0.111 0.907 0.155
9-oxo-ODE 8.159 0.758 4.583 0.209 4.872 0.341 25.956 1.614 24.260 2.863 26.602 0.663 4.974 0.747
14(15)-EpETE 0.255 0.048 0.033 0.003 0.037 0.004 0.072 0.017 0.051 0.008 0.066 0.008 <LOQ
8-HETE 1.754 0.086 1.744 0.096 1.465 0.108 1.069 0.045 1.107 0.059 1.306 0.084 1.556 0.166
12-HETE 3.485 0.153 6.291 0.343 4.824 0.282 2.557 0.187 2.178 0.096 2.919 0.097 2.889 0.209
11(12)-EpETE 0.142 0.018 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
8(9)-EpETE 0.148 0.027 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
9-HETE 2.255 0.097 2.601 0.154 2.205 0.116 2.045 0.098 2.326 0.215 2.111 0.100 1.677 0.094
15(S)-HETrE 1.113 0.034 1.084 0.061 0.937 0.041 0.932 0.038 1.100 0.074 1.075 0.043 0.695 0.105
5-HETE 3.781 0.133 4.018 0.371 3.476 0.286 5.271 0.146 4.485 0.386 3.862 0.436 2.363 0.316
19(20)-EpDPE 1.005 0.107 0.227 0.028 0.234 0.019 0.323 0.054 0.206 0.016 0.355 0.018 0.215 0.014
12(13)-EpOME 5.580 0.220 2.214 0.121 2.165 0.109 3.686 0.724 2.073 0.196 3.569 0.085 3.277 0.147
14(15)-EpETrE 0.602 0.080 0.095 0.011 0.100 0.010 0.294 0.081 0.128 0.010 0.200 0.014 0.119 0.014
9(10)-EpOME 3.359 0.226 0.923 0.054 0.920 0.039 3.023 1.021 1.102 0.112 1.943 0.086 0.820 0.077
16(17)-EpDPE 0.533 0.093 0.039 0.004 0.046 0.008 0.114 0.045 0.058 0.008 0.135 0.013 <LOQ
13(14)-EpDPE 0.456 0.060 <LOQ <LOQ 0.103 0.053 <LOQ 0.110 0.012 <LOQ
5-oxo-ETE 0.895 0.349 0.809 0.111 0.673 0.052 1.363 0.146 1.748 0.217 0.930 0.043 0.689 0.071
10(11)-EpDPE 0.798 0.096 0.122 0.011 0.145 0.003 0.285 0.112 0.160 0.009 0.280 0.013 0.123 0.025
11(12)-EpETrE 0.572 0.069 0.081 0.016 0.072 0.005 0.426 0.190 0.110 0.010 0.220 0.017 0.070 0.015
8(9)-EpETrE 0.256 0.037 <LOQ <LOQ 0.202 0.108 0.043 0.011 0.082 0.015 <LOQ
5(6)-EpETrE 1.413 0.192 0.252 0.040 0.261 0.019 1.082 0.460 0.414 0.061 1.064 0.053 0.360 0.079
Oasis-MeOH LLESepPak AnionEX-
Strong
AnionEX-
Weak
Oasis-EA StrataX
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Table 9.1.8: Modified LC-MS quantification method using the SepPak protocol. Because of 
strong ion supression occuring for 
2
H4-PGE2 in this protocol, the quantification method (Tab S1) 
is modified and 
2
H4-PGD2 is used for several analytes. 
The calculated concentrations of PGE3, PGD3, 9,12,13-TriHOME, 9,10,13-TriHOME, PGF2α, 
PGE2, PGE1, PGD1, PGD2, LXA4, 11,12-,15-TriHETrE, PGJ2, PGB2 with different internal 
standards is shown for the original (left) and modified method (right). Shown is the mean ± SD 
(n=5). 
 
Original Quantification Method Modified Method 
 
IS Mean [pM] IS Mean [pM] 
PGE
3
 
2
H
4
-PGE
2
 <LOQ 
2
H
4
-PGD
2
 <LOQ 
PGD
3
 
2
H
4
-PGD
2
 <LOQ 
2
H
4
-PGD
2
 <LOQ 
9,12,13-TriHOME 
2
H
4
-PGE
2
 8300 ± 670 
2
H
4
-PGD
2
 4700 ± 360 
9,10,13-TriHOME 
2
H
4
-PGE
2
 1600 ± 130 
2
H
4
-PGD
2
 890 ± 42 
PGF2
2α
 
2
H
4
-PGE
2
 190 ± 20 
2
H
4
-PGD
2
 100 ± 11 
PGE
2
 
2
H
4
-PGE
2
 250 ± 22 
2
H
4
-PGE
2
 250 ± 22 
PGE
1
 
2
H
4
-PGE
2
 200 ± 28 
2
H
4
-PGD
2
 110 ± 12 
PGD
1
 
2
H
4
-PGD
2
 <LOQ 
2
H
4
-PGD
2
 <LOQ 
PGD
2
 
2
H
4
-PGD
2
 523 ± 25 
2
H
4
-PGD
2
 520 ± 25 
LXA
4
 
2
H
4
-PGE
2
 440 ± 35 
2
H
4
-PGD
2
 250 ± 20 
11,12-,15-TriHETrE 
2
H
4
-PGE
2
 <LOQ 
2
H
4
-PGD
2
 <LOQ 
PGJ
2
 
2
H
4
-PGE
2
 <LOQ 
2
H
4
-PGD
2
 <LOQ 
PGB
2
 
2
H
4
-PGE
2
 <LOQ 
2
H
4
-PGD
2
 <LOQ 
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9.2 Chapter 5 
 
Fig. 9.2.1: Separation efficacy of the developed method. Shown are the SRM signals of DHA 
derived OH-FAs used for quantification following injection of a mulianalyte standard (20 nM). 
The DHA derived HDHAs are shown in two panels allowing to assess the individual peaks of 
the OH-FAs. 
 
Fig. 9.2.2A: Formation of hydroxy-FAs in cell culture medium. HCT-116 cells were incubated 
with PUFA ethyl esters (50 µM) for 24 hours. Shown is the concentration of an incubation with 
(orange) and without cells (blue) reflecting formation by hydrolysis and autoxidation. In panel A 
incubations were carried out with ARA ethyl ester, in panel B with EPA ethyl ester and in panel 
C with DHA ethyl ester. The concentration in the media before incubation and in incubations 
without added PUFA were below 10 nM (not shown). All results are given as mean±SD (n=4). 
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Fig. 9.2.2B: Formation of hydroxy-FAs in cell culture medium. HT-29 cells were incubated with 
PUFA ethyl esters (50 µM) for 24 hours. Shown is the concentration of an incubation with 
(orange) and without cells (blue) reflecting formation by hydrolysis and autoxidation. In panel A 
incubations were carried out with ARA ethyl ester, in panel B with EPA ethyl ester and in panel 
C with DHA ethyl ester. The concentration in the media before incubation and in incubations 
without added PUFA were below 10 nM (not shown). All results are given as mean±SD (n=4). 
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9.3 Chapter 6 
Table 9.3.1: Determined fat content
#
, peroxide value
+
 and fatty acid composition* of the 
experimental diets. Diets were based on a standard experimental diet from ssniff Spezialdiäten 
GmbH (product number: E15051; with 17.6% crude protein, 5.0% crude fiber, 5.3% crude ash, 
31.4% starch, 11.0% sugar and 10.1% fat as specified by the manufacturer). All results are 
shown as mean ± deviation from the mean (n=2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#
For the determination of the fatty acid composition and the peroxide value, lipids were first 
extracted from the pellets according to the Weibull-Stoldt method, performed as rapid 
microextraction [1].  
+
Determination of the peroxide value was performed by iodometry as described [3]. Briefly, after 
dissolving the lipid extract in acetic acid/isooctane (3:2, v:v) and addition of potassium iodide the 
formed iodine titrated with sodium thiosulfate.  
*The fatty acid composition was determined after derivatization to fatty acid methyl esters by 
means of gas chromatography with flame ionization detection using response factors [2]. 
 STD STD+n3 
Determined fat content 
in the diet [g/100g] 9.7 ± 0.2 9.9 ± 0.2 
Peroxide value  
[mEq O2/kg] 2.6 ± 0.1 3.6 ± 0.1 
[%] Fatty Acid 
in lipid extract   
C14:0 0.15 ± 0.05 0.19 ± 0.04 
C15:0 0.07 ± 0.02 - 
C16:0 7.995 ± 0.008 6.61 ± 0.05 
C16:1n7 0.217 ± 0.008 0.24 ± 0.03 
C17:0 0.071 ± 0.007 0.058 ± 0.007 
C18:0 3.288 ± 0.001 2.64 ± 0.03 
C18:1n9 27.064 ± 0.004 21.65 ± 0.06 
C18:1n7 1.26 ± 0.04 1.047 ± 0.003 
C18:2n6 58.306 ± 0.003 46.5 ± 0.1 
C18:3n3 0.335 ± 0.005 0.287 ± 0.003 
C20:0 0.218 ± 0.003 0.184 ± 0.004 
C20:1n9 0.167 ± 0.002 0.14 ± 0.01 
C20:4n6 - 0.303 ± 0.003 
C20:5n3 - 8.91 ± 0.07 
C22:0 0.653 ± 0.008 0.95 ± 0.03 
C22:5n3 - 1.18 ± 0.05 
C24:0 0.204 ± 0.008 - 
C22:6n3 - 8.91 ± 0.09 
C24:1n9 - 0.17 ± 0.02 
APPENDIX 
 
182 
 
Table 9.3.2: Fatty acid composition of the standard mouse diet according to the manufacturer 
ssniff Spezialdiäten GmbH (product number: V1530; with 19.0% crude protein, 4.9% crude 
fiber, 6.4% crude ash, 36.5% starch, 4.7% sugar and 3.3% fat as specified by the 
manufacturer). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9.3.1: Bodyweight of wild type C57BL/5 mice at baseline (days 0) and after 7-45 days on a 
standard sunflower based diet or the same diet enriched with EPA and DHA and of transgenic 
fat-1 mice on a standard sunflower based diet (0 and 30 days). 
 
 
 
Table 9.3.3A: Absolute concentrations of fatty acids in blood of wild type mice at the beginning 
of the experiment (Day 0) and during the course of the feeding experiment on a standard 
sunflower based diet (STD) or on the same diet enriched with n3-PUFA (1% EPA and 1% DHA 
as ethyl ester, STD+n3). Absolute concentrations in transgenic fat-1 mice are shown at baseline 
(Day 0) and after 30 days on a standard sunflower based diet. 
In case an analyte was below limit of quantification (<LOQ) in more than 50% of samples within 
one group, the LOQ is shown. 
 
 
[%] Fatty Acid 
in diet 
C14:0 0.01 
C16:0 0.47 
C16:1 0.01 
C18:0 0.08 
C18:1 0.62 
C18:2 1.80 
C18:3 0.23 
C20:0 0.01 
C20:1 0.02 
C20:5 - 
C22:6 - 
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Table 9.3.3A: Whole Blood. 
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Table 9.3.3B: Relative distribution of fatty acids in blood and tissues of wild type mice at the 
beginning of the experiment (Day 0) and during the course of the feeding experiment on a 
standard sunflower based diet (STD) or on the same diet enriched with n3-PUFA (1% EPA and 
1% DHA as ethyl ester, STD+n3). Fatty acid pattern in transgenic fat-1 mice are shown at 
baseline (Day 0) and after 30 days on a standard sunflower based diet. The relative amount of 
an analyte was not calculated if it was below the limit of quantification (<LOQ, S/N<9) in more 
than 50% of the samples within one group. 
* the analyte could not be quantified in the samples due to chromatographic interferences. 
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Table 9.3.3B: Whole Blood. 
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Table 9.3.3B: Blood Cells. 
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Table 9.3.3B: Plasma. 
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Table 9.3.3B: Liver. 
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Table 9.3.3B: Kidney. 
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Table 9.3.3B: Spleen. 
 
M
e
a
n
S
E
M
M
e
a
n
S
E
M
M
e
a
n
S
E
M
M
e
a
n
S
E
M
M
e
a
n
S
E
M
M
e
a
n
S
E
M
M
e
a
n
S
E
M
M
e
a
n
S
E
M
M
e
a
n
S
E
M
M
e
a
n
S
E
M
M
e
a
n
S
E
M
C
1
0
:0
C
1
1
:0
C
1
2
:0
0
.0
7
0
.0
1
0
.0
7
0
.0
0
0
.0
6
0
.0
1
0
.0
7
0
.0
0
0
.1
0
0
.0
1
0
.0
6
0
.0
0
0
.0
6
0
.0
1
0
.0
7
0
.0
1
0
.0
6
0
.0
0
C
1
3
:0
0
.0
5
0
.0
1
0
.0
4
0
.0
1
0
.0
3
0
.0
1
0
.0
5
0
.0
0
0
.0
7
0
.0
1
0
.0
4
0
.0
0
0
.0
5
0
.0
1
0
.0
4
0
.0
1
0
.0
4
0
.0
0
C
1
4
:0
0
.6
9
0
.0
9
0
.6
5
0
.0
8
0
.8
4
0
.1
2
0
.6
7
0
.0
7
0
.5
7
0
.0
2
0
.5
9
0
.0
6
0
.3
8
0
.0
9
0
.5
8
0
.0
4
0
.6
6
0
.0
4
0
.6
3
0
.0
3
0
.4
9
0
.0
7
C
1
5
:0
0
.1
8
0
.0
1
0
.1
4
0
.0
1
0
.1
8
0
.0
1
0
.1
5
0
.0
1
0
.1
3
0
.0
0
0
.1
5
0
.0
0
0
.1
8
0
.0
0
0
.1
4
0
.0
0
0
.1
7
0
.0
1
C
1
6
:0
2
4
.9
5
0
.1
8
2
3
.1
1
0
.3
3
2
4
.4
7
0
.2
8
2
2
.8
4
0
.2
0
2
3
.0
5
0
.0
7
2
3
.4
4
0
.3
1
2
4
.2
4
0
.3
1
2
3
.7
9
0
.1
8
2
4
.6
1
0
.1
8
2
4
.6
1
0
.1
7
2
5
.1
5
0
.3
0
C
1
7
:0
0
.2
4
0
.0
1
0
.1
7
0
.0
1
0
.2
4
0
.0
2
0
.2
1
0
.0
1
0
.2
1
0
.0
1
0
.1
9
0
.0
1
0
.1
8
0
.0
1
0
.2
3
0
.0
0
0
.1
8
0
.0
0
0
.1
9
0
.0
0
0
.1
8
0
.0
1
C
1
8
:0
1
4
.7
9
0
.7
4
1
5
.3
6
0
.9
0
1
3
.1
1
1
.0
2
1
5
.1
8
0
.8
4
1
6
.7
7
0
.2
8
1
6
.3
4
0
.4
5
1
5
.6
1
0
.8
6
1
6
.3
7
0
.3
4
1
5
.5
6
0
.2
7
1
6
.0
3
0
.3
6
1
4
.8
3
0
.6
3
C
2
0
:0
0
.2
5
0
.0
1
0
.2
5
0
.0
2
0
.2
1
0
.0
2
0
.2
9
0
.0
2
0
.2
9
0
.0
1
0
.2
9
0
.0
1
0
.2
6
0
.0
1
0
.2
9
0
.0
1
0
.2
4
0
.0
1
0
.2
6
0
.0
1
0
.2
4
0
.0
1
C
2
1
:0
0
.0
4
0
.0
1
0
.0
3
0
.0
1
0
.0
4
0
.0
1
0
.0
6
0
.0
1
0
.0
6
0
.0
1
0
.0
4
0
.0
0
0
.0
3
0
.0
0
0
.0
6
0
.0
0
0
.0
4
0
.0
1
0
.0
4
0
.0
0
0
.0
2
0
.0
0
C
2
2
:0
0
.5
3
0
.0
4
0
.6
7
0
.0
5
0
.4
3
0
.0
6
0
.7
5
0
.0
5
0
.8
0
0
.0
2
0
.8
3
0
.0
3
0
.5
6
0
.0
4
0
.7
3
0
.0
2
0
.6
7
0
.0
2
0
.7
1
0
.0
3
0
.4
7
0
.0
3
C
2
4
:0
0
.6
7
0
.0
6
0
.7
1
0
.0
7
0
.4
6
0
.0
7
0
.7
3
0
.0
6
0
.7
9
0
.0
2
0
.7
8
0
.0
4
0
.7
3
0
.0
7
0
.8
5
0
.0
2
0
.7
8
0
.0
3
0
.8
4
0
.0
4
0
.7
4
0
.0
5
C
1
4
:1
n
5
0
.0
5
0
.0
0
0
.0
2
0
.0
0
C
1
5
:1
n
5
C
1
6
:1
n
7
1
.7
9
0
.3
2
1
.3
1
0
.2
4
2
.6
1
0
.5
5
1
.6
5
0
.3
4
0
.9
6
0
.0
9
1
.3
5
0
.2
9
1
.3
0
0
.2
9
1
.0
5
0
.1
6
1
.3
7
0
.1
4
1
.2
2
0
.1
4
1
.3
7
0
.2
5
C
1
7
:1
n
7
C
1
8
:1
n
7
2
.7
2
0
.1
0
2
.0
5
0
.0
9
2
.8
6
0
.0
5
2
.1
6
0
.0
5
2
.0
8
0
.0
5
2
.1
3
0
.0
3
2
.3
5
0
.1
3
1
.8
7
0
.0
4
1
.8
1
0
.0
3
1
.8
0
0
.0
4
1
.7
5
0
.0
5
C
1
8
:1
n
9
1
3
.3
2
2
.6
3
1
3
.1
5
2
.5
0
1
8
.5
2
3
.5
5
1
2
.7
6
2
.0
2
9
.0
7
0
.5
9
1
0
.3
7
1
.3
0
1
1
.4
1
2
.1
1
8
.4
4
0
.7
9
9
.9
6
0
.7
1
8
.2
8
0
.6
3
1
1
.0
5
1
.6
4
C
2
0
:1
n
9
0
.3
9
0
.0
2
0
.3
9
0
.0
1
0
.4
4
0
.0
1
0
.4
0
0
.0
1
0
.3
8
0
.0
1
0
.3
8
0
.0
0
0
.3
6
0
.0
1
0
.3
0
0
.0
0
0
.2
8
0
.0
1
0
.2
7
0
.0
0
0
.2
3
0
.0
1
C
2
2
:1
n
9
0
.0
9
0
.0
1
0
.1
2
0
.0
2
0
.0
7
0
.0
1
0
.0
9
0
.0
1
0
.1
4
0
.0
1
0
.1
0
0
.0
1
0
.0
9
0
.0
0
0
.0
9
0
.0
1
0
.1
0
0
.0
1
C
2
4
:1
n
9
1
.4
6
0
.1
6
1
.2
5
0
.1
5
1
.2
0
0
.2
0
1
.2
7
0
.1
2
1
.4
6
0
.0
6
1
.3
8
0
.0
6
1
.3
6
0
.1
2
1
.5
3
0
.0
6
1
.3
3
0
.0
6
1
.4
4
0
.0
5
1
.2
7
0
.0
9
C
1
8
:2
n
6
1
2
.0
0
0
.4
4
1
3
.5
0
1
.5
4
1
0
.7
2
0
.8
7
1
2
.9
6
0
.9
9
1
1
.5
3
0
.4
2
1
1
.8
2
0
.5
9
1
1
.7
0
1
.4
8
1
2
.3
6
0
.3
4
1
2
.7
1
0
.4
2
1
2
.9
1
0
.2
9
1
4
.1
9
0
.7
8
C
1
8
:3
n
6
0
.0
7
0
.0
2
0
.0
6
0
.0
1
0
.0
6
0
.0
0
0
.0
6
0
.0
1
0
.0
7
0
.0
0
0
.0
6
0
.0
0
0
.0
8
0
.0
1
0
.0
3
0
.0
0
0
.0
4
0
.0
0
0
.0
3
0
.0
0
0
.0
5
0
.0
0
C
2
0
:2
n
6
0
.8
6
0
.0
9
1
.0
1
0
.0
7
0
.6
8
0
.1
0
1
.1
1
0
.0
8
1
.2
0
0
.0
3
1
.1
4
0
.0
5
1
.1
4
0
.0
7
0
.9
2
0
.0
3
0
.7
7
0
.0
2
0
.8
8
0
.0
3
0
.8
4
0
.0
5
C
2
0
:3
n
6
1
.1
4
0
.1
2
0
.9
8
0
.0
8
0
.8
1
0
.1
1
0
.9
3
0
.0
8
1
.0
3
0
.0
1
1
.0
2
0
.0
5
1
.0
0
0
.0
8
1
.0
5
0
.0
4
1
.1
5
0
.0
4
1
.2
5
0
.0
2
1
.2
1
0
.0
9
C
2
0
:4
n
6
1
0
.1
8
0
.9
4
1
3
.5
2
1
.3
1
1
4
.1
7
2
.1
8
1
7
.3
2
1
.4
9
2
0
.7
0
0
.4
5
2
0
.3
8
0
.8
3
1
9
.9
7
1
.7
6
1
0
.5
3
0
.4
8
8
.2
9
0
.4
0
7
.6
9
0
.1
9
6
.9
2
0
.5
1
C
2
2
:2
n
6
0
.0
5
0
.0
1
0
.0
6
0
.0
1
0
.0
5
0
.0
1
0
.0
7
0
.0
1
0
.0
8
0
.0
0
0
.0
7
0
.0
0
0
.0
8
0
.0
1
0
.0
6
0
.0
0
0
.0
5
0
.0
0
0
.0
5
0
.0
0
0
.0
5
0
.0
0
C
2
2
:4
n
6
1
.0
9
0
.1
0
2
.0
8
0
.1
8
2
.4
7
0
.4
0
3
.5
8
0
.3
0
4
.3
9
0
.1
0
4
.8
8
0
.1
7
4
.6
4
0
.4
3
0
.8
0
0
.0
4
0
.4
4
0
.0
2
0
.3
8
0
.0
1
0
.3
3
0
.0
2
C
1
8
:3
n
3
0
.3
5
0
.0
7
0
.1
1
0
.0
3
0
.2
9
0
.0
7
0
.0
9
0
.0
2
0
.0
2
0
.0
0
0
.0
2
0
.0
0
0
.0
2
0
.0
1
0
.0
5
0
.0
1
0
.0
3
0
.0
0
0
.0
2
0
.0
0
0
.0
3
0
.0
1
C
2
0
:3
n
3
0
.1
1
0
.0
2
0
.0
4
0
.0
1
C
2
0
:5
n
3
2
.0
4
0
.2
6
1
.5
8
0
.2
2
0
.1
1
0
.0
1
0
.0
9
0
.0
1
0
.0
4
0
.0
0
0
.0
4
0
.0
1
3
.5
8
0
.0
7
3
.9
8
0
.1
2
4
.2
9
0
.1
4
3
.8
2
0
.1
8
C
2
2
:5
n
3
3
.8
6
0
.5
2
2
.6
9
0
.3
1
0
.8
2
0
.1
2
0
.5
1
0
.0
5
0
.3
5
0
.0
2
0
.2
8
0
.0
1
0
.2
2
0
.0
1
4
.3
6
0
.0
9
4
.3
8
0
.1
0
4
.6
3
0
.1
3
4
.2
3
0
.2
5
C
2
2
:6
n
3
6
.0
4
0
.6
2
4
.8
9
0
.6
1
3
.9
9
0
.6
6
3
.9
4
0
.4
0
3
.7
1
0
.1
4
2
.6
3
0
.1
0
2
.3
6
0
.2
1
9
.8
0
0
.2
6
1
0
.3
1
0
.2
1
1
1
.1
7
0
.2
2
1
0
.5
2
0
.6
1
S
F
A
3
5
.3
7
7
.0
9
4
1
.2
2
1
.3
0
4
0
.0
6
1
.0
8
4
1
.0
0
0
.7
8
4
2
.8
3
0
.3
0
4
2
.7
6
0
.5
3
4
2
.0
0
1
.1
6
4
3
.1
9
0
.2
2
4
2
.9
9
0
.3
2
4
3
.5
9
0
.3
0
4
2
.1
4
0
.8
7
M
U
F
A
1
6
.4
8
3
.9
6
1
8
.2
8
2
.5
4
2
5
.7
4
3
.8
6
1
8
.3
4
2
.1
9
1
4
.0
7
0
.6
2
1
5
.7
2
1
.5
1
1
6
.7
9
2
.2
5
1
3
.2
8
0
.8
8
1
4
.8
4
0
.7
2
1
3
.1
1
0
.7
3
1
5
.6
7
1
.7
6
n
6
-P
U
F
A
2
1
.1
5
4
.2
8
3
1
.2
2
0
.2
5
2
8
.9
6
2
.0
8
3
6
.0
4
1
.0
2
3
8
.9
9
0
.2
5
3
8
.5
5
1
.0
8
3
8
.6
1
0
.9
0
2
5
.7
5
0
.3
5
2
3
.4
5
0
.4
2
2
3
.1
9
0
.1
7
2
3
.5
9
0
.1
7
n
3
-P
U
F
A
1
0
.3
3
2
.3
3
9
.2
9
1
.1
5
5
.2
5
0
.7
3
4
.6
2
0
.4
3
4
.1
2
0
.1
5
2
.9
7
0
.1
0
2
.6
0
0
.2
1
1
7
.7
9
0
.3
7
1
8
.7
2
0
.3
7
2
0
.1
1
0
.4
7
1
8
.6
0
1
.0
2
D
a
y 
1
4
S
T
D
+
n
3
S
T
D
W
il
d
 T
y
p
e
fa
t-
1
[%
 o
f 
to
ta
l 
F
A
]
M
U
F
A
n
6
-P
U
F
A
n
3
-P
U
F
A
S
u
m
s
D
a
y 
7
D
a
y 
4
5
D
a
y 
3
0
D
a
y 
1
4
D
a
y 
7
D
a
y 
0
S
F
A
D
a
y 
3
0
D
a
y 
0
D
a
y 
4
5
D
a
y 
3
0
   APPENDIX 
 
193 
 
Table 9.3.3B: Brain. 
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Fig. 9.3.2: Mean% difference of relative levels of EPA (A), DHA (B), n3 DPA (C) and ARA (D) in 
WT animals after 30 days on a sunflower diet enriched with EPA and DHA in comparison to 
baseline (WT mice, D0). Shown is the mean %difference in all investigated tissues and blood 
fractions. It was calculated using the formula [%difference = (conc
D30
 – conc
D0
)/conc
D0
 * 100]. 
 
 
Fig. 9.3.3: Relative distribution of n3-polyunsaturated fatty acids (PUFA), n6-PUFA, 
monounsaturated fatty acids (MUFA) and saturated fatty acids (SFA) in transgenic fat-1 mice 
and wild type animals (WT-STD) after 30 days on a sunflower based diet, as well as in wild type 
mice on the same diet enriched with EPA and DHA (WT-STD+n3) during the course of the 
feeding period (45 days) in tissues. (A): liver, (B): kidney, (C): spleen, (D): brain and (E): colon. 
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Fig. 9.3.4: Mean% difference of relative levels of EPA (A), DHA (B), n3 DPA (C) and ARA (D) in 
WT animals after 30 days on a sunflower diet enriched with EPA and DHA in comparison to fat-
1 mice after 30 days on standard sunflower diet. Shown is the mean %difference in all 
investigated tissues and blood fractions. It was calculated using the formula [%difference = 
(conc
D30
 – conc
Fat-1
)/conc
Fat-1
 * 100]. 
 
 
Fig. 9.3.5: %EPA+DHA in blood fractions (A) and in tissues (B) in transgenic fat-1 mice and 
wild type animals (WT-STD) on a sunflower based diet, as well as in wild type mice on the same 
diet enriched with EPA and DHA (WT-STD+n3) after 30 days of supplementation. 
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Table 9.3.4: n6/n3 ratio and %EPA+DHA in blood and tissues of wild type mice at the beginning 
of the experiment (Day 0) and during the course of the feeding experiment on a standard 
sunflower based diet (STD) or on the same diet enriched with n3-PUFA (1% EPA and 1% DHA 
as ethyl ester, STD+n3). Ratios in transgenic fat-1 mice are shown at baseline (Day 0) and after 
30 days on a standard sunflower based diet. The n6/n3 ratio was calculated as Ʃ%(18:2 n6, 
18:3 n6, 20:3 n6, 20:4 n6, C22:4n6)/ Ʃ%(18:3 n3, 20:5 n3, 22:5 n3, 22:6 n3). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9.3.5: Absolute concentrations of oxylipins in plasma, colon and brain of wild type mice at 
the beginning of experiment (Day 0) and during the course of the feeding experiment on a 
standard sunflower based diet (STD) or on the same diet enriched with n3-PUFA (1% EPA and 
1% DHA as ethyl ester, STD+n3). Absolute concentrations in transgenic fat-1 mice are shown at 
baseline (Day 0) and after 30 days on a standard sunflower based diet. 
In case an analyte was below limit of quantification (<LOQ) in more than 50% of samples within 
one group, the LOQ is shown. 
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Table 9.3.5: Plasma. 
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Table 9.3.5: Plasma Continued. 
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Table 9.3.5: Plasma Continued. 
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Table 9.3.5: Brain.  
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Table 9.3.5: Brain Continued. 
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Table 9.3.5: Brain Continued. 
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Table 9.3.5: Colon Continued. 
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Table 9.3.5: Colon Continued. 
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Fig. 9.3.6: Mean% difference of selected oxylipin concentrations in (A) plasma (B) brain and (C) 
colon in WT animals after 30 days on a sunflower diet enriched with EPA and DHA in 
comparison to baseline (WT mice, D0). It was calculated using the formula [%difference = 
(conc
D30
 – conc
D0
)/conc
D0
 * 100]. # mean %difference was not calculated because more than 
50% of samples of one group (D30 or D0) were <LOQ. 
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Fig. 9.3.7: Mean%difference of selected oxylipin concentrations in (A) plasma (B) brain and (C) 
colon in WT animals after 30 days on a sunflower diet enriched with EPA and DHA (WT-
STD+n3) in comparison to fat-1 mice after 30 days on standard sunflower diet. It was calculated 
using the formula [%difference = (conc
WT-STD+n3
 – conc
fat-1
)/conc
fat-1
 * 100]. # mean %difference 
was not calculated because more than 50% of samples of one group (D30 or D0) were <LOQ. 
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9.4 Chapter 7 
Table 9.4.1: Absolute concentrations of fatty acids in brain tissue of C57BL/6 and NMRI mice in 
after 30 days of feeding a standard sunflower oil based diet (STD) or the same diet enriched 
with n3-PUFA (1% EPA and 1% DHA as ethyl ester in the diet, STD+n3). Shown are mean ± 
SEM. 
[µg/mg tissue] FA 
C57BL/6 NMRI 
STD STD+n3 STD STD+n3 
SFA C10:0 < 0.0017 < 0.0017 < 0.0017 < 0.0017 
 
C11:0 < 0.0017 < 0.0017 < 0.0017 < 0.0017 
 
C12:0 0.0023 ± 0.0003 0.0027 ± 0.0005 < 0.0017 < 0.0017 
 
C13:0 < 0.0017 < 0.0017 < 0.0017 < 0.0017 
 
C14:0 0.069 ± 0.004 0.08 ± 0.01 0.033 ± 0.001 0.032 ± 0.001 
 
C15:0 0.019 ± 0.002 0.022 ± 0.003 0.0148 ± 0.0002 0.013 ± 0.002 
 
C16:0 8.2 ± 0.6 8.2 ± 0.6 7.09 ± 0.06 7.1 ± 0.2 
 
C17:0 0.06 ± 0.003 0.062 ± 0.004 0.0461 ± 0.0004 0.047 ± 0.002 
 
C18:0 9 ± 0.6 9.2 ± 0.4 7.45 ± 0.05 7.5 ± 0.2 
 
C19:0 0.017 ± 0.001 0.019 ± 0.001 0.0129 ± 0.0004 0.013 ± 0.001 
 
C20:0 0.23 ± 0.03 0.28 ± 0.03 0.123 ± 0.003 0.12 ± 0.01 
 
C21:0 < 0.0017 < 0.0017 0.01 ± 0.001 0.009 ± 0.001 
 
C22:0 0.26 ± 0.02 0.3 ± 0.02 0.145 ± 0.003 0.14 ± 0.01 
 
C23:0 0.08 ± 0.01 0.09 ± 0.01 0.04 ± 0.002 0.041 ± 0.004 
 C24:0 0.37 ± 0.03 0.44 ± 0.04 0.26 ± 0.01 0.24 ± 0.02 
 
sum SFA 18 ± 1 19 ± 1 15.2 ± 0.1 15.2 ± 0.4 
 
  
  
  
  
  
  
  
   
MUFA C14:1n5 < 0.0017 < 0.0017 < 0.0017 < 0.0017 
 
C15:1n5 < 0.0017 < 0.0017 < 0.0017 < 0.0017 
 
C16:1n7 0.2 ± 0.01 0.22 ± 0.01 0.151 ± 0.004 0.151 ± 0.004 
 
C17:1n7 < 0.0017 < 0.0017 < 0.0017 < 0.0017 
 
C18:1n7 1.5 ± 0.1 1.59 ± 0.06 5.2 ± 0.1 5.2 ± 0.1 
 
C18:1n9 6.7 ± 0.4 7.5 ± 0.3 1.22 ± 0.02 1.16 ± 0.03 
 
C20:1n9 0.77 ± 0.08 0.95 ± 0.07 0.54 ± 0.02 0.53 ± 0.04 
 
C22:1n9 0.083 ± 0.003 0.11 ± 0.01 0.082 ± 0.003 0.08 ± 0.01 
 C24:1n9 0.93 ± 0.07 1.14 ± 0.08 0.74 ± 0.02 0.75 ± 0.06 
 
sum MUFA 10.2 ± 0.6 11.5 ± 0.5 7.9 ± 0.1 7.8 ± 0.3 
 
  
  
  
  
  
  
  
   
n3  PUFA C18:3n3 < 0.0017 < 0.0017 0.0075 ± 0.0002 0.008 ± 0.001 
 
C20:3n3 < 0.0017 < 0.0017 < 0.0017 < 0.0017 
 
C20:4n3 < 0.0017 < 0.0017 < 0.0017 < 0.0017 
 
C20:5n3 < 0.0017 0.084 ± 0.005 < 0.0017 0.032 ± 0.002 
 
C22:5n3 0.037 ± 0.003 0.18 ± 0.01 0.036 ± 0.002 0.112 ± 0.003 
  C22:6n3 6.1 ± 0.5 6.9 ± 0.4 5.4 ± 0.07 6.1 ± 0.2 
 
sum n3 PUFA 6.2 ± 0.5 7.2 ± 0.4 5.4 ± 0.1 6.3 ± 0.2 
 
  
  
  
  
  
  
  
   
n6  PUFA C18:2n6 0.33 ± 0.02 0.31 ± 0.02 0.25 ± 0.01 0.273 ± 0.005 
 
C18:3n6 < 0.0017 < 0.0017 < 0.0017 < 0.0017 
 
C20:2n6 0.1 ± 0.01 0.09 ± 0.01 0.057 ± 0.002 0.061 ± 0.003 
 
C20:3n6 0.17 ± 0.01 0.25 ± 0.01 0.118 ± 0.004 0.2 ± 0.01 
 
C20:4n6 4.6 ± 0.4 3.9 ± 0.3 3.5 ± 0.03 3.04 ± 0.08 
 
C22:2n6 < 0.0017 < 0.0017 0.007 ± 0.001 0.007 ± 0.001 
 
C22:4n6 1.18 ± 0.09 0.88 ± 0.04 1.12 ± 0.02 0.88 ± 0.02 
 C22:5n6 0.35 ± 0.02 0.09 ± 0.01 0.32 ± 0.02 0.079 ± 0.004 
 
sum n6 PUFA 6.7 ± 0.5 5.5 ± 0.3 5.4 ± 0.1 4.5 ± 0.1 
 
  
  
  
  
  
  
  
   
n9 PUFA C20:3 n9 0.06 ± 0.01 0.07 ± 0.02 0.023 ± 0.002 0.025 ± 0.001 
 
sum all PUFA 13 ± 1 12.8 ± 0.8 10.5 ± 0.1 10.8 ± 0.3 
                           
 
sum ALL FA 41 ± 3 43 ± 2 33.9 ± 0.3 33.9 ± 0.8 
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Table 9.4.2: Relative distribution of fatty acids in brain tissue of C57BL/6 and NMRI mice after 
30 days of feeding a standard sunflower oil based diet (STD) or the same diet enriched with n3-
PUFA (1% EPA and 1% DHA as ethyl ester in the diet, STD+n3). Wt%n3 and wt%n6 in HUFA 
were calculated as follows: %n3 in HUFA = 100*(C20:5 n3 + C22:5 n3 + C22:6 n3)/(C20:3 n6 + 
C20:4 n6 + C22:4 n6 + C22:5n6 + C20:3 n9 + C20:5 n3 + C22:5 n3 + C22:6 n3); %n6 in HUFA 
= 100*(C20:3 n6 + C20:4 n6 + C22:4 n6 + C22:5n6)/(C20:3 n6 + C20:4 n6 + C22:4 n6 + C22:5 
n6 + C20:3 n9 + C20:5 n3 + C22:5 n3 + C22:6 n3). Shown are mean ± SEM. 
[% FA of all FA]   
C57BL/6 NMRI 
STD STD+n3 STD STD+n3 
SFA C10:0 < LOQ < LOQ <LOQ <LOQ 
 
C11:0 < LOQ < LOQ <LOQ <LOQ 
 
C12:0 0.007 ± 0.001 0.007 ± 0.001 <LOQ <LOQ 
 
C13:0 < LOQ < LOQ <LOQ <LOQ 
 
C14:0 0.166 ± 0.004 0.173 ± 0.007 0.098 ± 0.001 0.096 ± 0.003 
 
C15:0 0.045 ± 0.001 0.05 ± 0.005 0.044 ± 0.001 0.043 ± 0.002 
 
C16:0 19.8 ± 0.4 19.1 ± 0.4 20.89 ± 0.09 20.8 ± 0.2 
 
C17:0 0.145 ± 0.002 0.144 ± 0.003 0.136 ± 0.001 0.14 ± 0.003 
 
C18:0 21.7 ± 0.1 21.4 ± 0.2 22 ± 0.1 22.1 ± 0.1 
 
C19:0 0.041 ± 0.003 0.045 ± 0.002 0.038 ± 0.001 0.038 ± 0.001 
 
C20:0 0.56 ± 0.07 0.65 ± 0.05 0.362 ± 0.007 0.35 ± 0.02 
 
C21:0 < LOQ < LOQ 0.028 ± 0.003 0.025 ± 0.003 
 
C22:0 0.63 ± 0.05 0.7 ± 0.03 0.428 ± 0.009 0.42 ± 0.03 
 
C23:0 0.2 ± 0.02 0.22 ± 0.01 0.119 ± 0.005 0.12 ± 0.01 
  C24:0 0.9 ± 0.07 1.02 ± 0.09 0.77 ± 0.02 0.71 ± 0.06 
 
sum SFA 44.2 ± 0.3 43.4 ± 0.4 44.9 ± 0.1 44.9 ± 0.2 
 
  
  
  
  
  
  
  
   
MUFA C14:1n5 < LOQ < LOQ <LOQ <LOQ 
 
C15:1n5 < LOQ < LOQ <LOQ <LOQ 
 
C16:1n7 0.475 ± 0.008 0.51 ± 0.06 0.446 ± 0.008 0.446 ± 0.006 
 
C17:1n7 < LOQ < LOQ <LOQ <LOQ 
 
C18:1n7 3.71 ± 0.06 3.7 ± 0.1 3.59 ± 0.05 3.43 ± 0.05 
 
C18:1n9 16.1 ± 0.4 17.6 ± 0.5 15.2 ± 0.2 15.2 ± 0.2 
 
C20:1n9 1.9 ± 0.2 2.2 ± 0.1 1.58 ± 0.04 1.6 ± 0.1 
 
C22:1n9 0.2 ± 0.01 0.25 ± 0.02 0.24 ± 0.01 0.25 ± 0.02 
  C24:1n9 2.3 ± 0.2 2.7 ± 0.2 2.17 ± 0.06 2.2 ± 0.2 
 
sum MUFA 24.6 ± 0.7 26.9 ± 0.9 23.2 ± 0.3 23.1 ± 0.5 
 
  
  
  
  
  
  
  
   
n3 PUFA C18:3n3 < LOQ < LOQ 0.022 ± 0.001 0.023 ± 0.002 
 
C20:3n3 < LOQ < LOQ <LOQ <LOQ 
 
C20:4n3 < LOQ < LOQ < LOQ < LOQ 
 
C20:5n3 < LOQ 0.2 ± 0.01 <LOQ 0.094 ± 0.007 
 
C22:5n3 0.09 ± 0.002 0.41 ± 0.01 0.107 ± 0.005 0.329 ± 0.006 
  C22:6n3 14.8 ± 0.5 16.1 ± 0.4 15.9 ± 0.2 18.1 ± 0.2 
 
sum n3 PUFA 14.9 ± 0.5 16.7 ± 0.4 16 ± 0.2 18.5 ± 0.2 
 
  
  
  
  
  
  
  
   
n6 PUFA C18:2n6 0.8 ± 0.01 0.72 ± 0.02 0.72 ± 0.03 0.81 ± 0.02 
 
C18:3n6 < LOQ < LOQ <LOQ <LOQ 
 
C20:2n6 0.25 ± 0.03 0.2 ± 0.02 0.168 ± 0.007 0.18 ± 0.008 
 
C20:3n6 0.4 ± 0.02 0.588 ± 0.007 0.35 ± 0.01 0.58 ± 0.02 
 
C20:4n6 11 ± 0.2 9 ± 0.2 10.31 ± 0.08 9 ± 0.1 
 
C22:2n6 < LOQ < LOQ 0.021 ± 0.001 0.021 ± 0.002 
 
C22:4n6 2.84 ± 0.09 2.06 ± 0.06 3.3 ± 0.05 2.61 ± 0.03 
  C22:5n6 0.84 ± 0.03 0.2 ± 0.02 0.94 ± 0.04 0.23 ± 0.01 
 
sum n6 PUFA 16.3 ± 0.3 13 ± 0.2 15.9 ± 0.1 13.5 ± 0.1 
 
  
  
  
  
  
  
  
   
n9 PUFA C20:3 n9 0.14 ± 0.03 0.16 ± 0.03 0.068 ± 0.005 0.072 ± 0.003 
 
sum all PUFA 31.2 ± 0.5 29.7 ± 0.5 31.9 ± 0.3 32 ± 0.3 
                            
wt % n3 in HUFA 49 ± 1 58.1 ± 0.5 51.7 ± 0.3 59.7 ± 0.3 
wt % n6 in HUFA 50.3 ± 0.9 41.4 ± 0.5 48.1 ± 0.3 40 ± 0.3 
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Fig. 9.4.1: Fatty acid (FA) pattern in brain tissue of C57BL/6 (A) and NMRI-mice (B) fed with a 
standard sunflower diet (STD) or the same diet enriched with n3-PUFA (STD+n3). Shown are (I) 
relative amounts of saturated (SFA), monounsaturated (MUFA), n3 and n6 polyunsaturated fatty 
acids (PUFA) as well as (II) selected n3- and n6-PUFA. n9-PUFA not shown in (I) due to relative 
amounts below 0.2 % of total FA. # Analyte was below LOQ. Statistical differences were 
determined with a two-tailed t-test for unpaired samples (* p<0.05, ** p<0.01, *** p≤0.0001). No 
t-test was performed for C18:3 n3 and C20:5 n3. Results are shown as mean ± SEM. 
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11 Abbreviations 
ARA      arachidonic acid 
ACN     acetonitrile 
ARA      arachidonic acid 
BF3     boron trifluoride 
BMI     body mass index 
CAD     collision activated dissociation 
CE      cholesterol ester 
CE      collision energy 
CID     collision-induced dissociation 
CNS     central nervous system 
COX     cyclooxygenase 
CXP     collision cell exit potential 
CYP     cytochrom P450 
D5D / D6D   delta-5/delta-6 desaturase 
DGLA     dihomo gamma-linolenic acid 
DHA     docosahexaenoic acid 
DiHDPE    dihydroxy docosapentaenoic acid 
DiHETE    dihydroxy eicosatetraenoic acid 
DiHETrE    dihydroxy eicosatrienoic acid 
DiH-FA    dihydroxy fatty acid 
DiHODE    dihydroxy octadecadienoic acid 
DiHOME    dihydroxy octadecenoic acid 
DMEM    Dulbecco’s modified Eagle’s medium 
DP      declustering potential 
DPA     docosapentaenoic acid 
EA      ethyl acetate 
EDTA     ethylenediaminetetraacetic acid 
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EKODE    epoxyketooctadecenoic acid 
EPA     eicosapentaenoic acid 
EpDPE    epoxy docosapentaenoic acid 
EpETE    epoxy eicosatetraenoic acid 
EpETrE    epoxy eicosatrienoic acid 
Ep-FA     epoxy fatty acid 
EpODE    epoxy octadecadienoic acid 
EpOME    epoxy octadecenoic acid 
ESI     electrospray ionization 
FA      fatty acid 
FAME     fatty acid methyl ester 
FCS     fetal calf serum 
FFA     free fatty acid (non-esterified FA, non-amide-bound FA) 
FWHM    full width at half maximal height 
GC-FID    gas chromatography flame ionization detection 
GLA     gamma-linolenic acid 
HAc     acetic acid 
HDHA     hydroxy docosahexaenoic acid 
HEPE     hydroxy eicosapentaenoic acid 
HETE     hydroxy eicosatetraenoic acid 
HETrE    hydroxyl eicosatrienoic acid 
HODE     hydroxy octadecadienoic acid 
HOTrE    hydroxy octadecatrienoic acid 
HpETE    hydroperoxyeicosatetraenoic acid 
IS      internal standard 
LA      linoleic acid 
LC-MS    liquid chromatography mass spectrometry 
LLE     liquid-liquid extraction 
LLOQ     lower limit of quantification 
LOD     limit of detection 
LOQ     limit of quantification 
LOX     lipoxygenase 
LT      leukotriene  
LTB     leukotriene  
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LXA     lipoxin 
MeOH     methanol 
mRNA    messenger ribonucleic acid 
MTBE     tert-butyl methyl ether 
MUFA     monounsaturated fatty acid 
n3-DPA    n3 docosapentaenoic acid 
NaOH     sodium hydroxide 
NMRI     Naval Medical Research Institute 
OH-FA    hydroxy fatty acid 
oxo-ETE oxo   eicosatetraenoic acid 
oxo-ODE oxo   octadecadienoic acid 
PC      phosphatidylcholine 
PG     prostaglandin 
PL      phospholipid 
PUFA     polyunsaturated fatty acid 
qRT-PCR    quantitative real-time polymerase chain reaction 
RBC     red blood cells 
RP      reversed phase 
RSD     relative standard deviation 
Rv      resolvin 
SD      standard deviation 
sEH     soluble epoxide hydrolyse 
SEM     standard error of the mean 
SFA     saturated fatty acids 
SPE     solid phase extraction 
SPM     specialized pro-resolving lipid mediator 
SRM     selected reaction monitoring 
TG      triacylglycerols  
THF diol    tetrahydrofurandiol 
TMSH     trimethylsulfonium hydroxide 
TriHETrE    trihydroxy-eicosatrienoic acid 
TriHOME    trihydroxy-ocadecenoic acid 
Tx      thromboxane 
WT     wild type 
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